Kinase inhibitors

ABSTRACT

Compounds, pharmaceutical compositions and kits are provided for use with kinases that comprise a compound selected from the group consisting of: 
                         
wherein the variables are as defined herein.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/619,302 filed Oct. 15, 2004 and U.S. Provisional Application No. 60/679,690 filed May 11, 2005, which are incorporated herein by reference.

FIELD OF THE INVENTION

The invention relates to compounds that may be used to inhibit kinases as well as compositions of matter and kits comprising these compounds. The present invention also relates to methods for inhibiting kinases as well as treatment methods using compounds according to the present invention.

BACKGROUND OF THE INVENTION

The invention relates to inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating or modulating disease in which phosphoryl transferases, including kinases, may be involved, symptoms of such disease, or the effect of other physiological events mediated by phosphoryl transferases, including kinases. The invention also provides for methods of making the inhibitor compounds and methods for treating diseases in which one or more phosphoryl transferase, including kinase, activities is involved.

Phosphoryl transferases are a large family of enzymes that transfer phosphorous-containing groups from one substrate to another. By the conventions set forth by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB) enzymes of this type have Enzyme Commission (EC) numbers starting with 2.7.-.- (See, Bairoch A., The ENZYME database in Nucleic Acids Res. 28:204-305 (2000)). Kinases are a class of enzymes that function in the catalysis of phosphoryl transfer. The protein kinases constitute the largest subfamily of structurally related phosphoryl transferases and are responsible for the control of a wide variety of signal transduction processes within the cell. (See, Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Book, I and II, Academic Press, San Diego, Calif.). Protein kinases are thought to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The protein kinases may be categorized into families by the substrates they phosphorylate (e.g., protein-tyrosine, protein-serine/threonine, histidine, etc.). Protein kinase sequence motifs have been identified that generally correspond to each of these kinase families (See, for example, Hanks, S. K.; Hunter, T., FASEB J. 9:576-596 (1995); Kinghton et al., Science, 253:407-414 (1991); Hiles et al., Cell 70:419-429 (1992); Kunz et al., Cell, 73:585-596 (1993); Garcia-Bustos et al., EMBO J., 13:2352-2361 (1994)). Lipid kinases (e.g. PI3K) constitute a separate group of kinases with structural similarity to protein kinases.

Protein and lipid kinases regulate many different cell processes including, but not limited to, proliferation, growth, differentiation, metabolism, cell cycle events, apoptosis, motility, transcription, translation and other signaling processes, by adding phosphate groups to targets such as proteins or lipids. Phosphorylation events catalyzed by kinases act as molecular on/off switches that can modulate or regulate the biological function of the target protein. Phosphorylation of target proteins occurs in response to a variety of extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.), cell cycle events, environmental or nutritional stresses, etc. Protein and lipid kinases can function in signaling pathways to activate or inactivate, or modulate the activity of (either directly or indirectly) the targets. These targets may include, for example, metabolic enzymes, regulatory proteins, receptors, cytoskeletal proteins, ion channels or pumps, or transcription factors. Uncontrolled signaling due to defective control of protein phosphorylation has been implicated in a number of diseases and disease conditions, including, for example, inflammation, cancer, allergy/asthma, diseases and conditions of the immune system, disease and conditions of the central nervous system (CNS), cardiovascular disease, dermatology, and angiogenesis.

Initial interest in protein kinases as pharmacological targets was stimulated by the findings that many viral oncogenes encode structurally modified cellular protein kinases with constitutive enzyme activity. These findings pointed to the potential involvement of oncogene related protein kinases in human proliferatives disorders. Subsequently, deregulated protein kinase activity, resulting from a variety of more subtle mechanisms, has been implicated in the pathophysiology of a number of important human disorders including, for example, cancer, CNS conditions, and immunologically related diseases. The development of selective protein kinase inhibitors that can block the disease pathologies and/or symptoms resulting from aberrant protein kinase activity has therefore generated much interest.

Cancer results from the deregulation of the normal processes that control cell division, differentiation and apoptotic cell death. Protein kinases play a critical role in this regulatory process. A partial non-limiting list of such kinases includes abl, Aurora-A, Aurora-B, Aurora-C, ATK, bcr-abl, Blk, Brk, Btk, c-Kit, c-Met, c-Src, CDK1, CDK2, CDK4, CDK6, cRaf1, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, ERK, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, FLK-4, Flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, Ros, Tie1, Tie2, Trk, Yes and Zap70. In mammalian biology, such protein kinases comprise mitogen activated protein kinase (MAPK) signaling pathways. MAPK signaling pathways are inappropriately activated by a variety of common disease-associated mechanisms such as mutation of ras genes and deregulation of growth factor receptors (Magnuson et al., Seminars in Cancer Biology 5:247-252 (1994)). Therefore the inhibition of protein kinases is an object of the present invention.

Aurora kinases (Aurora-A, Aurora-B, Aurora-C) are serine/threonine protein kinases that have been implicated in human cancer, such as colon, breast and other solid tumors. Aurora-A (also sometimes referred to as AIK) is believed to be involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-A may play a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities. In human colon cancer tissue, Aurora-A, Aurora-B, Aurora-C have been found to be overexpressed (See, Bischoff et al., EMBO J., 17:3052-3065 (1998); Schumacher et al., J. Cell Biol. 143:1635-1646 (1998); Kimura et al., J. Biol. Chem., 272:13766-13771 (1997)).

There is a continued need to find new therapeutic agents to treat human diseases. The protein kinases, specifically but not limited to Aurora-A, Aurora-B and Aurora-C are especially attractive targets for the discovery of new therapeutics due to their important role in cancer, diabetes, Alzheimer's disease and other diseases.

SUMMARY OF THE INVENTION

The present invention relates to compounds that have activity for inhibiting kinases. The present invention also provides compositions, articles of manufacture and kits comprising these compounds.

In one embodiment, a pharmaceutical composition is provided that comprises a kinase inhibitor according to the present invention as an active ingredient. Pharmaceutical compositions according to the invention may optionally comprise 0.001%-100% of one or more kinase inhibitors of this invention. These pharmaceutical compositions may be administered or coadministered by a wide variety of routes, including for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally. The compositions may also be administered or coadministered in slow release dosage forms.

The invention is also directed to kits and other articles of manufacture for treating disease states associated with kinases.

In one embodiment, a kit is provided that comprises a composition comprising at least one kinase inhibitor of the present invention in combination with instructions. The instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also comprise packaging materials. The packaging material may comprise a container for housing the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.

In another embodiment, an article of manufacture is provided that comprises a composition comprising at least one kinase inhibitor of the present invention in combination with packaging materials. The packaging material may comprise a container for housing the composition. The container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.

Also provided are methods for preparing compounds, compositions and kits according to the present invention. For example, several synthetic schemes are provided herein for synthesizing compounds according to the present invention.

Also provided are methods for using compounds, compositions, kits and articles of manufacture according to the present invention.

In one embodiment, the compounds, compositions, kits and articles of manufacture are used to inhibit kinases.

In another embodiment, the compounds, compositions, kits and articles of manufacture are used to treat a disease state for which kinases possesses activity that contributes to the pathology and/or symptomology of the disease state.

In another embodiment, a compound is administered to a subject wherein kinases activity within the subject is altered, preferably reduced.

In another embodiment, a prodrug of a compound is administered to a subject that is converted to the compound in vivo where it inhibits kinases.

In another embodiment, a method of inhibiting kinases is provided that comprises contacting kinases with a compound according to the present invention.

In another embodiment, a method of inhibiting kinases is provided that comprises causing a compound according to the present invention to be present in a subject in order to inhibit kinases in vivo.

In another embodiment, a method of inhibiting kinases is provided that comprises administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits kinases in vivo. It is noted that the compounds of the present invention may be the first or second compounds.

In another embodiment, a therapeutic method is provided that comprises administering a compound according to the present invention.

In another embodiment, a method of inhibiting cell proliferation is provided that comprises contacting a cell with an effective amount of a compound according to the present invention.

In another embodiment, a method of inhibiting cell proliferation in a patient is provided that comprises administering to the patient a therapeutically effective amount of a compound according to the present invention.

In another embodiment, a method of treating a condition in a patient which is known to be mediated by kinases, or which is known to be treated by kinase inhibitors, comprising administering to the patient a therapeutically effective amount of a compound according to the present invention.

In another embodiment, a method is provided for using a compound according to the present invention in order to manufacture a medicament for use in the treatment of disease state which is known to be mediated by kinases, or which is known to be treated by kinase inhibitors.

In another embodiment, a method is provided for treating a disease state for which kinases possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: causing a compound according to the present invention to be present in a subject in a therapeutically effective amount for the disease state.

In another embodiment, a method is provided for treating a disease state for which kinases possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: administering a first compound to a subject that is converted in vivo to a second compound such that the second compound is present in the subject in a therapeutically effective amount for the disease state. It is noted that the compounds of the present invention may be the first or second compounds.

In another embodiment, a method is provided for treating a disease state for which kinases possesses activity that contributes to the pathology and/or symptomology of the disease state, the method comprising: administering a compound according to the present invention to a subject such that the compound is present in the subject in a therapeutically effective amount for the disease state.

It is noted in regard to all of the above embodiments that the present invention is intended to encompass all pharmaceutically acceptable ionized forms (e.g., salts) and solvates (e.g., hydrates) of the compounds, regardless of whether such ionized forms and solvates are specified since it is well know in the art to administer pharmaceutical agents in an ionized or solvated form. It is also noted that unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all possible stereoisomers (e.g., enantiomers or diastereomers depending on the number of chiral centers), independent of whether the compound is present as an individual isomer or a mixture of isomers. Further, unless otherwise specified, recitation of a compound is intended to encompass all possible resonance forms and tautomers. With regard to the claims, the language “compound comprising the formula” is intended to encompass the compound and all pharmaceutically acceptable ionized forms and solvates, all possible stereoisomers, and all possible resonance forms and tautomers unless otherwise specifically specified in the particular claim.

It is further noted that prodrugs may also be administered which are altered in vivo and become a compound according to the present invention. The various methods of using the compounds of the present invention are intended, regardless of whether prodrug delivery is specified, to encompass the administration of a prodrug that is converted in vivo to a compound according to the present invention. It is also noted that certain compounds of the present invention may be altered in vivo prior to inhibiting kinases and thus may themselves be prodrugs for another compound. Such prodrugs of another compound may or may not themselves independently have kinase inhibitory activity.

Definitions

Unless otherwise stated, the following terms used in the specification and claims shall have the following meanings for the purposes of this Application.

“Alicyclic” means a moiety comprising a non-aromatic ring structure. Alicyclic moieties may be saturated or partially unsaturated with one, two or more double or triple bonds. Alicyclic moieties may also optionally comprise heteroatoms such as nitrogen, oxygen and sulfur. The nitrogen atoms can be optionally quaternerized or oxidized and the sulfur atoms can be optionally oxidized. Examples of alicyclic moieties include, but are not limited to moieties with C₃₋₈ rings such as cyclopropyl, cyclohexane, cyclopentane, cyclopentene, cyclopentadiene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, cyclooctane, cyclooctene, and cyclooctadiene.

“Aliphatic” means a moiety characterized by a straight or branched chain arrangement of constituent carbon atoms and may be saturated or partially unsaturated with one, two or more double or triple bonds.

“Alkoxy” means an oxygen moiety having a further alkyl substituent. The alkoxy groups of the present invention can be optionally substituted.

“Alkyl” represented by itself means a straight or branched, saturated or unsaturated, aliphatic radical having a chain of carbon atoms, optionally with oxygen (See “oxaalkyl”) or nitrogen atoms (See “aminoalkyl”) between the carbon atoms. C_(X) alkyl and C_(X-Y) alkyl are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C₁₋₆ alkyl includes alkyls that have a chain of between 1 and 6 carbons (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, and the like). Alkyl represented along with another radical (e.g., as in arylalkyl, heteroarylalkyl) means a straight or branched, saturated or unsaturated aliphatic divalent radical having the number of atoms indicated or when no atoms are indicated means a bond (e.g., (C₆₋₁₀)aryl(C₁₋₃)alkyl includes, benzyl, phenethyl, 1-phenylethyl, 3-phenylpropyl, 2-thienylmethyl, 2-pyridinylmethyl and the like).

“Alkenyl” means a straight or branched, carbon chain that contains at least one carbon-carbon double bond. Examples of alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

“Alkynyl” means a straight or branched, carbon chain that contains at least one carbon-carbon triple bond. Examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl and the like.

“Alkylene”, unless indicated otherwise, means a straight or branched, saturated or unsaturated, aliphatic, divalent radical. C_(X) alkylene and C_(X-Y) alkylene are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C₁₋₆ alkylene includes methylene (—CH₂—), ethylene (—CH₂CH₂—), trimethylene (—CH₂CH₂CH₂—), tetramethylene (—CH₂CH₂CH₂CH₂—) 2-butenylene (—CH₂CH═CHCH₂—), 2-methyltetramethylene (—CH₂CH(CH₃)CH₂CH₂—), pentamethylene (—CH₂CH₂CH₂CH₂CH₂—) and the like).

“Alkylidene” means a straight or branched saturated or unsaturated, aliphatic radical connected to the parent molecule by a double bond. C_(X) alkylidene and C_(X-Y) alkylidene are typically used where X and Y indicate the number of carbon atoms in the chain. For example, C₁₋₆ alkylidene includes methylene (═CH₂), ethylidene (═CHCH₃), isopropylidene (═C(CH₃)₂), propylidene (═CHCH₂CH₃), allylidene (═CH—CH═CH₂), and the like).

“Amino” means a nitrogen moiety having two further substituents where, for example, a hydrogen or carbon atom is attached to the nitrogen. For example, representative amino groups include —NH₂, —NHCH₃, —N(CH₃)₂, —NHC₁₋₁₀-alkyl, —N(C₁₋₁₀-alkyl)₂, —NHaryl, —NHheteroaryl, —N(aryl)₂, —N(heteroaryl)₂, and the like. Optionally, the two substituents together with the nitrogen may also form a ring. Unless indicated otherwise, the compounds of the invention containing amino moieties may include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like.

“Aminoalkyl” means an alkyl, as defined above, except where one or more substituted or unsubstituted nitrogen atoms (—N—) are positioned between carbon atoms of the alkyl. For example, an (C₂₋₆) aminoalkyl refers to a chain comprising between 2 and 6 carbons and one or more nitrogen atoms positioned between the carbon atoms.

“Animal” includes humans, non-human mammals (e.g., dogs, cats, rabbits, cattle, horses, sheep, goats, swine, deer, and the like) and non-mammals (e.g., birds, and the like).

“Aromatic” means a moiety wherein the constituent atoms make up an unsaturated ring system, all atoms in the ring system are sp² hybridized and the total number of pi electrons is equal to 4n+2. An aromatic ring may be such that the ring atoms are only carbon atoms or may include carbon and non-carbon atoms (see Heteroaryl).

“Aryl” means a monocyclic or polycyclic ring assembly wherein each ring is aromatic or when fused with one or more rings forms an aromatic ring assembly. If one or more ring atoms is not carbon (e.g., N, S), the aryl is a heteroaryl. C_(X) aryl and C_(X-Y) aryl are typically used where X and Y indicate the number of atoms in the ring.

“Bicycloalkyl” means a saturated or partially unsaturated fused bicyclic or bridged polycyclic ring assembly.

“Bicycloaryl” means a bicyclic ring assembly wherein the rings are linked by a single bond or fused and at least one of the rings comprising the assembly is aromatic. C_(X) bicycloaryl and C_(X-Y) bicycloaryl are typically used where X and Y indicate the number of carbon atoms in the bicyclic ring assembly and directly attached to the ring.

“Bridging ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure where two ring atoms that are common to both rings are not directly bound to each other. Non-exclusive examples of common compounds having a bridging ring include borneol, norbornane, 7-oxabicyclo[2.2.1]heptane, and the like. One or both rings of the bicyclic system may also comprise heteroatoms.

“Carbamoyl” means the radical —OC(O)NR_(a)R_(b) where R_(a) and R_(b) are each independently two further substituents where a hydrogen or carbon atom is attached to the nitrogen.

“Carbocycle” means a ring consisting of carbon atoms.

“Carbocyclic ketone derivative” means a carbocyclic derivative wherein the ring contains a —CO— moiety.

“Carbonyl” means the radical —CO—. It is noted that the carbonyl radical may be further substituted with a variety of substituents to form different carbonyl groups including acids, acid halides, aldehydes, amides, esters, and ketones.

“Carboxy” means the radical —CO₂—. It is noted that compounds of the invention containing carboxy moieties may include protected derivatives thereof, i.e., where the oxygen is substituted with a protecting group. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like.

“Cyano” means the radical —CN.

“Cycloalkyl” means a non-aromatic, saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly. C_(X) cycloalkyl and C_(X-Y) cycloalkyl are typically used where X and Y indicate the number of carbon atoms in the ring assembly. For example, C₃₋₁₀ cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, bicyclo[2.2.2]octyl, adamantan-1-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2-oxobicyclo[2.2.1]hept-1-yl, and the like.

“Cycloalkylene” means a divalent saturated or partially unsaturated, monocyclic or polycyclic ring assembly. C_(X) cycloalkylene and C_(X-Y) cycloalkylene are typically used where X and Y indicate the number of carbon atoms in the ring assembly.

“Disease” specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition that may be caused by, or incident to, medical or veterinary therapy applied to that animal, i.e., the “side effects” of such therapy.

“Fused ring” as used herein refers to a ring that is bonded to another ring to form a compound having a bicyclic structure when the ring atoms that are common to both rings are directly bound to each other. Non-exclusive examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, and the like. Compounds having fused ring systems may be saturated, partially saturated, carbocyclics, heterocyclics, aromatics, heteroaromatics, and the like.

“Halo” means fluoro, chloro, bromo or iodo.

“Halo-substituted alkyl”, as an isolated group or part of a larger group, means “alkyl” substituted by one or more “halo” atoms, as such terms are defined in this Application. Halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl and the like (e.g. halo-substituted (C₁₋₃)alkyl includes chloromethyl, dichloromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,2-trifluoro-1,1-dichloroethyl, and the like).

“Heteroatom” refers to an atom that is not a carbon atom. Particular examples of heteroatoms include, but are not limited to nitrogen, oxygen, and sulfur.

“Heteroatom moiety” includes a moiety where the atom by which the moiety is attached is not a carbon. Examples of heteroatom moieties include —N═, —NR_(c)—, —N⁺(O⁻)═, —O—, —S— or —S(O)₂—, wherein R_(c) is further substituent.

“Heterobicycloalkyl” means bicycloalkyl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom. For example hetero(C₉₋₁₂)bicycloalkyl as used in this application includes, but is not limited to, 3-aza-bicyclo[4.1.0]hept-3-yl, 2-aza-bicyclo[3.1.0]hex-2-yl, 3-aza-bicyclo[3.1.0]hex-3-yl, and the like.

“Heterocycloalkylene” means cycloalkylene, as defined in this Application, provided that one or more of the ring member carbon atoms is replaced by a heteroatom.

“Heteroaryl” means a cyclic aromatic group having five or six ring atoms, wherein at least one ring atom is a heteroatom and the remaining ring atoms are carbon. The nitrogen atoms can be optionally quaternerized and the sulfur atoms can be optionally oxidized. Heteroaryl groups of this invention include, but are not limited to, those derived from furan, imidazole, isothiazole, isoxazole, oxadiazole, oxazole, 1,2,3-oxadiazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrroline, thiazole, 1,3,4-thiadiazole, triazole and tetrazole. “Heteroaryl” also includes, but is not limited to, bicyclic or tricyclic rings, wherein the heteroaryl ring is fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, a cycloalkenyl ring, and another monocyclic heteroaryl or heterocycloalkyl ring. These bicyclic or tricyclic heteroaryls include, but are not limited to, those derived from benzo[b]furan, benzo[b]thiophene, benzimidazole, imidazo[4,5-c]pyridine, quinazoline, thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine, indolizine, imidazo[1,2a]pyridine, quinoline, isoquinoline, phthalazine, quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, benzoxazole, benzopyrazole, benzothiazole, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridine, imidazo[1,2-a]pyrimidine, imidazo[1,2-c]pyrimidine, imidazo[1,5-a]pyrimidine, imidazo[1,5-c]pyrimidine, pyrrolo[2,3-b]pyridine, pyrrolo[2,3-c]pyridine, pyrrolo[3,2-c]pyridine, pyrrolo[3,2-b]pyridine, pyrrolo[2,3-d]pyrimidine, pyrrolo[3,2-d]pyrimidine, pyrrolo[2,3-b]pyrazine, pyrazolo[1,5-a]pyridine, pyrrolo[1,2-b]pyridazine, pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrimidine, pyrrolo[1,2-a]pyrazine, triazo[1,5-a]pyridine, pteridine, purine, carbazole, acridine, phenazine, phenothiazene, phenoxazine, 1,2-dihydropyrrolo[3,2,1-hi]indole, indolizine, pyrido[1,2-a]indole and 2(1H)-pyridinone. The bicyclic or tricyclic heteroaryl rings can be attached to the parent molecule through either the heteroaryl group itself or the aryl, cycloalkyl, cycloalkenyl or heterocycloalkyl group to which it is fused. The heteroaryl groups of this invention can be substituted or unsubstituted.

“Heterobicycloaryl” means bicycloaryl, as defined in this Application, provided that one or more of the atoms within the ring is a heteroatom. For example, hetero(C₄₋₁₂)bicycloaryl as used in this Application includes, but is not limited to, 2-amino-4-oxo-3,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl, and the like.

“Heterocycloalkyl” means cycloalkyl, as defined in this Application, provided that one or more of the atoms forming the ring is a heteroatom selected, independently from N, O, or S. Non-exclusive examples of heterocycloalkyl include piperidyl, 4-morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolizinyl, 1,4-diazaperhydroepinyl, 1,3-dioxanyl, 1,4-dioxanyl and the like.

“Hydroxy” means the radical —OH.

“Iminoketone derivative” means a derivative comprising the moiety —C(NR)—, wherein R comprises a hydrogen or carbon atom attached to the nitrogen.

“Isomers” mean any compound having an identical molecular formulae but differing in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereomers” and stereoisomers that are nonsuperimposable mirror images are termed “enantiomers” or sometimes “optical isomers.” A carbon atom bonded to four nonidentical substituents is termed a “chiral center.” A compound with one chiral center has two enantiomeric forms of opposite chirality. A mixture of the two enantiomeric forms is termed a “racemic mixture.” A compound that has more than one chiral center has 2^(n−1) enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as ether an individual diastereomer or as a mixture of diastereomers, termed a “diastereomeric mixture.” When one chiral center is present a stereoisomer may be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog. Conventions for stereochemical nomenclature, methods for the determination of stereochemistry and the separation of stereoisomers are well known in the art (e.g., see “Advanced Organic Chemistry”, 4th edition, March, Jerry, John Wiley & Sons, New York, 1992).

“Nitro” means the radical —NO₂.

“Oxaalkyl” means an alkyl, as defined above, except where one or more oxygen atoms (—O—) are positioned between carbon atoms of the alkyl. For example, an (C₂₋₆)oxaalkyl refers to a chain comprising between 2 and 6 carbons and one or more oxygen atoms positioned between the carbon atoms.

“Oxoalkyl” means an alkyl, further substituted with a carbonyl group. The carbonyl group may be an aldehyde, ketone, ester, amide, acid or acid chloride.

“Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use.

“Pharmaceutically acceptable salts” means salts of inhibitors of the present invention which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4′-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like.

Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.

“Prodrug” means a compound that is convertible in vivo metabolically into an inhibitor according to the present invention. The prodrug itself may or may not also have kinase inhibitory activity. For example, an inhibitor comprising a hydroxy group may be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound. Suitable esters that may be converted in vivo into hydroxy compounds include acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, cyclohexylsulfamates, quinates, esters of amino acids, and the like. Similarly, an inhibitor comprising an amine group may be administered as an amide that is converted by hydrolysis in vivo to the amine compound.

“Protected derivatives” means derivatives of inhibitors in which a reactive site or sites are blocked with protecting groups. Protected derivatives are useful in the preparation of inhibitors or in themselves may be active as inhibitors. A comprehensive list of suitable protecting groups can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999.

“Substituted or unsubstituted” means that a given moiety may consist of only hydrogen substituents through available valencies (unsubstituted) or may further comprise one or more non-hydrogen substituents through available valencies (substituted) that are not otherwise specified by the name of the given moiety. For example, isopropyl is an example of an ethylene moiety that is substituted by —CH₃. In general, a non-hydrogen substituent may be any substituent that may be bound to an atom of the given moiety that is specified to be substituted. Examples of substituents include, but are not limited to, aldehyde, alicyclic, aliphatic, (C₁₋₁₀)alkyl, alkylene, alkylidene, amide, amino, aminoalkyl, aromatic, aryl, bicycloalkyl, bicycloaryl, carbamoyl, carbocyclyl, carboxyl, carbonyl group, cycloalkyl, cycloalkylene, ester, halo, heterobicycloalkyl, heterocycloalkylene, heteroaryl, heterobicycloaryl, heterocycloalkyl, oxo, hydroxy, iminoketone, ketone, nitro, oxaalkyl, and oxoalkyl moieties, each of which may optionally also be substituted or unsubstituted.

“Sulfinyl” means the radical —SO—. It is noted that the sulfinyl radical may be further substituted with a variety of substituents to form different sulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters, and sulfoxides.

“Sulfonyl” means the radical —SO₂—. It is noted that the sulfonyl radical may be further substituted with a variety of substituents to form different sulfonyl groups including sulfonic acids, sulfonamides, sulfonate esters, and sulfones.

“Therapeutically effective amount” means that amount which, when administered to an animal for treating a disease, is sufficient to effect such treatment for the disease.

“Thiocarbonyl” means the radical —CS—. It is noted that the thiocarbonyl radical may be further substituted with a variety of substituents to form different thiocarbonyl groups including thioacids, thioamides, thioesters, and thioketones.

“Treatment” or “treating” means any administration of a compound of the present invention and includes:

-   -   (1) preventing the disease from occurring in an animal which may         be predisposed to the disease but does not yet experience or         display the pathology or symptomatology of the disease,     -   (2) inhibiting the disease in an animal that is experiencing or         displaying the pathology or symptomatology of the diseased         (i.e., arresting further development of the pathology and/or         symptomatology), or     -   (3) ameliorating the disease in an animal that is experiencing         or displaying the pathology or symptomatology of the diseased         (i.e., reversing the pathology and/or symptomatology).

It is noted in regard to all of the definitions provided herein that the definitions should be interpreted as being open ended in the sense that further substituents beyond those specified may be included. Hence, a C₁ alkyl indicates that there is one carbon atom but does not indicate what are the substituents on the carbon atom. Hence, a C₁ alkyl comprises methyl (i.e., —CH₃) as well as —CR_(a)R_(b)R_(c) where R_(a), R_(b), and R_(c) may each independently be hydrogen or any other substituent where the atom attached to the carbon is a heteroatom or cyano. Hence, CF₃, CH₂OH and CH₂CN, for example, are all C₁ alkyls.

Kinase Inhibitors

In one embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   X is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, arylalkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   X is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In a further embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   L₁, L₂, and L₅ are each independently selected from the group         consisting of CR₄ and NR₅, with the proviso that R₅ is absent         when the atom to which it is attached forms part of a double         bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In still another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In a further embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In still a further embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   p is selected from the group consisting of 0, 1, 2, 3, 4 and 5;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   X is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted; and     -   R₂₃ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,         hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,         hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,         or two R₂₃ are taken together to form a ring.

In another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   p is selected from the group consisting of 0, 1, 2, 3, 4 and 5;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   X is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted; and     -   R₂₃ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,         hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,         hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,         or two R₂₃ are taken together to form a ring.

In yet another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   p is selected from the group consisting of 0, 1, 2, 3, 4 and 5;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₄ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted; and     -   R₂₃ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl,         hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl,         hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted,         or two R₂₃ are taken together to form a ring.

In another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   J₁, J₂, and J₃ are selected from the group consisting of CR₂ and         N;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N, with the proviso that K₃ is not N in         Formula IIa when K₁ is CR₂, and K₂ and J₃ are each CH;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent, with the proviso         that Q is not absent in Formula Ia when J₁ is CH, K₁ is N, K₂ is         CR₃, and K₃ is CH or N;     -   X is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O, with the provisos that Z is not NH or NC(O)—CH₃ in Formula         IIIa when K₃ is N and J₁, K₁ and K₂ are all C; and Z is not NH         or N—C(O)—O—C(CH₃)₃ when K₃ is N and J₁, K₁ and K₂ are all C;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   J₁, J₂, and J₃ are selected from the group consisting of CR₂ and         N;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N, with the proviso that K₃ is not N in         Formula IIa when K₁ is CR₂, and K₂ and J₃ are each CH;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent, with the proviso         that Q is not absent in Formula Ia when J₁ is CH, K₁ is N, K₂ is         CR₃, and K₃ is CH or N;     -   X′ is selected from the group consisting of pyrazolyl and         indazolyl, each substituted or unsubstituted;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In a further embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   J₁, J₂, and J₃ are selected from the group consisting of CR₂ and         N;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N, with the proviso that K₃ is not N in         Formula IIa when K₁ is CR₂, and K₂ and J₃ are each CH;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent, with the proviso         that Q is not absent in Formula Ia when J₁ is CH, K₁ is N, K₂ is         CR₃, and K₃ is CH or N;     -   X is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Z is selected from the group consisting of NR₁′, S, SO, SO₂ and         O;     -   R₁′ is selected from the group consisting of hydrogen and         unsubstituted or substituted (C₁₋₄)alkyl;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In still another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   J₁, J₂, and J₃ are selected from the group consisting of CR₂ and         N;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N, with the proviso that K₃ is not N in         Formula IIa when K₁ is CR₂, and K₂ and J₃ are each CH;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent, with the proviso         that Q is not absent in Formula Ib when J₁ is CH, K₁ is N, K₂ is         CR₃, and K₃ is CH or N;     -   X is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In yet another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   J₁, J₂ and J₃ are each independently selected from the group         consisting of CR₂ and N;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent, with the proviso         that Q is not absent in Formula Ic when J₁ is CH, K₁ is N, K₂ is         CR₃, and K₃ is CH or N;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R_(3a), R_(3b), and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₃ are taken together to form a substituted or unsubstituted         ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In a further embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent, with the proviso         that Q is not absent in Formula IId when R_(3a) is H or in         Formula VId;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R_(3a), R_(3b), and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₃ are taken together to form a substituted or unsubstituted         ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In still another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R_(3a), R_(3b), and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₃ are taken together to form a substituted or unsubstituted         ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In yet another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R_(3a), R_(3b), and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₃ are taken together to form a substituted or unsubstituted         ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In one embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R_(3a), R_(3b), and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₃ are taken together to form a substituted or unsubstituted         ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one P4 and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R_(3a), R_(3b), and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₃ are taken together to form a substituted or unsubstituted         ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In a further embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R_(3a), R_(3b), and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₃ are taken together to form a substituted or unsubstituted         ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In still another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   L₁, L₂, L₃, L₄, and L₅ are each independently selected from the         group consisting of CR₄ and NR₅, with the proviso that R₅ is         absent when the atom to which it is attached forms part of a         double bond;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R_(3a), R_(3b), and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two of R_(3a), R_(3b), and R₃, are taken together to form a         substituted or unsubstituted ring;     -   each R₄ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₄ are taken together         to form part of a substituted or unsubstituted ring;     -   each R₅ is independently selected from the group consisting of         hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         two R₅, or one R₄ and one R₅, are taken together to form part of         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In yet another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   m is selected from the group consisting of 0, 1 and 2;     -   J₁, J₂ and J₃ are each independently selected from the group         consisting of CR₂ and N;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₉ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁₀ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl, carbonyl         (C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In another embodiment, kinase inhibitors of the present invention comprise one of the following formulae:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   m is selected from the group consisting of 0, 1 and 2;     -   n is selected from the group consisting of 0, 1, 2, 3, 4, and 5;     -   J₁, J₂ and J₃ are each independently selected from the group         consisting of CR₂ and N;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₉ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₁₀ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring;     -   each R₁₁ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₁₁ are taken together         to form a ring; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In a further embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   m is selected from the group consisting of 0, 1 and 2;     -   n is selected from the group consisting of 0, 1, 2, 3, 4, and 5;     -   J₁ is selected from the group consisting of CR₂ and N;     -   K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₉ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₁₀ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring;     -   each R₁₁ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₁₁ are taken together         to form a ring; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In still another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   m is selected from the group consisting of 0, 1 and 2;     -   n is selected from the group consisting of 0, 1, 2, 3, 4, and 5;     -   J₂ is selected from the group consisting of CR₂ and N;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₉ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₁₀ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring;     -   each R₁₁ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₁₁ are taken together         to form a ring; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In yet another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   m is selected from the group consisting of 0, 1 and 2;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R_(3a) and R_(3b) are each independently selected from the group         consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,         alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         R_(3a) and R_(3b) are taken together to form a substituted or         unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₉ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₁₀ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In a further embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   m is selected from the group consisting of 0, 1 and 2;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R_(3a), R_(3b) and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         any two of R_(3a), R_(3b) and R_(3c) are taken together to form         a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₉ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   each R₁₀ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   m is selected from the group consisting of 0, 1 and 2;     -   n is selected from the group consisting of 0, 1, 2, 3, 4, and 5;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R_(3a) and R_(3b) are each independently selected from the group         consisting of hydrogen, halo, nitro, cyano, thio, hydroxy,         alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         R_(3a) and R_(3b) are taken together to form a substituted or         unsubstituted ring;     -   R₉ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁₀ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring;     -   R₁₁ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₁₁ are taken together         to form a ring; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In yet another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   m is selected from the group consisting of 0, 1 and 2;     -   n is selected from the group consisting of 0, 1, 2, 3, 4, and 5;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R_(3a), R_(3b) and R_(3c) are each independently selected from         the group consisting of hydrogen, halo, nitro, cyano, thio,         hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl,         (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl,         (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl,         aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or         any two of R_(3a), R_(3b) and R_(3c) are taken together to form         a substituted or unsubstituted ring;     -   R₉ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁₀ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring;     -   R₁₁ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₁₁ are taken together         to form a ring; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In still another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   m is selected from the group consisting of 0, 1 and 2;     -   n is selected from the group consisting of 0, 1, 2, 3, 4, and 5;     -   R_(3b) is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R₁₀ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring; and     -   R₁₁ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₁₁ are taken together         to form a ring.

In a further embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   m is selected from the group consisting of 0, 1 and 2;     -   n is selected from the group consisting of 0, 1, 2, 3, 4, and 5;     -   R_(3b) is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R₁₀ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring; and     -   R₁₁ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₁₁ are taken together         to form a ring.

In yet another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   m is selected from the group consisting of 0, 1 and 2;     -   n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O, with the provisos that Z is not NH, NC(O)—CH₃ or         N—C(O)—O—C(CH₃)₃;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R_(3b) is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₁₀ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring;     -   R₁₁ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₁₁ are taken together         to form a ring; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In a further embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   m is selected from the group consisting of 0, 1 and 2;     -   n is selected from the group consisting of 0, 1, 2, 3, 4 and 5;     -   R_(3b) is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   R₁₀ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₉ and R₁₀ are taken         together to form a ring; and     -   R₁₁ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or two R₁₁ are taken together         to form a ring.

In another embodiment, kinase inhibitors of the present invention comprise the following formula:

wherein:

-   -   l is selected from the group consisting of 1, 2, 3, 4 and 5;     -   J₁, J₂, and J₃ are selected from the group consisting of CR₂ and         N;     -   K₁, K₂, and K₃ are each independently selected from the group         consisting of CR₃ and N, with the proviso that K₃ is not N in         Formula IIa when K₁ is CR₂, and K₂ and J₃ are each CH;     -   Q is selected from the group consisting of S, SO, SO₂, O, NR₆,         NR₆—(CR₂₁R₂₂)_(l), NR₆—(CR₂₁R₂₂)_(l)—O, and a substituted or         unsubstituted (C₂₋₅)alkylene, or Q is absent, with the proviso         that Q is not absent in Formula Ia when J₁ is CH, K₁ is N, K₂ is         CR₃, and K₃ is CH or N;     -   X is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl,         and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   Z is selected from the group consisting of NR₁, S, SO, SO₂ and         O, with the provisos that Z is not NH or NC(O)—CH₃ in Formula         IIIa when K₃ is N and J₁, K₁ and K₂ are all C; and Z is not NH         or N—C(O)—O—C(CH₃)₃ when K₃ is N and J₁, K₁ and K₂ are all C;     -   R₁ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted;     -   R₂ is selected from the group consisting of hydrogen, halo,         nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy,         carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino,         sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted;     -   each R₃ is independently selected from the group consisting of         hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy,         heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido,         imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl,         thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl,         sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl,         heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl,         each substituted or unsubstituted, or R₂ and one R₃, or two R₃         are taken together to form a substituted or unsubstituted ring;     -   R₆ is selected from the group consisting of hydrogen, nitro,         thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino,         sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl,         halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl,         aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and     -   R₂₁ and R₂₂ are each independently selected from the group         consisting of hydrogen, halo, hydroxy, alkoxy, carbonyl, amino,         (C₁₋₅)alkylamino, (C₁₋₅)alkyl, halo(C₁₋₅)alkyl,         carbonyl(C₁₋₃)alkyl and amino(C₁₋₅)alkyl, each substituted or         unsubstituted.

In one variation of each of the above embodiments, m is selected from the group consisting of 1 and 2.

In another variation of each of the above embodiments and variations, one R₁₀ is bound at the 5-position of the pyrazole ring to which it is attached to form:

In one variation of each of the above embodiments and variations, X is selected from the group consisting of:

wherein

-   -   R_(7a) and R_(7b) are each independently selected from the group         consisting of hydrogen, cyano, alkyl, hydroxyalkyl, alkoxyalkyl,         aminoalkyl, cycloalkyl, and aryl, each unsubstituted or         substituted, or R_(7a) and R_(7b) are taken together to form         part of an unsubstituted or substituted ring; and     -   R₈ is selected from the group consisting of hydrogen, nitro,         cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl,         amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl,         sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl,         hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl,         hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl,         heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl,         (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl,         carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl,         sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl,         imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and         hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In a particular variation of the above embodiments and variations, R_(7a) and R_(7b) are each independently selected from the group consisting of —H, —CN, —CH₃, —CH₂CH₃, —CH₂CH₂CH₃, —CH(CH₃)₂, —CH₂CH₂CH₂OH, —CH₂CH₂CH₂OCH₃, —CH₂CH₂CH₂OCH₂Ph, —CH₂CH₂CH₂NHBoc, cyclopropyl, cyclobutyl, cyclopentyl, and phenyl, each substituted or unsubstituted.

In another variation of each of the above embodiments and variations, X is selected from the group consisting of pyrazolyl and indazolyl, each substituted or unsubstituted.

In a further variation of each of the above embodiments and variations, Y is selected from the group consisting of phenyl, cyclohexyl, pyridinyl, piperidinyl, hexahydroazepinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl, each unsubstituted or substituted.

In still a further variation of each of the above embodiments and variations, Y is phenyl, unsubstituted or substituted with one or more substituents selected from the group consisting of halo, cyano, amino, alkyl, haloalkyl, alkoxy, alkylcarboxy, alkylsulfinyl, aryl, and aryloxy, each unsubstituted or substituted.

In yet a further variation of each of the above embodiments and variations, Y is selected from the group consisting of:

In another variation of each of the above embodiments and variations, Y is selected from the group consisting of:

In still another variation of each of the above embodiments and variations, Y is selected from the group consisting of carboxyaminoaryl, carboxyaminoheteroaryl, aminocarboxyaryl, aminocarboxyheteroaryl, sulfinylaminoary, sulfinylaminoheteroaryl, aminosulfinylaryl and aminosulfinylheteroaryl, each unsubstituted or substituted.

In a further variation of each of the above embodiments and variations, Y is selected from the group consisting of acetamidophenyl and cyclopropylcarboxyaminophenyl, each substituted or unsubstituted.

In yet another variation of each of the above embodiments and variations, Y is substituted with a substituent selected from the group consisting of amino, alkylamino, alkyl, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy and heterocycloalkyloxy, each unsubstituted or substituted.

In still a further variation of each of the above embodiments and variations, Q is selected from the group consisting of S, SO, SO₂, O and NR₆, or Q is absent. In another variation, Q is S. In yet another variation of each of the above embodiments and variations, Q is N. In a further variation of each of the above embodiments and variations, Q is absent.

In yet a further variation of each of the above embodiments and variations, R₁ is selected from the group consisting of H and a substituted or unsubstituted C₁₋₄ alkyl.

In another variation of each of the above embodiments and variations, at least one of L₁, L₂, L₃, L₄, and L₅ is NR₆. In still another variation of each of the above embodiments and variations, at least two of L₁, L₂, L₃, L₄, and L₅ are NR₆. In yet another variation of each of the above embodiments and variations, L₃ and L₄ are NR₆.

In a further variation of each of the above embodiments and variations, each R₃ is independently selected from the group consisting of hydrogen, halo, amino, aminocarboxy, alkyl, hydroxyalkyl, aminoalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, each unsubstituted or substituted. Similarly, in a further variation of each of the above embodiments and variations, each R_(3a), R_(3b) and R_(3c) is independently selected from the group consisting of hydrogen, halo, amino, aminocarboxy, alkyl, hydroxyalkyl, aminoalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, each unsubstituted or substituted.

In another variation of each of the above embodiments and variations, R_(3b) is selected from the group consisting of hydrogen, halo, amino, (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, alkoxy(C₁₋₆)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₆)alkyl and aryl, each substituted or unsubstituted. In yet another variation of each of the above embodiments and variations, R_(3b) is selected from the group consisting of methyl, ethyl, isopropyl, cyclopropyl, fluoromethyl, difluoromethyl, methylamino and dimethylamino.

In still a further variation of each of the above embodiments and variations, two R₅ are taken together to from part of a substituted or unsubstituted ring.

In another variation of each of the above embodiments and variations, R₁₀ is selected from the group consisting of hydrogen, (C₁₋₆)alkyl, (C₃₋₁₂)cycloalkyl and heteroaryl, each substituted or unsubstituted. In yet another variation of each of the above embodiments and variations, R₁₀ is selected from the group consisting of (C₁₋₄)alkyl and (C₃₋₁₀)cycloalkyl, each substituted or unsubstituted. In yet another variation of each of the above embodiments and variations, R₁₀ is selected from the group consisting of methyl, ethyl, isopropyl and cyclopropyl, each substituted or unsubstituted. In a further variation of each of the above embodiments and variations, R₁₀ is a substituted or unsubstituted cyclopropyl. In another variation of each of the above embodiments and variations, R₁₀ is selected from the group consisting of —CH₂—NHR₁₇ and —CO₂—NHR₁₇, wherein R₁₇ is selected from the group consisting of hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In another variation of each of the above embodiments and variations, R₁₁ is selected from the group consisting of hydrogen, halo, cyano, alkoxy, amino, imino, sulfonyl, carbonyl, (C₁₋₆)alkyl, hetero(C₃₋₁₂)cycloalkyl and heteroaryl, each substituted or unsubstituted. In a further variation of each of the above embodiments and variations, R₁₁ is —CO—NR₁₂R₁₃, wherein R₁₂ and R₁₃ are each independently selected from the group consisting of hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In yet another variation of each of the above embodiments and variations, R₁₁ is —NH—CO—R₁₄, wherein R₁₄ is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In a further variation of each of the above embodiments and variations, R₁₁ is —NH—SO₂—R₂₀, wherein R₂₀ is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In still another variation of each of the above embodiments and variations, R₁₁ is —SO—R₁₅, wherein R₁₅ is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In yet another variation of each of the above embodiments and variations, R₁₁ is —SO₂—R₁₆, wherein R₁₆ is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In a further variation of each of the above embodiments and variations, R₁₁ is —SO₂—NHR₁₈, wherein R₁₈ is selected from the group consisting of hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In still another variation of each of the above embodiments and variations, R₁₁ is —CH₂—NHR₁₉, wherein R₁₉ is selected from the group consisting of hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.

In a further variation of each of the above embodiments and variations, R₁₁ is selected from the group consisting of —NH—C(O)H, —NH—CO-cyclopropyl, —NH—SO₂—CH₃, —NH—SO₂—CH₂CH₃, —CO—NH—CH₂CH₃, —SO₂—NH—CH₃, —SO₂—NH—CH₂CH₃, —SO₂—NH-cyclopropyl, —SO₂—CH₃ and —SO₂—CH₂CH₃, each substituted or unsubstituted.

In another variation of each of the above embodiments and variations, two R₁₁ are taken together to form a ring selected from the group consisting of:

Particular examples of kinase inhibitors according to the present invention include, but are not limited to:

-   -   2-(3-(ethylsulfonyl)phenyl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   2-(3-(ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-2-(3-(methylsulfonyl)phenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-2-phenylpyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   2-(1-(Ethylsulfonyl)-1H-indol-6-yl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   2-(1-(Ethylsulfonyl)-1H-indol-6-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   2-(3-((dimethylamino)methyl)-1-(ethylsulfonyl)-1H-indol-6-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   2(3-(dimethylamino)methyl-1-(ethylsulfonyl)-1H-indol-6-yl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;         and     -   N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-ylthio)phenyl)acetamide.

Particular examples of kinase inhibitors according to the present invention also include, but are not limited to:

-   -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-phenylimidazo[1,2-f]pyrimidin-5-amine;     -   N-cyclopentyl-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-(piperazin-1-ylmethyl)phenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   4-((3-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methyl)piperazin-2-one;     -   4-((3-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methyl)piperazin-2-one;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-[7-(2,3-dihydro-benzofuran-5-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   N-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-acetamide;     -   3-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-imidazolidine-2,4-dione;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[3-(3-methyl-3H-imidazol-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   N-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-methanesulfonamide;     -   Cyclopropane carboxylic acid         3-[5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide;     -   1-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-imidazolidin-2-one;     -   Cyclopropane carboxylic acid         3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzonitrile;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-p-tolylimidazo[1,2-f]pyrimidin-5-amine;     -   7-(5-chloro-2-methoxyphenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxy-5-methylphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-methoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(pyrimidin-5-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(pyridin-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,4-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,3-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(benzo[d][1,3]dioxol-5-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,6-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,6-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxypyridin-4-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-phenoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-biphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-biphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-biphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-fluorophenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-difluorophenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-methylbenzamide;     -   3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-ethylbenzamide;     -   N-cyclopropyl-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide;     -   N-(2-cyanoethyl)-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide;     -   (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(pyrrolidin-1-yl)methanone;     -   Methyl         3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzoate;     -   (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanol;     -   (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-styrylimidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-7-phenylimidazo[1,2-f]pyrimidin-5-amine;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)acetamide;     -   7-(2-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-o-tolylimidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-m-tolylimidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-(dimethylamino)phenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(1H-indol-5-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(3-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(3-(1H-pyrazol-1-yl)phenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(morpholino)methanone;     -   (4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(morpholino)methanone;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-morpholinophenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-morpholinophenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-(piperidin-1-yl)phenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-((4-methylpiperazin-1-yl)methyl)phenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-{3-[5-(5-Cyclopropyl-2H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-methanesulfonamide;     -   N-{3-[5-(5-Cyclopropyl-2H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-acetamide;     -   N-{3-[5-(5-Methyl-2H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-methanesulfonamide;     -   [7-(3-Ethanesulfonyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-2H-pyrazol-3-yl)-amine;     -   N-{3-[5-(5-Cyclopropyl-2H-pyrazol-3-ylamino)-2-hydroxymethyl-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-methanesulfonamide;     -   (5-Cyclopropyl-2H-pyrazol-3-yl)-[7-(3-ethanesulfonyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   [7-(4-Methyl-piperazin-1-yl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   (5-Methyl-1H-pyrazol-3-yl)-(7-piperidin-1-yl-imidazo[1,2-c]pyrimidin-5-yl)-amine;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-[7-(2,3-dihydro-indol-1-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-[7-(3,4-dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   Ethyl         5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-7-(4-((2,5-dioxoimidazolidin-1-yl)methyl)phenyl)imidazo[1,2-f]pyrimidine-2-carboxylate;     -   Ethyl         5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-7-(4-(pyrrolidine-1-carbonyl)phenyl)imidazo[1,2-f]pyrimidine-2-carboxylate;     -   Ethyl         5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-7-(4-(cyclopropylcarbamoyl)phenyl)imidazo[1,2-f]pyrimidine-2-carboxylate;     -   Cyclopentanecarboxylic acid         3-[5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-phenylimidazo[1,2-f]pyrimidin-5-amine;     -   N-cyclopropyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide;     -   (3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(4-methylpiperazin-1-yl)methanone;     -   (4-aminopiperidin-1-yl)(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanone;     -   3-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-(piperidin-4-yl)benzamide;     -   (3-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(piperazin-1-yl)methanone;     -   (S)-Pyrrolidine-2-carboxylic acid         3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide;     -   N-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-(4-methyl-piperazin-1-ylmethyl)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-methanesulfonamide;     -   [7-(3-Methanesulfonyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-7-(3-ethanesulfonyl-phenyl)-imidazo[1,2-c]pyrimidin-2-yl]-methanol;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-[7-(3-ethanesulfonyl-phenyl)-2-(4-methyl-piperazin-1-ylmethyl)-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   [7-(3-Ethanesulfonyl-phenyl)-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-2-yl]-methanol;     -   [7-(3-Ethanesulfonyl-phenyl)-2-(4-methyl-piperazin-1-ylmethyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-phenylimidazo[1,2-f]pyrimidin-5-amine;     -   N-cyclopropyl-2-(3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)acetamide;     -   7-(3-(ethylsulfonyl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-methylsulfonyl)phenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   2-methoxy-N-methyl-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-yl         amino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   2-methoxy-N-methyl-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-ethyl-N-methyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-ethyl-N-methyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-(3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)cyclopropanesulfonamide;     -   N-Ethyl-2-methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-yl         amino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-(3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)ethanesulfonamide;     -   N-(2-Methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-yl         amino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)cyclopropanesulfonamide;     -   N-(3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanesulfonamide;     -   N-(4-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanesulfonamide;     -   Cyclopropane carboxylic acid         4-fluoro-3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide;     -   Cyclopropane carboxylic acid         4-fluoro-3-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide;     -   5-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-1,3-dihydro-benzoimidazol-2-one;     -   Cyclopropanesulfonic acid         methyl-{3-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-amide;     -   (5-Methyl-1H-pyrazol-3-yl)-(2-methyl-7-pyridin-2-yl-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   [7-(1-Ethanesulfonyl-1H-indol-6-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-(5-methyl-1H-pyrazol-3-yl)-amine;     -   Ethanesulfonic acid         methyl-{3-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-amide;     -   Ethanesulfonic acid         {5-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-1H-indol-7-yl}-amide;     -   N-ethyl-2-methoxy-N-methyl-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-(cyclopropylmethyl)-2-methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-cyclopropyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-ethyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   7-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(isopropoxymethyl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(isopropoxymethyl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(isopropoxymethyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-7-phenyl-2-(trifluoromethyl)imidazo[1,2-f]pyrimidin-5-amine;     -   3-(2-(Chloromethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl0-N-cyclopropylbenzamide;     -   2-Ethyl-7-(3-(ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(3-(ethylsulfonyl)phenyl)-2-isopropyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-ethyl-1H-pyrazol-3-yl)-7-(3-(ethylsulfonyl)phenyl)-2-methylimidazo[1,2-f]pyrimidin-5-amine;     -   N-(methyl-N-(3-(2-methyl-5-(5-methyl-1H-pyrazol-3-yl         amino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)cyclopropanesulfonamide;     -   2-(3-(ethylsulfonyl)phenyl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   2-(3-(ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-2-(3-(methylsulfonyl)phenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-2-phenylpyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   2-(1-(Ethylsulfonyl)-1H-indol-6-yl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   2-(1-(Ethylsulfonyl)-1H-indol-6-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   2-(3-((dimethylamino)methyl)-1-(ethylsulfonyl)-1H-indol-6-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   Cyclobutanecarboxylic acid         3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide;     -   Azetidine-3-carboxylic acid         3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide;     -   [7-(3-Aminomethyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   Cyclopropanesulfonic acid         3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide;     -   (7-{3-[(Cyclopropylmethyl-amino)-methyl]-phenyl}-imidazo[1,2-c]pyrimidin-5-yl)-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [7-(3-Methylaminomethyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   (5-Methyl-1H-pyrazol-3-yl)-[7-(1,2,3,4-tetrahydro-isoquinolin-7-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   [7-(2-Methanesulfonyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [7-(3-Ethanesulfonylmethyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [7-(3-Ethanesulfonylmethyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   {2-Methyl-7-[3-(3-methyl-pyridin-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine;     -   {7-[3-(3,5-Dimethyl-1H-pyrazol-4-yl)-phenyl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine;     -   {2-Methyl-7-[3-(3-methyl-3H-imidazol-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine;     -   (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[3-(1,3,5-trimethyl-1H-pyrazol-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   {7-[3-(3,5-Dimethyl-isoxazol-4-yl)-phenyl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine;     -   {7-[3-(5-Cyclopropyl-3-methyl-1H-pyrazol-4-yl)-phenyl}-2-methyl-imidazo[1,2-c]pyrimidin-5-yl)-(5-methyl-1H-pyrazol-3-yl)-amine;     -   (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[3-(thiazole-2-sulfonyl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   [7-(3-Dimethylaminomethyl-1-ethanesulfonyl-1H-indol-6-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[3-(S)-(pyrrolidine-3-sulfonyl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   {7-[3-(3-Amino-propane-1-sulfonyl)-phenyl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [7-(3-Ethylsulfanyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [7-(3-Ethanesulfinyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   7-(3-(ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-5-amine;     -   N-(5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-2-(2-morpholinoethoxy)phenyl)cyclopropanesulfonamide;     -   4-methyl-5-(3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)thiazol-2-amine;     -   3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-phenylbenzenesulfonamide;     -   (4-hydroxypiperidin-1-yl)(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)methanone;     -   N-isobutyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzamide;     -   N-cyclopentyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzamide;     -   3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(pyrrolidin-3-ylmethyl)benzamide;     -   3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(pyrrolidin-2-ylmethyl)benzamide;     -   N-isopropyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzamide;     -   3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-phenylbenzamide;     -   N-benzyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzamide;     -   3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(thiazol-2-yl)benzenesulfonamide;     -   N-(2-aminoethyl)-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzenesulfonamide;     -   N-ethyl-N-(3-(2-isopropyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)methanesulfonamide;     -   N-isopropyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)-2-(trifluoromethyl)imidazo[1,2-c]pyrimidin-7-yl)benzamide;     -   N-(5-methyl-1H-pyrazol-3-yl)-2,7-diphenylimidazo[1,2-c]pyrimidin-5-amine;     -   N-(4-(2-(hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(3-(2-(hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)methanesulfonamide;     -   [7-(3-Ethanesulfonyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [7-(3-Isopropoxy-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [2-Methyl-7-(3-propoxy-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [7-(3-Ethanesulfonyl-phenyl)-2-imidazol-1-ylmethyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   3-{3-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-propionic         acid methyl ester;     -   3-{3-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-propionic         acid;     -   5-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-thiophene-2-carboxylic         acid cyclopropylamide;     -   [7-(1-Benzyl-1H-pyrazol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-cyclopropyl-1H-pyrazol-3-yl)-amine;     -   [7-(1-Benzyl-1H-pyrazol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   N-{2-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-methanesulfonamide;     -   N-{2-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-acetamide;     -   [7-(1H-Indol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [7-(2-Amino-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   [7-(1-Isobutyl-1H-pyrazol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;     -   4-{4-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzoic         acid methyl ester;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(3-methoxy-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-[2-methyl-7-(1-quinolin-8-ylmethyl-1H-pyrazol-4-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzoic         acid methyl ester;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(4-methanesulfonyl-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(4-methoxy-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(2,3-dimethoxy-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(3,5-dimethoxy-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   [7-(1-Benzo[1,2,5]oxadiazol-5-ylmethyl-1H-pyrazol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-cyclopropyl-1H-pyrazol-3-yl)-amine;     -   2-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzonitrile;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-[2-methyl-7-(1-pyridin-2-ylmethyl-1H-pyrazol-4-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-N-ethyl-benzamide;     -   3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzonitrile;     -   3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-N-thiazol-2-yl-benzamide;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-[2-methyl-7-(1-phenethyl-1H-pyrazol-4-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(4-pyrazol-1-yl-benzyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   2-{4-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzonitrile;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(3-pyrrol-1-yl-benzyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   N-Ethyl-4-{4-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzamide;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(3-nitro-benzyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   (5-Cyclopropyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(2-morpholin-4-yl-ethyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   {7-[1-(3-Amino-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-cyclopropyl-1H-pyrazol-3-yl)-amine;     -   {7-[1-(2,5-Dichloro-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine;     -   {2-Methyl-7-[1-(2-piperidin-1-yl-ethyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine;     -   2-{4-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-yl}-N-phenyl-acetamide;     -   {2-Methyl-7-[1-(1-methyl-2-phenyl-ethyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine;     -   N-(3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-phenyl)-2-methoxy-acetamide;     -   4-Fluoro-2-{4-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzonitrile;     -   (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(2-trifluoromethoxy-benzyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzonitrile;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-p-tolylimidazo[1,2-f]pyrimidin-5-amine;     -   7-(5-chloro-2-methoxyphenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxy-5-methylphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-methoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(pyrimidin-5-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(pyridin-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,4-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,3-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(benzo[d][1,3]dioxol-5-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,6-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,6-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxypyridin-4-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-phenoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-biphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-biphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-biphenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-fluorophenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-difluorophenyl)imidazo[1,2-f]pyrimidin-5-amine;     -   3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-methylbenzamide;     -   3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-ethylbenzamide;     -   N-cyclopropyl-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide;     -   N-(2-cyanoethyl)-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide;     -   (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(pyrrolidin-1-yl)methanone;     -   Methyl         3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzoate;     -   (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanol;     -   N-ethyl-2-methoxy-N-methyl-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-(cyclopropylmethyl)-2-methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-cyclopropyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-ethyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide;     -   N-(2-hydroxyethyl)-2-methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzenesulfonamide;     -   7-(4-methoxy-3-(morpholinosulfonyl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine;     -   7-(4-methoxy-3-(tetrahydro-2H-pyran-4-ylsulfonyl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine;     -   N-(2-(2-(dimethylamino)ethoxy)-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)cyclopropanesulfonamide;     -   N-(2-hydroxyethyl)-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzenesulfonamide;     -   3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide;     -   7-(3-(2-(dimethylamino)ethoxy)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine;     -   2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(pyrrolidin-1-ylsulfonyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine;     -   7-(3-(3-aminopyrrolidin-1-ylsulfonyl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine;     -   3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(3-(pyrrolidin-1-yl)propyl)benzenesulfonamide;     -   3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-p-tolylbenzenesulfonamide;     -   N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(4-methylpiperazin-1-ylsulfonyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine;     -   7-(1-(ethylsulfonyl)-1H-indol-6-yl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine;     -   N-(6-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-1H-indol-3-yl)ethanesulfonamide;     -   (3-(7-phenylimidazo[1,2-c]pyrimidin-5-ylamino)-1H-pyrazol-5-yl)methanol;     -   7-(3-(5-amino-2-methylthiophen-3-yl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine;     -   2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-phenyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5-amine;     -   7-(3-(Ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine;     -   2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(piperazin-1-ylmethyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine;     -   (S)-1-(3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenylsulfonyl)pyrrolidin-3-ol;     -   2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(3-(methylamino)pyrrolidin-1-ylsulfonyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine;     -   2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(piperidin-1-ylmethyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine;     -   N,4-Dimethyl-5-(3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)thiazol-2-amine;     -   2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(piperazin-1-ylsulfonyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine;     -   3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(pyrrolidin-3-yl)benzenesulfonamide;     -   N-Cyclopropyl-2-(3-(7-phenylimidazo[1,2-c]pyrimidin-5-ylamino)-1H-pyrazol-5-yl)acetamide;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(ethoxymethyl)-7-(3-(ethylsulfonyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine;     -   N1-(3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-yl)phenyl)-N-4-ethylsuccinamide;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(1-isopentyl-1H-pyrazol-4-yl)-2-methylimidazo[1,2-c]pyrimidin-5-amine;     -   7-(3-(diethylamino)pyrrolidin-1-yl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine;     -   2(3-(dimethylamino)methyl-1-(ethylsulfonyl)-1H-indol-6-yl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine;     -   7-(4-(dimethylamino)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-7-(pyridin-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   1-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)piperidin-4-ol;     -   7-(azepan-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(isoindolin-2-yl)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-7-phenyl-[1,2,4]triazolo[1,5-f]pyrimidin-5-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-7-(piperidin-1-yl)-[1,2,4]triazolo[1,5-f]pyrimidin-5-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-6-phenylimidazo[1,2-a]pyrazin-8-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-6-(piperidin-1-yl)imidazo[1,2-a]pyrazin-8-amine;     -   N-(5-methyl-1H-pyrazol-3-yl)-7-phenylimidazo[1,5-f]pyrimidin-5-amine;         and     -   N-(5-methyl-1H-pyrazol-3-yl)-7-(piperidin-1-yl)imidazo[1,5-f]pyrimidin-5-amine.

Particular examples of kinase inhibitors according to the present invention also include, but are not limited to:

-   -   N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(2-(piperidin-1-yl)ethyl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(2-(diethylamino)ethyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(2,5-difluorobenzyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(thiophen-2-ylmethyl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(2-chlorophenethyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(3-chlorophenethyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(4-chlorophenethyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-phenethylimidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(3-phenylpropyl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(2-phenoxyethyl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   (R)-2-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylamino)-1-phenylethanol;     -   (S)-2-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylamino)-1-phenylethanol;     -   2-(methyl(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)amino)-1-phenylethanol;     -   (R)-2-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylamino)-4-phenylbutan-1-ol;     -   N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(pyridin-2-ylmethyl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(3-fluorobenzyl)-N⁷-methyl-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(3-chlorobenzyl)-N⁷-methyl-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(3,4-dimethoxybenzyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(2-Methoxy-benzyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)-imidazo[1,2-c]pyrimidine-5,7-diamine;     -   N⁷-(4-Methoxy-benzyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine;     -   N⁷-(1-Benzyl-piperidin-4-yl)-2-methyl-N⁵-(5-methyl-1H-pyrazol-3-yl)-imidazo[1,2-c]pyrimidine-5,7-diamine;     -   N7,2-dimethyl-N-5-(5-methyl-1H-pyrazol-3-yl)-N-7-(1-methylpyrrolidin-3-yl)imidazo[1,2-c]pyrimidine-5,7-diamine;     -   6-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylamino)-1,2-dihydroindazol-3-one;     -   N-(4-(7-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,5-f]pyrimidin-5-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(7-(5-methyl-1H-pyrazol-3-yl         amino)imidazo[1,5-f]pyrimidin-5-ylthio)phenyl)acetamide;     -   N-(4-(7-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-5-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(7-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-5-ylthio)phenyl)acetamide;     -   N-(4-(6-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrazin-8-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(6-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrazin-8-ylthio)phenyl)acetamide;     -   N-(4-(7-(5-methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-5-ylthio)phenyl)cyclopropanecarboxamide;         and     -   N-(4-(7-(5-methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-5-ylthio)phenyl)acetamide.

Further, particular examples of kinase inhibitors according to the present invention include, but are not limited to:

-   -   N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(3-Cyclopropyl-1H-pyrazol-5-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   7-(4-Aminophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(8-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrazin-6-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(8-(5-Methyl-1H-pyrazol-3-yl         amino)imidazo[1,2-a]pyrazin-6-ylthio)phenyl)acetamide;     -   N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)thiophene-2-sulfonamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanesulfonamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)propane-2-sulfonamide;     -   1-amino-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   (R)-2-amino-3-methyl-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)butanamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-methoxyacetamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)picolinamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)morpholine-4-carboxamide;     -   2-methoxyethyl         4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   Ethyl         4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   Isobutyl         4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   Ethyl         4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   {4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl}-carbamic         acid but-2-ynyl ester;     -   {4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl}-carbamic         acid allyl ester;     -   Propyl         4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)pyrrolidine-2-carboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)butyramide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclobutanecarboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)isobutyramide;     -   2-methoxy-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-propoxyacetamide;     -   2-ethoxy-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   2-(allyloxy)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   2-(dimethylamino)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   2-(cyclopropylamino)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   2-(1H-imidazol-1-yl)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-(ethyl(methyl)amino)acetamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-(dimethylamino)acetamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-(cyclopropylamino)acetamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-ethoxyacetamide;     -   2-(ethyl(methyl)amino)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(2-(hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-methoxyacetamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)nicotinamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-methylcyclopropanecarboxamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)pyrrolidine-1-carboxamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-3-methylbutanamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-(methoxymethyl)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)isonicotinamide;     -   6-chloro-N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)nicotinamide;     -   N-(4-(2-(Hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(2-(Hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-dimethylaminomethyl-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl}acetamide;     -   N-(4-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-((4-methylpiperazin-1-yl)methyl)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(5-methyl-1H-pyrazol-3-yl)-7-(o-tolylthio)imidazo[1,2-f]pyrimidin-5-amine;     -   ((5-fluoro-2-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)methanol;     -   7-(3-aminophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   Methyl         3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzoate;     -   3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzoic         acid;     -   Methyl         4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzoate;     -   4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzoic         acid;     -   (E)-methyl         3-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acrylate;     -   3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzamide;     -   7-(2-Amino-4-chlorophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetic         acid;     -   N-cyclopropyl-2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-methyl-2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-ethyl-2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-ethylbenzamide;     -   (4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)(piperazin-1-yl)methanone;     -   N-cyclopropyl-4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzamide;     -   Azetidin-1-yl(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)methanone;     -   4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(pyrrolidin-3-yl)benzamide;     -   4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(piperidin-4-yl)benzamide;     -   4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(piperidin-3-yl)benzamide;     -   4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-methoxybenzamide;     -   4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N′,N′-dimethylbenzohydrazide;     -   4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(2-(dimethylamino)ethyl)benzamide;     -   4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(2-hydroxyethyl)benzamide;     -   (4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)(morpholino)methanone;     -   N-cyclopropyl-4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzamide;     -   N-ethyl-4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzamide;     -   N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-(5-ethyl-1,3,4-oxadiazol-2-yl)phenylthio)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(4-(5-ethyl-1,3,4-oxadiazol-2-yl)phenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(4-(1,3,4-Oxadiazol-2-yl)phenylthio)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(4-(1,3,4-oxadiazol-2-yl)phenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(4-(5-Methyl-1,3,4-oxadiazol-2-yl)phenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   N-(5-Cyclopropyl-1H-pyrazol-3-yl)-7-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenylthio)imidazo[1,2-f]pyrimidin-5-amine;     -   N-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl}-acetamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-((dimethylamino)methyl)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(2-ethyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(2-((dimethylamino)methyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)-2-((methylamino)methyl)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(2-((2-hydroxyethylamino)methyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-{4-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl}-acetamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-(methoxymethyl)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-2-methoxyacetamide;     -   Ethyl         2-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenylamino)-2-oxoacetate;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-yl         amino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)tetrahydrofuran-2-carboxamide;     -   N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)furan-2-carboxamide;     -   (S)-N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)tetrahydrofuran-2-carboxamide;     -   N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)isoxazole-5-carboxamide;     -   5-methyl-N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)isoxazole-3-carboxamide;     -   4-methyl-N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)oxazole-5-carboxamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-5-methylfuran-2-carboxamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-1,5-dimethyl-1H-pyrazole-3-carboxamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide;     -   N1-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-N-2-ethyl-N-2-methyloxalamide;     -   N1-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-N-2-(thiazol-2-yl)oxalamide;     -   N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-ylthio)phenyl)acetamide;     -   N-(4-(5-(5-methyl-1H-1,2,4-triazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)thiophene-2-sulfonamide;     -   N-(4-(5-(5-isopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-isopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(5-(5-ethyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-ethyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(5-(1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-propyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(1H-indazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-(3-hydroxypropyl)-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-(3-methoxypropyl)-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-cyclobutyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-cyclopentyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(3-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(3-fluoro-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(3-chloro-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(3-bromo-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)-2-((4-methylpiperazin-1-yl)methyl)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(2-(aminomethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)-2-(morpholinomethyl)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(3-amino-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(2-amino-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   7-(4-(cyclopropanecarboxamido)phenylthio)-N-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidine-2-carboxamide;     -   6-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-1,2-dihydroindazol-3-one;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-morpholinoacetamide;     -   3-(dimethylamino)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)propanamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-(methylamino)acetamide;     -   N-(2-(dimethylamino)ethyl)-4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzamide;     -   4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(2-morpholinoethyl)benzamide;     -   N-(5-methyl-1H-pyrazol-3-yl)-7-(4-(methylamino)phenylthio)imidazo[1,2-f]pyrimidin-5-amine;     -   7-(4-(cyclopropylmethylamino)phenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine;     -   2-amino-2-methyl-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)propanamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)propionamide;     -   1-amino-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclobutanecarboxamide;     -   1-amino-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopentanecarboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)pyrrolidine-3-carboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-tetrahydro-2H-pyran-4-carboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)piperidine-4-carboxamide;     -   2-amino-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopentanecarboxamide;     -   3-amino-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopentanecarboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)piperidine-2-carboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)piperidine-3-carboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)morpholine-4-carboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)piperazine-1-carboxamide;     -   1-cyclopropyl-3-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)urea;     -   1,1-diethyl-3-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)urea;     -   1-ethyl-3-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)urea;     -   1-isopropyl-3-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)urea;     -   isopropyl         4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   cyclopropyl         4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   cyclobutyl         4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   cyclopentyl         4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   pyrrolidin-3-yl         4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate;     -   2-methyl-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)propane-1-sulfonamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)benzenesulfonamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)thiazole-5-sulfonamide;     -   1-methyl-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-1H-imidazole-5-sulfonamide;     -   N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(1H-indazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(2-amino-5-(5-methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(2-methyl-8-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrazin-6-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(3-methyl-8-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrazin-6-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(3-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(3-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,5-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;     -   N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,5-f]pyrimidin-7-ylthio)phenyl)acetamide;     -   N-(4-(5-(1H-indazol-3-ylamino)imidazo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide;         and     -   N-(4-(3-chloro-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide.

Further, particular examples of kinase inhibitors according to the present invention include, but are not limited to N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yloxy)phenyl)acetamide.

It is noted that the compounds of the present invention may be in the form of a pharmaceutically acceptable salt, biohydrolyzable ester, biohydrolyzable amide, biohydrolyzable carbamate, solvate, hydrate or prodrug thereof. For example, the compound optionally comprises a substituent that is convertible in vivo to a different substituent such as a hydrogen.

It is further noted that the compounds of the present invention may optionally be solely or predominantly in the enol tautomer in its active state. It is further noted that the compound may be present in a mixture of stereoisomers, or the compound comprises a single stereoisomer.

The invention also provides pharmaceutical compositions comprising, as an active ingredient, a compound according to any one of the above embodiments and variations. In addition, the composition may be a solid or liquid formulation adapted for oral administration. In a further variation, the pharmaceutical composition may be a tablet. In yet another variation, the pharmaceutical composition may be a liquid formulation adapted for parenteral administration.

In one embodiment, there is provided the pharmaceutical composition comprising a compound according to any one of the above embodiments and variations wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, and intrathecally.

The invention also provides a kit comprising a compound or composition according to any one of the above embodiments and variations, and instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound. In one variation, the kit comprises the compound or composition in a multiple dose form.

In another embodiment, the present invention provides an article of manufacture comprising a compound or composition according to any one of the above embodiments and variations, and packaging materials. In one variation, the packaging material comprises a container for housing the compound or composition. The container optionally comprises a label indicating a disease state for which the compound or composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the compound or composition. In regard to the above embodiments and variations, the article of manufacture optionally comprises the compound or composition in a multiple dose form.

In another embodiment, the present invention provides a therapeutic method comprising administering a compound or composition according to any one of the above embodiments and variations to a subject.

In yet another embodiment, the present invention provides a method of inhibiting a kinase comprising contacting a kinase with a compound or composition according to any one of the above embodiments and variations.

In still another embodiment, there is provided a method of inhibiting kinase comprising causing a compound or composition according to any one of the above embodiments and variations to be present in a subject in order to inhibit kinase in vivo.

The present invention also provides a method of inhibiting kinase comprising administering a first compound to a subject that is converted in vivo to a second compound wherein the second compound inhibits kinase in vivo, the second compound being a compound according to any one of the above embodiments and variations.

In yet another embodiment, there is provided a method of preventing or treating a disease state for which kinase possesses activity that contributes to the pathology and/or symptomology of the disease state comprising causing a compound or composition according to any one of the above embodiments and variations to be present in a subject in a therapeutically effective amount for the disease state.

The present invention also provides a method of preventing or treating a disease state for which kinase possesses activity that contributes to the pathology and/or symptomology of the disease state comprising administering a first compound to a subject that is converted in vivo to a second compound according to any one of the above embodiments and variations wherein the second compound is present in a subject in a therapeutically effective amount for the disease state.

In addition, there is provided a method of preventing or treating a disease state for which kinase possesses activity that contributes to the pathology and/or symptomology of the disease state comprising administering a compound or composition according to any one of the above embodiments and variations, wherein the compound or composition is present in the subject in a therapeutically effective amount for the disease state.

In each of the above embodiments and variations, the kinase is optionally an Aurora kinase. In particular variations of each of the above embodiments and variations, the kinase is an Aurora-B kinase.

In another embodiment, there is provided a method for treating cancer comprising administering a therapeutically effective amount of a compound or composition of the present invention to a mammalian species in need thereof. In one embodiment, the cancer is selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, non small-cell lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer, gastrointestinal cancer, thyroid cancer and skin cancer.

In another embodiment, there is provided a method for treating inflammation, inflammatory bowel disease, psoriasis, or transplant rejection, comprising administration to a mammalian species in need thereof of a therapeutically effective amount of a compound or composition according to the present invention.

In another embodiment, there is provided a method for preventing or treating amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, Parkinson's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication, comprising administration to a mammalian species in need thereof of a therapeutically effective amount of a compound or composition according to any one of the above embodiments.

In yet another embodiment, there is provided a method for preventing or treating mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment and androgenetic alopecia, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound or composition according to any one of the above embodiments.

In a further embodiment, there is provided a method for preventing or treating dementia related diseases, Alzheimer's Disease and conditions associated with kinases, comprising administration to a mammalian species in need thereof of a therapeutically effective amount of a compound or composition according to any one of the above embodiments. In one particular variation, the dementia related diseases are selected from the group consisting of Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies, predemented states, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and dementia pugilistica.

In another embodiment, there is provided a method for treating arthritis comprising administration to a mammalian species in need thereof of a therapeutically effective amount of a compound or composition according to any one of the above embodiment.

Salts, Hydrates, and Prodrugs of Kinase Inhibitors

It should be recognized that the compounds of the present invention may be present and optionally administered in the form of salts, hydrates and prodrugs that are converted in vivo into the compounds of the present invention. For example, it is within the scope of the present invention to convert the compounds of the present invention into and use them in the form of their pharmaceutically acceptable salts derived from various organic and inorganic acids and bases in accordance with procedures well known in the art.

When the compounds of the present invention possess a free base form, the compounds can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide; other mineral acids and their corresponding salts such as sulfate, nitrate, phosphate, etc.; and alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate; and other organic acids and their corresponding salts such as acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate and ascorbate. Further acid addition salts of the present invention include, but are not limited to: adipate, alginate, arginate, aspartate, bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptaoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-butyrate, lactate, lactobionate, malate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate and phthalate. It should be recognized that the free base forms will typically differ from their respective salt forms somewhat in physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base forms for the purposes of the present invention.

When the compounds of the present invention possess a free acid form, a pharmaceutically acceptable base addition salt can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Examples of such bases are alkali metal hydroxides including potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, e.g. potassium ethanolate and sodium propanolate; and various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N-methylglutamine. Also included are the aluminum salts of the compounds of the present invention. Further base salts of the present invention include, but are not limited to: copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium and zinc salts. Organic base salts include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, e.g., arginine, betaine, caffeine, chloroprocaine, choline, N,N′-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris-(hydroxymethyl)-methylamine (tromethamine). It should be recognized that the free acid forms will typically differ from their respective salt forms somewhat in physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid forms for the purposes of the present invention.

Compounds of the present invention that comprise basic nitrogen-containing groups may be quaternized with such agents as (C₁₋₄) alkyl halides, e.g., methyl, ethyl, iso-propyl and tert-butyl chlorides, bromides and iodides; di (C₁₋₄) alkyl sulfates, e.g., dimethyl, diethyl and diamyl sulfates; (C₁₀₋₁₈) alkyl halides, e.g., decyl, dodecyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and aryl (C₁₋₄) alkyl halides, e.g., benzyl chloride and phenethyl bromide. Such salts permit the preparation of both water-soluble and oil-soluble compounds of the present invention.

N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art. For example, N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0° C. Alternatively, the N-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.

Prodrug derivatives of compounds according to the present invention can be prepared by modifying substituents of compounds of the present invention that are then converted in vivo to a different substituent. It is noted that in many instances, the prodrugs themselves also fall within the scope of the range of compounds according to the present invention. For example, prodrugs can be prepared by reacting a compound with a carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like) or an acylating agent. Further examples of methods of making prodrugs are described in Saulnier et al. (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985.

Protected derivatives of compounds of the present invention can also be made. Examples of techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3^(rd) edition, John Wiley & Sons, Inc. 1999.

Compounds of the present invention may also be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.

A “pharmaceutically acceptable salt”, as used herein, is intended to encompass any compound according to the present invention that is utilized in the form of a salt thereof, especially where the salt confers on the compound improved pharmacokinetic properties as compared to the free form of compound or a different salt form of the compound. The pharmaceutically acceptable salt form may also initially confer desirable pharmacokinetic properties on the compound that it did not previously possess, and may even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body. An example of a pharmacokinetic property that may be favorably affected is the manner in which the compound is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of the compound. While the route of administration of the pharmaceutical composition is important, and various anatomical, physiological and pathological factors can critically affect bioavailability, the solubility of the compound is usually dependent upon the character of the particular salt form thereof, which it utilized. One of skill in the art will appreciate that an aqueous solution of the compound will provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid absorption of the compound.

Preparation of Kinase Inhibitors

Various methods may be developed for synthesizing compounds according to the present invention. Representative methods for synthesizing these compounds are provided in the Examples. It is noted, however, that the compounds of the present invention may also be synthesized by other synthetic routes that others may devise.

It will be readily recognized that certain compounds according to the present invention have atoms with linkages to other atoms that confer a particular stereochemistry to the compound (e.g., chiral centers). It is recognized that synthesis of compounds according to the present invention may result in the creation of mixtures of different stereoisomers (enantiomers, diastereomers). Unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all of the different possible stereoisomers.

Various methods for separating mixtures of different stereoisomers are known in the art. For example, a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds. The diastereomers may then be separated in order to recover the optically pure enantiomers. Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts). Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities. For example, diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility. A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).

Composition Comprising Kinase Inhibitors

A wide variety of compositions and administration methods may be used in conjunction with the kinase inhibitors of the present invention. Such compositions may include, in addition to the kinase inhibitors of the present invention, conventional pharmaceutical excipients, and other conventional, pharmaceutically inactive agents. Additionally, the compositions may include active agents in addition to the kinase inhibitors of the present invention. These additional active agents may include additional compounds according to the invention, and/or one or more other pharmaceutically active agents.

The compositions may be in gaseous, liquid, semi-liquid or solid form, formulated in a manner suitable for the route of administration to be used. For oral administration, capsules and tablets are typically used. For parenteral administration, reconstitution of a lyophilized powder, prepared as described herein, is typically used.

Compositions comprising kinase inhibitors of the present invention may be administered or coadministered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally. The compounds and/or compositions according to the invention may also be administered or coadministered in slow release dosage forms.

The kinase inhibitors and compositions comprising them may be administered or coadministered in any conventional dosage form. Co-administration in the context of this invention is intended to mean the administration of more than one therapeutic agent, one of which includes a kinase inhibitor, in the course of a coordinated treatment to achieve an improved clinical outcome. Such co-administration may also be coextensive, that is, occurring during overlapping periods of time.

Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application may optionally include one or more of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; agents for the adjustment of tonicity such as sodium chloride or dextrose, and agents for adjusting the acidity or alkalinity of the composition, such as alkaline or acidifying agents or buffers like carbonates, bicarbonates, phosphates, hydrochloric acid, and organic acids like acetic and citric acid. Parenteral preparations may optionally be enclosed in ampules, disposable syringes or single or multiple dose vials made of glass, plastic or other suitable material.

When kinase inhibitors according to the present invention exhibit insufficient solubility, methods for solubilizing the compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN, or dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as prodrugs of the compounds may also be used in formulating effective pharmaceutical compositions.

Upon mixing or adding kinase inhibitors according to the present invention to a composition, a solution, suspension, emulsion or the like may be formed. The form of the resulting composition will depend upon a number of factors, including the intended mode of administration, and the solubility of the compound in the selected carrier or vehicle. The effective concentration needed to ameliorate the disease being treated may be empirically determined.

Compositions according to the present invention are optionally provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, dry powders for inhalers, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds, particularly the pharmaceutically acceptable salts, preferably the sodium salts, thereof. The pharmaceutically therapeutically active compounds and derivatives thereof are typically formulated and administered in unit-dosage forms or multiple-dosage forms. Unit-dose forms, as used herein, refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent. Examples of unit-dose forms include ampoules and syringes individually packaged tablet or capsule. Unit-dose forms may be administered in fractions or multiples thereof. A multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form. Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pint or gallons. Hence, multiple dose form is a multiple of unit-doses that are not segregated in packaging.

In addition to one or more kinase inhibitors according to the present invention, the composition may comprise: a diluent such as lactose, sucrose, dicalcium phosphate, or carboxymethylcellulose; a lubricant, such as magnesium stearate, calcium stearate and talc; and a binder such as starch, natural gums, such as gum acaciagelatin, glucose, molasses, polyinylpyrrolidine, celluloses and derivatives thereof, povidone, crospovidones and other such binders known to those of skill in the art. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of auxiliary substances such as wetting agents, emulsifying agents, or solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents. Actual methods of preparing such dosage forms are known in the art, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a sufficient quantity of a kinase inhibitor of the present invention to reduce kinases activity in vivo, thereby treating the disease state of the subject.

Dosage forms or compositions may optionally comprise one or more kinase inhibitors according to the present invention in the range of 0.005% to 100% (weight/weight) with the balance comprising additional substances such as those described herein. For oral administration, a pharmaceutically acceptable composition may optionally comprise any one or more commonly employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, talcum, cellulose derivatives, sodium crosscarmellose, glucose, sucrose, magnesium carbonate, sodium saccharin, talcum. Such compositions include solutions, suspensions, tablets, capsules, powders, dry powders for inhalers and sustained release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others. Methods for preparing these formulations are known to those skilled in the art. The compositions may optionally contain 0.01%-100% (weight/weight) of one or more kinase inhibitors, optionally 0.1-95%, and optionally 1-95%.

Salts, preferably sodium salts, of the kinase inhibitors may be prepared with carriers that protect the compound against rapid elimination from the body, such as time release formulations or coatings. The formulations may further include other active compounds to obtain desired combinations of properties.

Formulations for Oral Administration

Oral pharmaceutical dosage forms may be as a solid, gel or liquid. Examples of solid dosage forms include, but are not limited to tablets, capsules, granules, and bulk powders. More specific examples of oral tablets include compressed, chewable lozenges and tablets that may be enteric-coated, sugar-coated or film-coated. Examples of capsules include hard or soft gelatin capsules. Granules and powders may be provided in non-effervescent or effervescent forms. Each may be combined with other ingredients known to those skilled in the art.

In certain embodiments, kinase inhibitors according to the present invention are provided as solid dosage forms, preferably capsules or tablets. The tablets, pills, capsules, troches and the like may optionally contain one or more of the following ingredients, or compounds of a similar nature: a binder; a diluent; a disintegrating agent; a lubricant; a glidant; a sweetening agent; and a flavoring agent.

Examples of binders that may be used include, but are not limited to, microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, sucrose and starch paste.

Examples of lubricants that may be used include, but are not limited to, talc, starch, magnesium or calcium stearate, lycopodium and stearic acid.

Examples of diluents that may be used include, but are not limited to, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.

Examples of glidants that may be used include, but are not limited to, colloidal silicon dioxide.

Examples of disintegrating agents that may be used include, but are not limited to, crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose.

Examples of coloring agents that may be used include, but are not limited to, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate.

Examples of sweetening agents that may be used include, but are not limited to, sucrose, lactose, mannitol and artificial sweetening agents such as sodium cyclamate and saccharin, and any number of spray-dried flavors.

Examples of flavoring agents that may be used include, but are not limited to, natural flavors extracted from plants such as fruits and synthetic blends of compounds that produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate.

Examples of wetting agents that may be used include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.

Examples of anti-emetic coatings that may be used include, but are not limited to, fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates.

Examples of film coatings that may be used include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate.

If oral administration is desired, the salt of the compound may optionally be provided in a composition that protects it from the acidic environment of the stomach. For example, the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine. The composition may also be formulated in combination with an antacid or other such ingredient.

When the dosage unit form is a capsule, it may optionally additionally comprise a liquid carrier such as a fatty oil. In addition, dosage unit forms may optionally additionally comprise various other materials that modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.

Compounds according to the present invention may also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like. A syrup may optionally comprise, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

The kinase inhibitors of the present invention may also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics. For example, if a compound is used for treating asthma or hypertension, it may be used with other bronchodilators and antihypertensive agents, respectively.

Examples of pharmaceutically acceptable carriers that may be included in tablets comprising kinase inhibitors of the present invention include, but are not limited to binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, and wetting agents. Enteric-coated tablets, because of the enteric-coating, resist the action of stomach acid and dissolve or disintegrate in the neutral or alkaline intestines. Sugar-coated tablets may be compressed tablets to which different layers of pharmaceutically acceptable substances are applied. Film-coated tablets may be compressed tablets that have been coated with polymers or other suitable coating. Multiple compressed tablets may be compressed tablets made by more than one compression cycle utilizing the pharmaceutically acceptable substances previously mentioned. Coloring agents may also be used in tablets. Flavoring and sweetening agents may be used in tablets, and are especially useful in the formation of chewable tablets and lozenges.

Examples of liquid oral dosage forms that may be used include, but are not limited to, aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.

Examples of aqueous solutions that may be used include, but are not limited to, elixirs and syrups. As used herein, elixirs refer to clear, sweetened, hydroalcoholic preparations. Examples of pharmaceutically acceptable carriers that may be used in elixirs include, but are not limited to solvents. Particular examples of solvents that may be used include glycerin, sorbitol, ethyl alcohol and syrup. As used herein, syrups refer to concentrated aqueous solutions of a sugar, for example, sucrose. Syrups may optionally further comprise a preservative.

Emulsions refer to two-phase systems in which one liquid is dispersed in the form of small globules throughout another liquid. Emulsions may optionally be oil-in-water or water-in-oil emulsions. Examples of pharmaceutically acceptable carriers that may be used in emulsions include, but are not limited to non-aqueous liquids, emulsifying agents and preservatives.

Examples of pharmaceutically acceptable substances that may be used in non-effervescent granules, to be reconstituted into a liquid oral dosage form, include diluents, sweeteners and wetting agents.

Examples of pharmaceutically acceptable substances that may be used in effervescent granules, to be reconstituted into a liquid oral dosage form, include organic acids and a source of carbon dioxide.

Coloring and flavoring agents may optionally be used in all of the above dosage forms.

Particular examples of preservatives that may be used include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol.

Particular examples of non-aqueous liquids that may be used in emulsions include mineral oil and cottonseed oil.

Particular examples of emulsifying agents that may be used include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate.

Particular examples of suspending agents that may be used include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia. Diluents include lactose and sucrose. Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as sodium cyclamate and saccharin.

Particular examples of wetting agents that may be used include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.

Particular examples of organic acids that may be used include citric and tartaric acid.

Sources of carbon dioxide that may be used in effervescent compositions include sodium bicarbonate and sodium carbonate. Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof.

Particular examples of flavoring agents that may be used include natural flavors extracted from plants such fruits, and synthetic blends of compounds that produce a pleasant taste sensation.

For a solid dosage form, the solution or suspension, in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule. Such solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. For a liquid dosage form, the solution, e.g., for example, in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g. water, to be easily measured for administration.

Alternatively, liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells. Other useful formulations include those set forth in U.S. Pat. Nos. Re 28,819 and 4,358,603.

Injectables, Solutions, and Emulsions

The present invention is also directed to compositions designed to administer the kinase inhibitors of the present invention by parenteral administration, generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables may be prepared in any conventional form, for example as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.

Examples of excipients that may be used in conjunction with injectables according to the present invention include, but are not limited to water, saline, dextrose, glycerol or ethanol. The injectable compositions may also optionally comprise minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins. Implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained (see, e.g., U.S. Pat. No. 3,710,795) is also contemplated herein. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.

Parenteral administration of the formulations includes intravenous, subcutaneous and intramuscular administrations. Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as the lyophilized powders described herein, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or nonaqueous.

When administered intravenously, examples of suitable carriers include, but are not limited to physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.

Examples of pharmaceutically acceptable carriers that may optionally be used in parenteral preparations include, but are not limited to aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.

Examples of aqueous vehicles that may optionally be used include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.

Examples of nonaqueous parenteral vehicles that may optionally be used include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil.

Antimicrobial agents in bacteriostatic or fungistatic concentrations may be added to parenteral preparations, particularly when the preparations are packaged in multiple-dose containers and thus designed to be stored and multiple aliquots to be removed. Examples of antimicrobial agents that may be used include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.

Examples of isotonic agents that may be used include sodium chloride and dextrose. Examples of buffers that may be used include phosphate and citrate. Examples of antioxidants that may be used include sodium bisulfate. Examples of local anesthetics that may be used include procaine hydrochloride. Examples of suspending and dispersing agents that may be used include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Examples of emulsifying agents that may be used include Polysorbate 80 (TWEEN 80). A sequestering or chelating agent of metal ions include EDTA.

Pharmaceutical carriers may also optionally include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.

The concentration of a kinase inhibitor in the parenteral formulation may be adjusted so that an injection administers a pharmaceutically effective amount sufficient to produce the desired pharmacological effect. The exact concentration of a kinase inhibitor and/or dosage to be used will ultimately depend on the age, weight and condition of the patient or animal as is known in the art.

Unit-dose parenteral preparations may be packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration should be sterile, as is know and practiced in the art.

Injectables may be designed for local and systemic administration. Typically a therapeutically effective dosage is formulated to contain a concentration of at least about 0.1% w/w up to about 90% w/w or more, preferably more than 1% w/w of the kinase inhibitor to the treated tissue(s). The kinase inhibitor may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment will be a function of the location of where the composition is parenterally administered, the carrier and other variables that may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the age of the individual treated. It is to be further understood that for any particular subject, specific dosage regimens may need to be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations. Hence, the concentration ranges set forth herein are intended to be exemplary and are not intended to limit the scope or practice of the claimed formulations.

The kinase inhibitor may optionally be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug. The form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle. The effective concentration is sufficient for ameliorating the symptoms of the disease state and may be empirically determined.

Lyophilized Powders

The kinase inhibitors of the present invention may also be prepared as lyophilized powders, which can be reconstituted for administration as solutions, emulsions and other mixtures. The lyophilized powders may also be formulated as solids or gels.

Sterile, lyophilized powder may be prepared by dissolving the compound in a sodium phosphate buffer solution containing dextrose or other suitable excipient. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. Briefly, the lyophilized powder may optionally be prepared by dissolving dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent, about 1-20%, preferably about 5 to 15%, in a suitable buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, typically, about neutral pH. Then, a kinase inhibitor is added to the resulting mixture, preferably above room temperature, more preferably at about 30-35° C., and stirred until it dissolves. The resulting mixture is diluted by adding more buffer to a desired concentration. The resulting mixture is sterile filtered or treated to remove particulates and to insure sterility, and apportioned into vials for lyophilization. Each vial may contain a single dosage or multiple dosages of the kinase inhibitor.

Topical Administration

The kinase inhibitors of the present invention may also be administered as topical mixtures. Topical mixtures may be used for local and systemic administration. The resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.

The kinase inhibitors may be formulated as aerosols for topical application, such as by inhalation (see, U.S. Pat. Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the formulation will typically have diameters of less than 50 microns, preferably less than 10 microns.

The kinase inhibitors may also be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the kinase inhibitor alone or in combination with other pharmaceutically acceptable excipients can also be administered.

Formulations for Other Routes of Administrations

Depending upon the disease state being treated, other routes of administration, such as topical application, transdermal patches, and rectal administration, may also be used. For example, pharmaceutical dosage forms for rectal administration are rectal suppositories, capsules and tablets for systemic effect. Rectal suppositories are used herein mean solid bodies for insertion into the rectum that melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients. Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax, (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used. Agents to raise the melting point of suppositories include spermaceti and wax. Rectal suppositories may be prepared either by the compressed method or by molding. The typical weight of a rectal suppository is about 2 to 3 gm. Tablets and capsules for rectal administration may be manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.

Examples of Formulations

The following are particular examples of oral, intravenous and tablet formulations that may optionally be used with compounds of the present invention. It is noted that these formulations may be varied depending on the particular compound being used and the indication for which the formulation is going to be used.

ORAL FORMULATION Compound of the Present Invention 10-100 mg Citric Acid Monohydrate 105 mg Sodium Hydroxide 18 mg Flavoring Water q.s. to 100 mL INTRAVENOUS FORMULATION Compound of the Present Invention 0.1-10 mg Dextrose Monohydrate q.s. to make isotonic Citric Acid Monohydrate 1.05 mg Sodium Hydroxide 0.18 mg Water for Injection q.s. to 1.0 mL TABLET FORMULATION Compound of the Present Invention  1% Microcrystalline Cellulose 73% Stearic Acid 25% Colloidal Silica  1%. Kits Comprising Kinase Inhibitors

The invention is also directed to kits and other articles of manufacture for treating diseases associated with kinases. It is noted that diseases are intended to cover all conditions for which the kinases possesses activity that contributes to the pathology and/or symptomology of the condition.

In one embodiment, a kit is provided that comprises a composition comprising at least one kinase inhibitor of the present invention in combination with instructions. The instructions may indicate the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also comprise packaging materials. The packaging material may comprise a container for housing the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.

In another embodiment, an article of manufacture is provided that comprises a composition comprising at least one kinase inhibitor of the present invention in combination with packaging materials. The packaging material may comprise a container for housing the composition. The container may optionally comprise a label indicating the disease state for which the composition is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition. The kit may also optionally comprise additional components, such as syringes for administration of the composition. The kit may comprise the composition in single or multiple dose forms.

It is noted that the packaging material used in kits and articles of manufacture according to the present invention may form a plurality of divided containers such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a “refill” of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container that is employed will depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle that is in turn contained within a box. Typically the kit includes directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral, topical, transdermal and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.

One particular example of a kit according to the present invention is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.

Another specific embodiment of a kit is a dispenser designed to dispense the daily doses one at a time in the order of their intended use. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter that indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.

EXAMPLES

1. Preparation of Kinase Inhibitors

Various methods may be developed for synthesizing compounds according to the present invention. Representative methods for synthesizing these compounds are provided in the Examples. It is noted, however, that the compounds of the present invention may also be synthesized by other synthetic routes that others may devise.

It will be readily recognized that certain compounds according to the present invention have atoms with linkages to other atoms that confer a particular stereochemistry to the compound (e.g., chiral centers). It is recognized that synthesis of compounds according to the present invention may result in the creation of mixtures of different stereoisomers (enantiomers, diastereomers). Unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all of the different possible stereoisomers.

Various methods for separating mixtures of different stereoisomers are known in the art. For example, a racemic mixture of a compound may be reacted with an optically active resolving agent to form a pair of diastereoisomeric compounds. The diastereomers may then be separated in order to recover the optically pure enantiomers. Dissociable complexes may also be used to resolve enantiomers (e.g., crystalline diastereoisomeric salts). Diastereomers typically have sufficiently distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) that they can be readily separated by taking advantage of these dissimilarities. For example, diastereomers can typically be separated by chromatography or by separation/resolution techniques based upon differences in solubility. A more detailed description of techniques that can be used to resolve stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).

Compounds according to the present invention can also be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds are set forth in the definitions section of this Application. Alternatively, the salt forms of the compounds can be prepared using salts of the starting materials or intermediates.

The free acid or free base forms of the compounds can be prepared from the corresponding base addition salt or acid addition salt form. For example, a compound in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid (e.g., hydrochloric acid, etc).

The N-oxides of compounds according to the present invention can be prepared by methods known to those of ordinary skill in the art. For example, N-oxides can be prepared by treating an unoxidized form of the compound with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0° C. Alternatively, the N-oxides of the compounds can be prepared from the N-oxide of an appropriate starting material.

Compounds in an unoxidized form can be prepared from N-oxides of compounds by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80° C.

Prodrug derivatives of the compounds can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al. (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985). For example, appropriate prodrugs can be prepared by reacting a non-derivatized compound with a suitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like).

Protected derivatives of the compounds can be made by methods known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3^(rd) edition, John Wiley & Sons, Inc. 1999.

Compounds according to the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran or methanol.

Compounds according to the present invention can also be prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diastereomeric derivatives of compounds, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, preferably, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).

As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or thee-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification:

g (grams); mg (milligrams); L (liters); mL (milliliters); μL (microliters); psi (pounds per square inch); M (molar); mM (millimolar); i.v. (intravenous); Hz (Hertz); MHz (megahertz); mol (moles); mmol (millimoles); RT (ambient temperature); min (minutes); h (hours); mp (melting point); TLC (thin layer chromatography); Tr (retention time); RP (reverse phase); MeOH (methanol); i-PrOH (isopropanol); TEA (triethylamine); TFA (trifluoroacetic acid); TFAA (trifluoroacetic anhydride); THF (tetrahydrofuran); DMSO (dimethylsulfoxide); EtOAc (ethyl acetate); DME (1,2-dimethoxyethane); DCM (dichloromethane); DCE (dichloroethane); DMF (N,N-dimethylformamide); DMPU (N,N′-dimethylpropyleneurea); CDI (1,1-carbonyldiimidazole); IBCF (isobutyl chloroformate); HOAc (acetic acid); HOSu (N-hydroxysuccinimide); HOBT (1- hydroxybenzotriazole); Et₂O (diethyl ether); EDCI (ethylcarbodiimide hydrochloride); BOC (tert-butyloxycarbonyl); FMOC (9- fluorenylmethoxycarbonyl); DCC (dicyclohexylcarbodiimide); CBZ (benzyloxycarbonyl); Ac (acetyl); atm (atmosphere); TMSE (2-(trimethylsilyl)ethyl); TMS (trimethylsilyl); TIPS (triisopropylsilyl); TBS (t-butyldimethylsilyl); DMAP (4-dimethylaminopyridine); Me (methyl); OMe (methoxy); Et (ethyl); Et (ethyl); tBu (tert-butyl); HPLC (high pressure liquid chromatography); BOP (bis(2-oxo-3- oxazolidinyl)phosphinic chloride); TBAF (tetra-n-butylammonium fluoride); mCPBA (meta-chloroperbenzoic acid.

All references to ether or Et₂O are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in ° C. (degrees Centigrade). All reactions conducted under an inert atmosphere at RT unless otherwise noted.

¹H NMR spectra were recorded on a Bruker Avance 400. Chemical shifts are expressed in parts per million (ppm). Coupling constants are in units of Hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad).

Low-resolution mass spectra (MS) and compound purity data were acquired on a Waters ZQ LC/MS single quadrupole system equipped with electrospray ionization (ESI) source, UV detector (220 and 254 nm), and evaporative light scattering detector (ELSD). Thin-layer chromatography was performed on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light, 5% ethanolic phosphomolybdic acid, Ninhydrin or p-anisaldehyde solution. Flash column chromatography was performed on silica gel (230-400 mesh, Merck).

The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as the Aldrich Chemical Company (Milwaukee, Wis.), Bachem (Torrance, Calif.), Sigma (St. Louis, Mo.), or may be prepared by methods well known to a person of ordinary skill in the art, following procedures described in such standard references as Fieser and Fieser's Reagents for Organic Synthesis, vols. 1-17, John Wiley and Sons, New York, N.Y., 1991; Rodd's Chemistry of Carbon Compounds, vols. 1-5 and supps., Elsevier Science Publishers, 1989; Organic Reactions, vols. 1-40, John Wiley and Sons, New York, N.Y., 1991; March J.: Advanced Organic Chemistry, 4th ed., John Wiley and Sons, New York, N.Y.; and Larock: Comprehensive Organic Transformations, VCH Publishers, New York, 1989.

The entire disclosure of all documents cited throughout this application are incorporated herein by reference.

2. Synthetic Schemes for Kinase Inhibitors of the Present Invention

Kinase inhibitors according to the present invention may be synthesized according to the reaction schemes shown below. Other reaction schemes could be readily devised by those skilled in the art. It should also be appreciated that a variety of different solvents, temperatures and other reaction conditions can be varied to optimize the yields of the reactions.

In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T. W. Greene and P. G. M. Wuts in “Protective Groups in Organic Chemistry” John Wiley and Sons, 1991.

Kinase inhibitors according to the present invention may be synthesized according to the reaction scheme shown below. Other reaction schemes could be readily devised by those skilled in the art. It should also be appreciated that a variety of different solvents, temperatures and other reaction conditions can be varied to optimize the yields of the reactions.

In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T. W. Greene and P. G. M. Wuts in “Protective Groups in Organic Chemistry” John Wiley and Sons, 1991.

Experimental Methods

A general synthetic route for producing compounds of the present invention is shown in Scheme 1. Cyclisation of Compound A with an aldehyde provides Compound B which, upon hydrolysis, produces Compound C. Halogenation gives Compound D. Compound D is then reacted with Compound E to produce Compound F. Microwave promoted addition of Compound G affords Compound H.

A synthetic route for producing other compounds of the present invention is shown in Scheme 2. Condensation of Compound I with hydrazine provides Compound J, which is then cyclized with formic acid to produce Compound K. Hydrolysis gives Compound L which, upon POCl₃ treatment, gives Compound M. Pyrazole displacement gives Compound O and microwave promoted addition of Compound G affords Compound Q.

A synthetic route for producing other compounds of the present invention is shown in Scheme 3. Bromination of Compound R with N-bromosuccinimide provides Compound S, which is cyclized with chloroacetaldehyde to form Compound T. Addition of pyrazole gives Compound V. Reaction with Compound G gives Compound X of the present invention.

A synthetic route for producing other compounds of the present invention is shown in Scheme 4. Reaction of Compound AA (Ann. N.Y. Acad. Sci., 1975, 255, 166-175) with compound E provides Compound AB, which is then reacted with Compound G to give Compound AC of the present invention.

A synthetic route for producing other compounds of the present invention is shown in Scheme 5. Reaction of Compound BA (J. Heterocyclic Chemistry, 1986, 23, 981-987) with Compound E provides Compound BB, which is then reacted with Compound G to give Compound BC of the present invention.

A synthetic route for producing other compounds of the present invention is shown in Scheme 6. 5,7-Dichloro-imidazo[1,2-c]pyrimidine (10 mol) may be dissolved in DMF and treated with solid K₂CO₃ (50 mol). The reaction may be stirred at 50-200° C. for 0-3 hours and then concentrated in vacuo. Product may be precipitated by adding water. Resulting solid may then be filtered and dried under vacuo to provide Compound F.

Reaction of Compound F (see Scheme 1) with Compound CA provides Compound CB. For example, Compound F (0.12 mol) and an amine (1.2 mol) may be dissolved in DMF (0.3 mL). This solution may then be heated at between 150-200° C. for 1-25 minutes using a microwave reactor. Purification by preparative HPLC may afford the product as a solid. Alternatively, Suzuki coupling of Compound F with Compound CC gives Compound CD of the present invention.

Additional compounds of the present invention can be prepared in an analogous manner using Compounds O, V, AB and BB in place of Compound F.

A synthetic route for producing other compounds of the present invention is shown in Scheme 7. Compound DA (9.5 mol) and a pyrrazole (10.5 mol) may be dissolved in ethanol (20 mL). This solution may then be heated at 30-75° C. for 1-90 minutes. Reaction mixture may be cooled to room temperature and resulting solid may be filtered and washed with small amount of alcohol then dried in vacuo to provide Compound DB.

Compound DB (1.66 mol) in anhydrous THF (3 mL) may be cooled to −20° C. under N₂. Solution of LiAlH₄ in THF (2.65 mol) may be added dropwise. This mixture may then be maintained at about 0° C. for 1-2 hours. The reaction mixture may be quenched with water (0.75 mL) and 1N NaOH (0.25 mL). Diluted with organic solvent such as ethyl acetate and resulting salts may be filtered off. The filtrate then be transferred to a seperatory funnel and washed with water and brine, and then dried (MgSO₄) and concentrated in vacuo to provide Compound DC.

Compound DC (0.64 mol), a boronic acid (0.96 mol) and Pd (PPh₃)₄ (0.32 mol) may be taken up in dioxane (3 mL), and saturated K₂CO₃ (1.5 mL) added. This solution may then be heated at 120-180° C. for 1-30 minutes using a microwave reactor. If a solid is observed upon cooling, it may be filtered. Filtrate may then be further purified by preparative HPLC to provide Compound DD.

Chlorination: Compound DD (0.25 mol) may be treated with thionyl chloride (0.6 mL). Reaction mixture may be stirred at room temperature for 0-60 minutes, and then concentrated in vacuo to provide Compound DE.

Compound DE (0.25 mol) in dimethylformamide (0.5 mL) may be treated with excess amine. This solution may be stirred at room temperature for 0-60 minutes. Purification by preparative HPLC may afford the product, Compound DF, as a solid.

A synthetic route for producing other compounds of the present invention is shown in Scheme 8. Displacement of the carboxylic acid of Compound EA with various amines in the presence of the coupling agents hydroxybenzotriazole and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride under basic conditions provides Compound EB.

A synthetic route for producing other compounds of the present invention is shown in Scheme 9. Microwave displacement of the chlorine atom of Compound F with 4-mercaptobenzoic acid provides Compound FB. This is then reacted with various amines using hydroxybenzotriazole and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride under basic conditions at room temperature to produce Compound FC. In reactions which showed little product, hydroxybenzotriazole and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride were replaced by 2 equivalents of PYBOP.

A synthetic route for producing other compounds of the present invention is shown in Scheme 10. Microwave condensation of Compound GA with triethyl orthopropionate provides HB, which is then cyclized in a microwave reactor with formic acid in dioxane to produce Compound GC. Removal of the trityl group with triethyl silane and trifluoroacetic acid gives Compound GD. Coupling to pyrazole linked imidazopyrimidine chloride, F, gives the title compound Compound GE.

A synthetic route for producing other compounds of the present invention is shown in Scheme 11. An ethyl 7-chloro-5-(1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidine-2-carboxylate (3.59 g, 10.4 ml 1 eq) is dissolved in anhydrous THF under nitrogen at 0° C. 1.0M lithium aluminum hydride in THF (15.5 ml, 15.5 mmol, 1.5 eq) is added dropwise. Upon completion of addition, the solution is stirred for 2 hours. The reaction can be seen to be complete by LCMS. Sodium sulfate decahydrate is slowly added until bubbling stopps and the reaction mixture is filtered. The solid is triturated in 20% methanol in methylene chloride and filtered. This can be repeated a further two times. The solvent is removed in vacuo and the product purified by flash chromatography.

The (7-chloro-5-(1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-2-yl)methanol (928 mg, 30.5 mmol, 1 eq), an N-(4-mercaptophenyl)acetamide (1.02 g, 61 mmol, 2 eq) and potassium carbonate (421 mg, 30.5 mmol, 1 eq) are dissolved in DMF. The mixture is placed in a microwave reactor at 160° C. for 15 minutes. LCMS can be used to confirm the product. The solvent can be evaporated and the residue purified by flash chromatography.

The N-(4-(5-(1H-pyrazol-3-ylamino)-2-(hydroxymethyl)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide (50 mg, 0.11 mmol, 1 eq) and 2.0M methylamine in THF (1 ml, 22 mmol, 180 eq) are mixed in DMF and stirred at room temperature. The reaction can be followed by LCMS. Upon completion, the reaction mixture can be evaporated and the residue purified by high-performance liquid chromatography.

A synthetic route for producing other compounds of the present invention is shown in Scheme 12. A mixture of a (7-Chloro-imidazo[1,2-c]pyrimidin-5-yl)-(1H-pyrazol-3-yl)-amine (125 mg, 0.46 mmol), an N-(4-Hydroxy-phenyl)-acetamide (689 mg, 4.56 mmol) and K₂CO₃ (630 mg) are mixed in DMF (1 ml) and heated at 200° C. in a microwave for 15 minutes. The reaction mixture can then be purified with HPLC.

An alternative method for producing Compound B (R_(x)=Me) of the present invention is shown in Scheme 13. Cyclisation of Compound A with chloroacetylchloride provides Compound B (R_(x)═—CH₂Cl), which upon hydrogenation produces Compound B (R_(x)=Me).

An alternative method for producing Compound CD (R_(x)=Me) of the present invention is shown in Scheme 14. Reaction of Compound A with amino alcohol followed by treatment with methane sulfonylchloride provides Compound B (R_(x)=Me), which upon hydrolysis produces Compound C (R_(x)=Me). Halogenation gives Compound D (R_(x)=Me). Compound D (R_(x)=Me) is then reacted with Compound E to produce Compound F (R_(x)=Me). Suzuki coupling of Compound F (R_(x)=Me) with Compound CC gives Compound CD (R_(i)=Me), which upon oxidation provides Compound CD (R_(x)=Me).

A synthetic route for producing other compounds of the present invention is shown in Scheme 15. Reaction of Compound JA with DMF and POCl₃ provides Compound JB, which is then treated with NH₂OSO₃H in presence of KOH to produce Compound JC. Hydrolysis gives Compound JD. Cyclization of Compound JD with the appropriate imidate provides Compound JE. Treatment of Compound JE with POCl₃, gives Compound JF, and pyrazole displacement affords Compound IG.

A synthetic route for producing still other compounds of the present invention is shown in Scheme 16. Cyclization of Compound KD with CDI provides Compound KH, which is then treated with (CF₃SO₂)₂O to produce Compound KI. Pyrazole displacement gives Compound KJ. Suzuki coupling of Compound KJ with the appropriate boronic acid affords Compound KK. Alternatively, displacement of the OTf group on Compound KJ with the appropriate thiol affords Compound KL.

For example, the above reaction schemes, and variations thereof, can be used to prepare the following:

N-(4-(5-(5-methyl-1H-1,2,4-triazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(5-isopropyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(5-ethyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(1H-pyrazol-3-ylamino)imidazo[1,2- f]pyrimidin-7-ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(1H-indazol-3-ylamino)imidazo[1,2- f]pyrimidin-7-ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(5-cyclopropyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)thiophene-2-sulfonamide

N-(4-(5-(5-isopropyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)acetamide

N-(4-(5-(5-ethyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)acetamide

N-(4-(5-(5-propyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(5-(3-hydroxypropyl)-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(5-(3-methoxypropyl)-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(5-cyclopentyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(3-fluoro-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(3-bromo-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(2-(aminomethyl)-5-(5-methyl-1H- pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin- 7-ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(5-cyclobutyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(3-methyl-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(3-chloro-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)-2- ((4-methylpiperazin-1-yl)methyl)imidazo[1,2- f]pyrimidin-7-ylthio)phenyl) cyclopropane carboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)-2- (morpholinomethyl)imidazo[1,2-f]pyrimidin- 7-ylthio)phenyl)cyclopropane carboxamide

N-(4-(3-amino-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

7-(4-(cyclopropanecarboxamido)phenylthio)- N-methyl-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidine-2-carboxamide

N-(5-methyl-1H-pyrazol-3-yl)-7-(pyridin-3- yl)imidazo[1,2-f]pyrimidin-5-amine

7-(azepan-1-yl)-N-(5-methyl-1H-pyrazol-3- yl)imidazo[1,2-f]pyrimidin-5-amine

N-(4-(2-amino-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

7-(4-(dimethylamino)phenyl)-N-(5-methyl- 1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

1-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7-yl)piperidin-4-ol

7-(isoindolin-2-yl)-N-(5-methyl-1H-pyrazol- 3-yl)imidazo[1,2-f]pyrimidin-5-amine

7-(3,4-dihydroisoquinolin-2(1H)-yl)-N-(5- methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

6-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylamino)-1,2-dihydroindazol-3-one

3-(dimethylamino)-N-(4-(5-(5-methyl-1H- pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin- 7-ylthio)phenyl)propanamide

N-(2-(dimethylamino)ethyl)-4-(5-(5-methyl- 1H-pyrazol-3-ylamino)imidazo[1,2- f]yrimidin-7-ylthio)benzamide

N-(5-methyl-1H-pyrazol-3-yl)-7-(4- (methylamino)phenylthio)imidazo[1,2- f]pyrimidin-5-amine

6-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)- 1,2-dihydroindazol-3-one

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)-2-morpholinoacetamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)-2-(methylamino)acetamide

4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)- N-(2-morpholinoethyl)benzamide

7-(4-(cyclopropylmethylamino)phenylthio)- N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2- f]pyrimidin-5-amine

2-amino-2-methyl-N-(4-(5-(5-methyl-1H- pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin- 7-ylthio)phenyl)propanamide

1-amino-N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclobutanecarboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)pyrrolidine-3-carboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)piperidine-4-carboxamide

3-amino-N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopentanecarboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)propionamide

1-amino-N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopentanecarboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)-tetrahydro-2H-pyran-4-carboxamide

2-amino-N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)cyclopentanecarboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)piperidine-2-carboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)piperidine-3-carboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)piperazine-1-carboxamide

1,1-diethyl-3-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)urea

1-isopropyl-3-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)urea

cyclopropyl 4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenylcarbamate

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)morpholine-4-carboxamide

1-cyclopropyl-3-(4-(5-(5-methyl-1H-pyrazol- 3-ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)urea

1-ethyl-3-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)urea

isopropyl 4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenylcarbamate

cyclobutyl 4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenylcarbamate

cyclopentyl 4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenylcarbamate

2-methyl-N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)propane-1-sulfonamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)thiazole-5-sulfonamide

N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3- ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7- ylthio)phenyl)acetamide

N-(5-methyl-1H-pyrazol-3-yl)-7-phenyl- [1,2,4]triazolo[1,5-f]pyrimidin-5-amine

pyrrolidin-3-yl 4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenylcarbamate

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)benzenesulfonamide

1-methyl-N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-7- ylthio)phenyl)-1H-imidazole-5-sulfonamide

N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3- ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(5-methyl-1H-pyrazol-3-yl)-7-(piperidin-1- yl)-[1,2,4]triazolo[1,5-f]pyrimidin-5-amine

N-(4-(5-(1H-indazol-3-ylamino)- [1,2,4]triazolo[1,5-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(5-methyl-1H-pyrazol-3-yl)-6- phenylimidazo[1,2-a]pyrazin-8-amine

N-(4-(2-methyl-8-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-a]pyrazin-6- ylthio)phenyl)cyclopropane carboxamide

N-(4-(3-methyl-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,5-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,5-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(2-amino-5-(5-methyl-1H-pyrazol-3- ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(5-methyl-1H-pyrazol-3-yl)-6-(piperidin-1- yl)imidazo[1,2-a]pyrazin-8-amine

N-(4-(3-methyl-8-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-a]pyrazin-6- ylthio)phenyl)cyclopropane carboxamide

N-(4-(3-methyl-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,5-f]pyrimidin-7- ylthio)phenyl)acetamide

N-(4-(5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,5-f]pyrimidin-7- ylthio)phenyl)acetamide

N-(5-methyl-1H-pyrazol-3-yl)-7- phenylimidazo[1,5-f]pyrimidin-5-amine

N-(4-(5-(1H-indazol-3-ylamino)imidazo[1,5- f]pyrimidin-7-ylthio)phenyl)cyclopropane carboxamide

N-(4-(7-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,5-f]pyrimidin-5- ylthio)phenyl)cyclopropane carboxamide

N-(4-(7-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-5- ylthio)phenyl)cyclopropane carboxamide

N-(5-methyl-1H-pyrazol-3-yl)-7-(piperidin-1- yl)imidazo[1,5-f]pyrimidin-5-amine

N-(4-(3-chloro-5-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,5-f]pyrimidin-7- ylthio)phenyl)cyclopropane carboxamide

N-(4-(7-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,5-f]pyrimidin-5- ylthio)phenyl)acetamide

N-(4-(7-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-f]pyrimidin-5- ylthio)phenyl)acetamide

N-(4-(6-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-a]pyrazin-8- ylthio)phenyl)cyclopropane carboxamide

N-(4-(7-(5-methyl-1H-pyrazol-3-ylamino)- [1,2,4]triazolo[1,5-f]pyrimidin-5- ylthio)phenyl)cyclopropane carboxamide

N-(4-(6-(5-methyl-1H-pyrazol-3- ylamino)imidazo[1,2-a]pyrazin-8- ylthio)phenyl)acetamide

N-(4-(7-(5-methyl-1H-pyrazol-3-ylamino)- [1,2,4]triazolo[1,5-f]pyrimidin-5- ylthio)phenyl)acetamide

In each of the above reaction procedures or schemes, the various substituents may be selected from among the various substituents otherwise taught herein.

Descriptions of the syntheses of particular compounds according to the present invention based on the above reaction scheme are set forth herein.

3. Examples of Kinase Inhibitors

The present invention is further exemplified, but not limited by, the following examples that describe the synthesis of particular compounds according to the invention.

Example 1 N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

Referring to Scheme 1, 4-amino-6-chloro-2-(methylthio)-pyrimidine (1.0 g, 5.7 mmol) and chloroacetaldehyde (2 ml, 14.2 mmol) were mixed in DMF (5 ml). The solution was stirred overnight at 100° C. DMF was removed in vacuo and the residue was purified by flash chromatography with 1:10 MeOH:DCM to leave 7-chloro-5-(methylthio)imidazo[1,2-f]pyrimidine as a brown solid (68 mg, 60%). ¹H NMR (400 MHz, CD₃OD) δ 7.93 (s, 1H) 7.74 (d, J=1.5 Hz, 1H) 7.62 (s, 1H) 3.27 (s, 3H). [M+H] calc'd for C₇H₆ClN₃S, 200; found, 200.

7-Chloro-5-(methylthio)imidazo[1,2-f]pyrimidine (500 mg, 2.5 mmol) was dissolved in methanol (5 ml). 2N KOH (15 ml) was added and the solution stirred at reflux overnight and the product confirmed by LC/MS. The solvent was removed in vacuo and the residue purified by flash chromatography with 1:10 MeOH:DCM to give 7-chloroimidazo[1,2-f]pyrimidin-5-ol (420 mg, 99%). ¹H NMR (400 MHz, DMSO) δ 7.73 (d, J=2.0 Hz, 1H) 7.46 (s, 1H) 6.66 (s, 1H). [M+H] calc'd for C₆H₄ClN₃O, 170; found, 170.

Phosphorous oxychloride (20 ml) was added to 7-chloroimidazo[1,2-f]pyrimidin-5-ol (420 mg, 2.47 mmol) and the suspension stirred at reflux for 4 hours under nitrogen. The volatiles were evaporated and the residue was filtered through a silica plug. The filtrate was evaporated to leave brown oil that solidified under high vacuum. Purification by flash chromatography afforded 5,7-dichloroimidazo[1,2-f]pyrimidine as a light yellow solid. ¹H NMR (300 MHz, CDCl₃) δ 7.72 (br.s, 2H) 7.55 (s, 1H). [M+H] calc'd for C₆H₃Cl₂N₃, 188; found, 188.

5,7-Dichloroimidazo[1,2-f]pyrimidine (100 mg, 0.5 mmol) and 3-amino-5-methyl pyrazole (52 mg, 0.5 mmol) were stirred in ethanol (1 ml) at 60° C. for 15 minutes. Alternatively, the pyrimidine and the pyrazole can be reacted in DMF at 100-150° C. for 15-30 minutes. The solvent was evaporated and the residue purified by flash chromatography using 1:1 EtOAc:Hexane then 1:10 MeOH/DCM. Evaporation of the solvent revealed 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine (100 mg, 75%). ¹H NMR (400 MHz, DMSO) δ 10.54 (s, 1H) 8.37 (s, 1H) 7.57 (s, 1H) 7.07 (s, 1H) 6.48 (s, 1H) 2.28 (s, 3H). [M+H] calc'd for C₁₀H₉ClN₆, 249; found, 249.

4-Aminothiophenol (5 g, 39.9 mmol) and triethylamine (4.44 g, 43.9 mmol) were stirred in chloroform (50 ml) at 0° C. Cyclopropanecarbonyl chloride (4 g, 39.9 mmol) was dissolved in chloroform (30 ml). The solution of cyclopropanecarbonyl chloride was added to the solution of 4-aminothiophenol drop wise over an hour. Once addition was complete, the mixture was stirred for an hour. Hydrochloric acid (50 ml) was added and the organic layer was separated. The aqueous layer was extracted with chloroform (2×30 ml). The organic extracts were combined and dried over MgSO₄, and the solvent removed in vacuo. LCMS confirmed the product N-(4-mercaptophenyl)cyclopropanecarboxamide (3.63 g, 47%). ¹H NMR (400 MHz, DMSO-D6) δ 10.16 (s, 1H) 7.46 (d, J=8.6, 2.0 Hz, 2H) 7.22 (d, J=8.8 Hz, 2H) 1.75-1.72 (m, 1H) 0.78 (m, 4H). [M+H] calc'd for C₁₀H₁₁NOS, 194; found, 194.

7-Chloro-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine (100 mg, 0.4 mmol), N-(4-mercaptophenyl)cyclopropanecarboxamide (155 mg, 0.8 mmol) and a catalytic amount of potassium carbonate (3 mg) were mixed in DMF (1 ml). This mixture was reacted in a microwave reactor at 160° C. for 15 minutes. DMF was removed in vacuo and the residue was purified by HPLC to afford Example 1 as a light yellow solid (84 mg, 51%). ¹H NMR (400 MHz, CD₃OD) δ 8.23 (s, 1H) 7.80 (s, 1H) 7.79 (d, J=10.3 Hz, 2H) 7.60 (dd, J=8.8 Hz, 2H) 6.71 (s, 1H) 5.94 (s, 1H) 2.21 (s, 3H) 1.81 (m, 1H) 0.98 (m, 2H) 0.91 (m, 2H). [M+H] calc'd for C₂₀H₁₉N₇OS, 406; found, 406.

Example 2 N-(4-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

The title compound was synthesized using 3-cyclopropyl-1H-pyrazol-5-amine following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, CD₃OD) δ 8.23 (d, J=1.7, 1H) 7.80 (s, 1H) 7.79 (d, J=8.6, 2H) 7.61 (d, J=8.6 Hz, 2H), 6.67 (s, 1H) 5.98 (s, 1H), 1.83 (m, 1H) 1.80 (m, 1H) 1.30 (m, 2H) 0.97 (m, 2H) 0.90 (m, 2H) 0.68 (m, 2H). [M+H] calc'd for C₂₂H₂₁N₇OS, 432; found, 432.

Example 3 N-(4-(5-(3-Cyclopropyl-1H-pyrazol-5-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized using 3-cyclopropyl-1H-pyrazol-5-amine and N-(4-mercaptophenyl)acetamide following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, CD₃OD) δ 8.23 (s, 1H) 7.78-7.84 (m, 3H) 7.60 (d, J=8.6 Hz, 2H) 6.65 (s, 1H) 6.31 (s, 1H) 2.16 (s, 3H), 1.87 (m, 1H) 1.00 (m, 2H) 0.69 (m, 2H). [M+H] calc'd for C₂₀H₁₉N₇OS, 406; found, 406.

Example 4 N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized using 5-methyl-1H-pyrazol-3-amine and N-(4-mercaptophenyl)acetamide following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, CD₃OD) δ 8.23 (s, 1H) 7.78-7.80 (m, 3H) 7.60 (d, J=9.0 Hz, 2H) 6.70 (s, 1H) 5.96 (s, 1H) 2.22 (s, 3H), 2.17 (s, 3H). [M+H] calc'd for C₁₈H₁₇N₇OS, 380; found, 380.

Example 5 7-(4-Aminophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 5-methyl-1H-pyrazol-3-amine and 4-aminothiophenol following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, CD₃OD) δ 8.24 (d, J=2.5 Hz, 1H) 7.80 (d, J=2.0 Hz, 1H) 7.50 (d, J=8.3 Hz, 2H) 7.0 (d, J=8.3 Hz, 2H) 6.63 (s, 1H) 6.17 (s, 1H), 3.30 (m, 4H) 2.31 (s, 3H) [M+H] calc'd for C₁₆H₁₅N₇S, 338; found, 338.

Example 6 N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

Referring to Scheme 2, anhydrous hydrazine (164 mg, 162 μl, 5.1 mmol) and dichloromethane (3 ml) were cooled to −78° C. 4,6-Dichloro-2-(methylthio)pyrimidine (1 g, 5.1 mmol) was slowly added. The mixture was allowed to stir for 10 minutes then the bath was replaced with an ice bath and the solution allowed to slowly reach 0° C. The precipitate was filtered and washed with DCM. 1-(6-Chloro-2-(methylthio)pyrimidin-4-yl)hydrazine (624 mg, 64%) was obtained. [M+H] calc'd for C₅H₇ClN₄S, 191; found, 191.

1-(6-chloro-2-(methylthio)pyrimidin-4-yl)hydrazine (300 mg, 1.6 mmol) was dissolved in formic acid (5 ml). The solution was stirred at reflux overnight LC/MS confirmed mass of intended product. The solution was evaporated in vacuo. The residue was purified by flash chromatography with 1:10 MeOH:DCM to leave 7-Chloro-5-methylsulfanyl-[1,2,4]triazolo[1,5-c]pyrimidine as a yellow oil (278 mg, 88%). ¹H NMR (400 MHz, CDCl₃) δ 8.78 (s, 1H) 7.45 (s, 2H) 2.85 (s, 3H). [M+H] calc'd for C₆H₅ClN₄S, 201; found, 201.

7-Chloro-5-methylsulfanyl-[1,2,4]triazolo[1,5-c]pyrimidine (181 mg, 0.91 mmol) was dissolved in MeOH (4 ml). 2N KOH (8 ml) was added and the mixture was stirred at reflux for 2 hours. The solvents were removed by a rotavap. The residue was added 4N HCl in dioxane and stirred for an hour before it was concentrated. Water was added and the mixture was extracted with DCM to give 7-Chloro-[1,2,4]triazolo[1,5-c]pyrimidin-5-ol (35 mg) as a solid. [M+H] calc'd for C₅H₃ClN₄O, 171; found, 171.

The mixture of 7-Chloro-[1,2,4]triazolo[1,5-c]pyrimidin-5-ol (35 mg) in POCl₃ was heated at reflux for 3 hours. After removal of the volatiles, the residue was purified by a short plug column eluting with 1:1 EtOAc/hexane to give 5,7-Dichloro-[1,2,4]triazolo[1,5-c]pyrimidine as an off-white solid (11 mg). ¹H NMR (400 MHz, CDCl₃) δ 8.49 (s, 1H) 7.72 (s, 1H). [M+H] calc'd for C₅H₂Cl₂N₄, 189; found, 189.

Example 6 was then prepared as follows. 5,7-Dichloro-[1,2,4]triazolo[1,5-c]pyrimidine (10 mg) and 3-amino-5-methylpyrazole (10 mg) were stirred in ethanol (1 ml) at 60° C. for 15 minutes. The solvent was evaporated and the residue purified by flash chromatography using 1:1 EtOAc:Hexane then 1:10 MeOH/DCM. Evaporation of the solvents provided 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-[1,2,4]triazolo[1,5-f]pyrimidin-5-amine as a white solid (11 mg). [M+H] calc'd for C₉H₈ClN₇, 250; found, 250.

7-Chloro-N-(5-methyl-1H-pyrazol-3-yl)-[1,2,4]triazolo[1,5-f]pyrimidin-5-amine (21 mg, 0.084 mmol), N-(4-mercaptophenyl)cyclopropanecarboxamide (32 mg, 0.16 mmol) and potassium carbonate (17 mg) were mixed in DMF (1 ml). This mixture was reacted in a microwave reactor at 160° C. for 15 minutes. DMF was removed in vacuo and the residue was purified by HPLC to afford the title compound Example 6 as a white solid (14.9 mg). ¹H NMR (400 MHz, CD₃OD) δ 8.29 (s, 1H) 7.77 (d, J=8.4 Hz, 2H) 7.59 (d, J=8.4 Hz, 2H) 6.67 (s, 1H) 5.97 (s, 1H) 2.20 (s, 3H) 1.76-1.86 (m, 1H) 0.84-0.90 (m, 4H). [M+H] calc'd for C₁₉H₁₈N₈OS, 407; found, 407.

Example 7 N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following the procedure described in the synthesis of Example 6. ¹H NMR (400 MHz, CD₃OD) δ 8.37 (s, 1H) 7.79 (d, J=8.5 Hz, 2H) 7.61 (d, J=8.5 Hz, 2H) 6.68 (s, 1H) 6.06 (s, 1H) 2.25 (s, 3H) 2.17 (s, 3H). [M+H] calc'd for C17H₁₆N₈OS, 381; found, 381.

Example 8 N-(4-(8-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrazin-6-ylthio)phenyl)cyclopropanecarboxamide

Referring to Scheme 3, pyrazin-2-ylamine (1 g, 10.5 mmol) was dissolved in a solution of DMSO (40 ml)/H₂O (1 ml) at 0° C. N-bromosuccinimide (3.93 g, 22 mmol) was added over an hour keeping the temperature below 5° C. Once addition was complete, the mixture was stirred for 6 hours at RT. The mixture was poured over ice water (150 ml) whilst stirring, then extracted with EtOAc (4×100 ml). The organic layers were combined, dried and evaporated to leave an orange oil, which solidified overnight under high vacuum. 3,5-dibromopyrazin-2-amine was produced as an orange/brown solid (2.24 g, 84%). The product was used for the next reaction without further purification. [M+H] calc'd for C₄H₃Br₂N₃, 254; found, 254.

3,5-Dibromopyrazin-2-amine (200 mg, 0.79 mmol) and chloroacetaldehyde (200 μl, 1.58 mmol) were dissolved in DMF (5 ml). The mixture was stirred at 100° C. overnight. LC/MS showed 6,8-dibromoimidazo[1,2-a]pyrazine plus the mass with one bromine displaced by chlorine. The crude material was used for the next step without further purification. ¹H NMR (400 MHz, CDCl₃) δ 8.28 (s, 1H) 7.88 (s, 1H) 7.80 (s, 1H). [M+H] calc'd for C₆H₃Br₂N₃, 276; found, 276.

Example 8 was then prepared as follows. 6,8-Dibromoimidazo[1,2-a]pyrazine (278 mg, 1 mmol) and 5-methyl-1H-pyrazol-3-amine (196 mg, 2 mmol) was suspended in EtOH (2 ml). The mixture was heated with microwave at 120° C. for four hours. The mixture was then purified with HPLC to give (6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(5-methyl-1H-pyrazol-3-yl)-amine as a solid (96 mg). ¹H NMR (400 MHz, DMSO) δ 8.29 (s, 1H) 7.98 (s, 1H) 7.70 (s, 1H) 6.48 (s, 1H) 2.27 (s, 3H). [M+H] calc'd for C₁₀H₉BrN₆, 293; found, 293.

(6-Bromo-imidazo[1,2-a]pyrazin-8-yl)-(5-methyl-1H-pyrazol-3-yl)-amine (21 mg, 0.072 mmol), N-(4-mercaptophenyl)cyclopropanecarboxamide (28 mg, 0.145 mmol) and potassium carbonate (20 mg) were mixed in DMF (1 ml). This mixture was reacted in a microwave reactor at 170° C. for 15 minutes. DMF was removed in vacuo and the residue was purified by HPLC to afford the title compound Example 8 as an off-white solid. (11.9 mg). ¹H NMR (400 MHz, DMSO) δ 10.39 (s, 1H) 7.99 (d, J=0.8 Hz, 1H) 7.96 (s, 1H) 7.70 (s, 1H) 7.69 (d, J=8.4 Hz, 2H) 7.49 (d, J=8.4 Hz, 2H) 6.03 (s, 1H) 2.14 (s, 3H) 1.75-1.82 (m, 1H) 0.77-0.81 (m, 2H). [M+H] calc'd for C₂₀H₁₉N₇OS, 406; found, 406.

Example 9 N-(4-(8-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrazin-6-ylthio)phenyl)acetamide

The title compound was synthesized using 3-methyl-1H-pyrazol-5-amine and N-(4-mercaptophenyl)acetamide following the procedure described in the synthesis of Example 8. ¹H NMR (400 MHz, DMSO) δ 10.15 (s, 1H) 8.03 (d, J=0.8 Hz, 1H) 7.98 (s, 1H) 7.76 (s, 1H) 7.69 (d, J=8.8 Hz, 2H) 7.51 (d, J=8.4 Hz, 2H) 7.47 (d, J=8.8 Hz, 1H) 7.21 (d, J=8.8 Hz, 1H) 6.05 (s, 1H) 2.16 (s, 3H) 2.06 (s, 3H). [M+H] calc'd for C₁₈H₁₇N₇OS, 380; found, 380.

Example 10 N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

Referring to Scheme 4, C₅₋₇-Dichloro-imidazo[1,2-a]pyrimidine (206 mg, 1.1 mmol) and 5-methyl-1H-pyrazol-3-amine (213 mg, 2.19 mmol) was mixed in EtOH (5 ml). The mixture was heated at 80° C. for 10 minutes. The mixture was then cooled to RT and the solid was collected and washed with EtOAc to give (7-Chloro-imidazo[1,2-a]pyrimidin-5-yl)-(5-methyl-1H-pyrazol-3-yl)-amine as a white solid (182 mg, 0.73 mmol, 66%). ¹H NMR (400 MHz, DMSO) δ 8.17 (s, 1H) 7.63 (s, 1H) 7.12 (s, 1H) 6.02 (s, 1H) 2.28 (s, 3H). [M+H] calc'd for C₁₀H₉ClN₆, 249; found, 249.

A mixture of (7-Chloro-imidazo[1,2-a]pyrimidin-5-yl)-(5-methyl-1H-pyrazol-3-yl)-amine (73 mg, 0.29 mmol), N-(4-mercaptophenyl)cyclopropanecarboxamide (170 mg, 0.88 mmol), potassium carbonate (81 mg, 0.58 mmol) in DMF (1 ml) was heated with microwave at 190° C. for 30 minutes. The reaction mixture was then purified by HPLC to give the title compound Example 10 as an off-white solid (110 mg). ¹H NMR (400 MHz, DMSO) δ 10.54 (s, 1H) 8.26 (d, J=2.8 Hz, 1H) 7.97 (d, J=2.4 Hz, 1H) 7.79 (d, J=8.8 Hz, 2H) 7.57 (d, J=8.8 Hz, 2H) 6.89 (s, 1H) 5.82 (s, 1H) 2.20 (s, 3H) 1.81-1.85 (m, 1H) 0.84-0.86 (m, 4H). [M+H] calc'd for C₂₀H₁₉N₇OS, 406; found, 406.

Example 11 N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized using 3-methyl-1H-pyrazol-5-amine and N-(4-mercaptophenyl)acetamide following the procedure described in the synthesis of Example 10. ¹H NMR (400 MHz, DMSO) δ 10.28 (s, 1H) 8.27 (d, J=2.7 Hz, 1H) 7.96 (d, J=2.4 Hz, 1H) 7.77 (d, J=8.8 Hz, 2H) 7.57 (d, J=8.8 Hz, 2H) 6.92 (s, 1H) 2.21 (s, 3H) 2.11 (s, 3H). [M+H] calc'd for C₁₈H₁₇N₇OS, 380; found, 380.

Example 12 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-phenylimidazo[1,2-f]pyrimidin-5-amine

Referring to Scheme 6, (7-Chloro-imidazo[1,2-c]pyrimidin-5-yl)-(5-cyclopropyl-1H-pyrazol-3-yl)-amine (43 mg, 0.16 mmol), phenylboronic acid (28.7 mg, 0.24 mmol), and Tetrakis(triphenylphosphine)palladium (36 mg, 0.03 mmol) were added to a mixture of dioxane (1.5 ml) and saturated potassium carbonate solution (0.5 ml). The mixture was heated at 150° C. for 20 minutes in a microwave reactor. The mixture was then filtered, concentrated and purified by high performance liquid chromatography to give the title compound as a tan solid (15 mg, 0.05 mmol, 31%). ¹H NMR (400 MHz, MeOD) δ 8.35 (s, 1H) 8.15-8.13 (m, 2H) 7.97 (d, J=2.5 Hz, 1H) 7.65 (s, 1H) 7.55-7.54 (m, 3H) 6.49 (s, 1H) 2.03-1.99 (m, 1H) 1.08-1.05 (m, 2H) 0.82-0.78 (m, 2H). [M+H] calc'd for C₁₈H₁₆N₆, 317; found, 317.

Example 13 N-cyclopentyl-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide

The title compound was synthesized in 37% yield using 3-(cyclopentylcarbamoyl)phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.55 (br.s, 1H), 8.37 (d, J=2.2 Hz, 1H), 8.25 (d, J=7.8 Hz, 1H), 7.99 (d, J=2.2 Hz, 1H), 7.92 (d, J=2.9 Hz, 1H), 7.71 (s, 1H), 7.60 (t, J=7.6 Hz, 1H), 7.18-7.22 (m, 1H), 6.48 (s, 1H), 4.32-4.38 (m, 1H), 1.95-2.10 (m, 4H), 1.55-1.90 (m, 5H), 1.03-1.08 (m, 2H), 0.80-0.84 (m, 2H). [M+H] calc'd for C₂₄H₂₆N₇O, 428; found, 428.

Example 14a tert-Butyl 4-(3-bromobenzyl)piperazine-1-carboxylate

To a stirred solution of 1-bromo-3-(bromomethyl)benzene (677 mg, 2.71 mmol) in THF (10 ml) was added triethylamine (380 μL, 2.71 mmol), followed by tert-butyl piperazine-1-carboxylate (504 mg, 2.71 mmol). The mixture was allowed to stir at RT for one hour. The solvent was evaporated and the residue was purified with a silica gel column eluting with 1:10 EtOAc/hexanes to give the title compound as an oil (888 mg, 2.49 mmol, 92%). [M+H] calc'd for C₁₆H₂₄BrN₂O₂, 355; found, 355.

Example 14b tert-Butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine-1-carboxylate

tert-Butyl 4-(3-bromobenzyl)piperazine-1-carboxylate (448 mg, 1.25 mmol), bis(pinacolato)diboron (352 mg, 1.38 mmol), potassium acetate (368 mg, 3.75 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (31 mg, 0.038 mmol) were combined in DMF (10 mL), and the reaction stirred at 80° C. under N₂ for 4 h. The cooled solution was partitioned between EtOAc and water. Organics were washed with brine, dried (MgSO₄), and concentrated in vacuo. Purification by silica gel chromatography (10% EtOAc/hexanes) gave 550 mg (90%) of the title compound as an oil. [M+H] calc'd for C₂₂H₃₆BN₂O₄, 403; found, 403.

Example 14 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-(piperazin-1-ylmethyl)phenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine-1-carboxylate following a procedure analogous to that described in the synthesis of Example 12, except that the reaction product was further treated with TFA (30 min) to give the title compound as a foam (22 mg). ¹H NMR (400 MHz, MeOD-d₄) δ 8.41 (s, 1H), 8.25-8.30 (m, 2H), 8.02 (t, J=2.0 Hz, 1H), 7.78 (s, 1H), 7.66-7.71 (m, 2H), 6.48 (s, 1H), 4.40 (s, 2H), 3.51-3.53 (m, 4H), 3.45-3.47 (m, 4H), 2.01-2.03 (m, 1H), 1.05-1.10 (m, 2H), 0.82-0.84 (m, 2H). [M+H] calc'd for C₂₃H₂₇N₈, 415; found, 415.

Example 15a 4-(3-Bromobenzyl)piperazin-2-one

The title compound was synthesized using a procedure analogous to that described in Example 14a. [M+H] calc'd for C₁₁H₁₄BrN₂O, 269, 271; found, 269, 271.

Example 15b 4-(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-2-one

4-(3-Bromobenzyl)piperazin-2-one (356 mg, 1.32 mmol), bis(pinacolato)diboron (370 mg, 1.46 mmol), potassium acetate (388 mg, 3.95 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (32 mg, 0.039 mmol) were combined in DMF (10 mL), and the reaction stirred at 80° C. under N₂ for 4 h. The cooled solution was partitioned between EtOAc and water. Organics were washed with brine, dried (MgSO₄), and concentrated in vacuo. Purification by silica gel chromatography (50% EtOAc/hexanes then 10% MeOH/DCM) gave 261 mg (63%) of the title compound as a tan solid. [M+H] calc'd for C₁₇H₂₆BN₂O₃, 317; found, 317.

Example 15 4-((3-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methyl)piperazin-2-one

The title compound was synthesized in 34% yield using 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-2-one following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.41 (br.s, 1H), 8.30-8.32 (m, 2H), 8.01-8.03 (m, 1H), 7.79 (s, 1H), 7.67-7.75 (m, 2H), 6.46 (s, 1H), 4.58 (s, 2H), 3.89-3.90 (m, 2H), 3.61-3.62 (m, 4H), 2.00-2.06 (m, 1H), 1.04-1.11 (m, 2H), 0.79-0.84 (m, 2H). [M+H] calc'd for C₂₃H₂₅N₈O, 429; found, 429.

Example 16 4-((3-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methyl)piperazin-2-one

The title compound was synthesized in 41% yield using 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazin-2-one and 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.42 (d, J=2.3 Hz, 1H), 8.30-8.33 (m, 2H), 8.03 (d, J=2.3 Hz, 1H), 7.79 (s, 1H), 7.68-7.74 (m, 2H), 6.59 (s, 1H), 4.59 (s, 2H), 3.89 (s, 2H), 3.59-3.65 (m, 4H), 2.41 (s, 3H). [M+H] calc'd for C₂₁H₂₃N₈O, 403; found, 403.

Example 17 (5-Cyclopropyl-1H-pyrazol-3-yl)-[7-(2,3-dihydro-benzofuran-5-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine

The title compound was synthesized in 39% yield using 2,3-dihydro-1-benzofuran-5-ylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO-d₆) δ 12.45 (br s, 1H), 10.92 (s, 1H), 8.55 (s, 1H), 7.94-8.09 (m, 3H), 7.61 (s, 1H), 6.93 (d, J=8.4 Hz, 1H), 6.49 (s, 1H), 4.64 (t, J=8.4 Hz, 2H), 3.28 (t, J=8.4 Hz, 2H), 1.91-1.99 (m, 1H), 0.92-1.01 (m, 2H), 0.68-0.78 (m, 2H). [M+H] calc'd for C₂₀H₁₈N₆O, 359; found, 359.

Example 18a 3-(Acetylamino-methyl)-phenylboronic acid

Acetic anhydride (76 μL, 0.80 mmol) was added dropwise to a stirred solution of (3-aminomethylphenyl)boronic acid, hydrochloride (150 mg, 0.80 mmol) and DIEA (560 μL, 3.2 mmol) in CH₂Cl₂ (5 mL) at 0° C. After 1 h, the solution was concentrated in vacuo and purified by preparatory HPLC to give 36 mg (23%) of the title compound as a white solid. [M+H] calc'd for C₉H₁₂BNO₃, 194; found, 194.

Example 18 N-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-acetamide

The title compound was synthesized in 33% yield using 3-(acetylamino-methyl)-phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO-d₆) δ 12.51 (br s, 1H), 11.01 (s, 1H), 8.63 (s, 1H), 8.45 (t, J=5.6 Hz, 1H), 8.11 (s, 1H), 8.01-8.06 (m, 2H), 7.72 (s, 1H), 7.53 (t, J=7.6 Hz, 1H), 7.42 (d, J=7.6 Hz, 1H), 6.58 (s, 1H), 4.36 (d, J=5.6 Hz, 2H), 1.99-2.07 (m, 1H), 1.89 (s, 3H), 0.93-1.01 (m, 2H), 0.72-0.80 (m, 2H). [M+H] calc'd for C₂₁H₂₁N₉O, 388; found, 388.

Example 19a 3-(3-Bromo-benzyl)-imidazolidine-2,4-dione

Hydantoin (300 mg, 3.0 mmol) was added to a solution of KOH (202 mg, 3.6 mmol) in 90% EtOH at r.t., and the reaction stirred for 30 min. 3-Bromobenzyl bromide (750 mg, 3.0 mmol) was added, and the reaction was heated at reflux for 18 h. The solution was diluted with EtOAc, washed with H₂O and brine, dried (MgSO₄) and concentrated in vacuo. Precipitation from 50% EtOAc/hexanes followed by collection by filtration gave 512 mg (63%) of the title compound as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.54 (s, 1H), 7.42 (d, J=7.6 Hz, 1H), 7.34 (d, J=7.6 Hz, 1H), 7.19 (t, J=7.6 Hz, 1H), 5.81 (s, 1H), 4.63 (s, 2H), 4.00 (s, 2H). [M+H] calc'd for C₁₀H₉BrN₂O₂, 269, 271; found, 269, 271.

Example 19b 3-(2,5-Dioxo-imidazolidin-1ylmethyl)-phenylboronic acid, pinacol ester

3-(3-Bromo-benzyl)-imidazolidine-2,4-dione (480 mg, 1.78 mmol), bis(pinacolato)diboron (475 mg, 1.97 mmol), potassium acetate (525 mg, 5.34 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (44 mg, 0.05 mmol) were combined in DMF (10 mL), and the reaction stirred at 80° C. under N₂ for 16 h. The cooled solution was partitioned between EtOAc and water. Organics were washed with brine, dried (MgSO₄), and concentrated in vacuo. Purification by silica gel chromatography (75% EtOAc/hexanes) gave 366 mg (65%) of the title compound as a tan solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.13 (s, 1H), 7.58 (s, 1H), 7.56 (d, J=7.6 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.33 (t, J=7.6 Hz, 1H), 4.51 (s, 2H), 3.96 (s, 2H), 1.28 (s, 12H). [M+H] calc'd for C₁₆H₂₁BN₂O₄, 317; found, 317.

Example 19 3-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-imidazolidine-2,4-dione

The title compound was synthesized in 13% yield using 3-(2,5-dioxo-imidazolidin-1ylmethyl)-phenylboronic acid, pinacol ester following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.37 (s, 1H), 8.19 (s, 1H), 8.07 (d, J=6.8 Hz, 1H), 7.98 (s, 1H), 7.64 (s, 1H), 7.50-7.56 (m, 2H), 6.56 (s, 1H), 4.75 (s, 2H), 4.00 (s, 2H), 2.00-2.08 (m, 1H), 1.00-1.08 (m, 2H), 0.79-0.86 (m, 2H). [M+H] calc'd for C₂₂H₂₀N₈O₂, 429; found, 429.

Example 20a 3-(3-Methyl-3H-imidazol-4-yl)-phenylboronic acid

1,3-Benzenediboronic acid (300 mg, 1.8 mmol), 5-bromo-1-methylimidazole (291 mg, 1.8 mmol), potassium phosphate (1.15 g, 5.4 mmol), tris(dibenzylideneacetone)dipalladium(0) (164 mg, 0.18 mmol), and 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (142 mg, 0.36 mmol) were combined with DMA (3 mL) in a sealed tube purged with N₂. The reaction was heated at 130° C. for 25 min in a microwave reactor. The solution was diluted with MeOH, filtered, and concentrated in vacuo. Purification by preparatory HPLC gave 166 mg (45%) of the title compound as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.12 (s, 1H), 7.91-7.98 (m, 2H), 7.83 (s, 1H), 7.63 (d, J=7.6 Hz, 1H), 7.52 (t, J=7.6 Hz, 1H), 3.83 (s, 3H). [M+H] calc'd for C₁₀H₁₁BN₂O₂, 202; found, 202.

Example 20 (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[3-(3-methyl-3H-imidazol-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine

The title compound was synthesized in 23% yield using 3-(3-methyl-3H-imidazol-4-yl)-phenylboronic acid following the procedure described in the synthesis of Example 12.

¹H NMR (400 MHz, MeOD-d₄) δ 9.08 (s, 1H), 8.32-8.46 (m, 3H), 8.02 (s, 1H), 7.83 (s, 1H), 7.75-7.80 (m, 2H), 7.56 (s, 1H), 6.46 (s, 1H), 3.94 (s, 3H), 1.94-2.02 (m, 1H), 0.98-1.05 (m, 2H), 0.70-0.76 (m, 2H). [M+H] calc'd for C₂₂H₂₀N₈, 397; found, 397.

Example 21a 3-(Methanesulfonylamino-methyl)-phenylboronic acid, pinacol ester

Methanesulfonyl chloride (60 μL, 0.78 mmol) was added to a stirred solution of (3-aminomethylphenyl)boronic acid pinacol ester, hydrochloride (200 mg, 0.74 mmol) and DIEA (260 μL, 1.48 mmol) in CH₂Cl₂ (5 mL) at r.t. After 1 h, the solution was washed with 0.5 N HCl and brine, dried (MgSO₄) and concentrated in vacuo to give 228 mg (99%) of the title compound as a clear oil. ¹H NMR (400 MHz, MeOD-d₄) δ 7.75 (s, 1H), 7.66 (d, J=7.6 Hz, 1H), 7.48 (d, J=7.6 Hz, 1H), 7.36 (t, J=7.6 Hz, 1H), 4.24 (s, 2H), 2.85 (s, 3H), 1.34 (s, 12H). [M+H] calc'd for C₁₄H₂₂BNO₄S, 312; found, 312.

Example 21 N-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-methanesulfonamide

The title compound was synthesized in 32% yield using 3-(methanesulfonylamino-methyl)-phenylboronic acid, pinacol ester following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.34 (d, J=2.0 Hz, 1H), 8.18 (s, 1H), 8.06 (d, J=7.6 Hz, 1H), 7.97 (d, J=2.0 Hz, 1H), 7.65 (s, 1H), 7.50-7.57 (m, 2H), 6.51 (s, 1H), 4.35 (s, 2H), 2.92 (s, 3H), 2.00-2.08 (m, 1H), 1.00-1.08 (m, 2H), 0.78-0.85 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₇O₂S, 424; found, 424.

Example 22a 3-[(Cyclopropanecarbonyl-amino)-methyl]-phenylboronic acid, pinacol ester

The title compound was synthesized in quantitative yield using cyclopropanecarbonyl chloride following the procedure described for the synthesis of Example 21a. ¹H NMR (400 MHz, MeOD-d₄) δ 7.68 (s, 1H), 7.63 (d, J=7.6 Hz, 1H), 7.38 (d, J=7.6 Hz, 1H), 7.32 (t, J=7.6 Hz, 1H), 4.38 (s, 2H), 1.60-1.67 (m, 1H), 1.33 (s, 12H), 0.84-0.90 (m, 2H), 0.71-0.77 (m, 2H). [M+H] calc'd for C₁₇H₂₄NO₃B, 302; found, 302.

Example 22 Cyclopropane carboxylic acid 3-[5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide

The title compound was synthesized in 33% yield using 3-[(cyclopropanecarbonyl-amino)-methyl]-phenylboronic acid, pinacol ester following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.50 (d, J=2.0 Hz, 1H), 8.02-8.12 (m, 3H), 7.85 (s, 1H), 7.50-7.56 (m, 2H), 6.57 (s, 1H), 4.48 (s, 2H), 2.11-2.18 (m, 1H), 1.61-1.68 (m, 1H), 1.20-1.26 (m, 2H), 0.94-1.01 (m, 2H), 0.81-0.87 (m, 2H), 0.73-0.79 (m, 2H). [M+H] calc'd for C₂₃H₂₃N₇O, 414; found, 414.

Example 23a 3-(3-Bromo-benzyl)-imidazolidine-2-one

3-Bromobenzyl bromide (1.0 g, 4.0 mmol) was added to a solution of 2-imidazolidone (1.03 g, 12.0 mmol) and potassium carbonate (1.66 g, 12.0 mmol) in 2-propanol (10 mL), and the reaction stirred at reflux for 40 h. The cooled solution was partitioned between EtOAc and water. Organics were washed with brine, dried (MgSO₄) and concentrated in vacuo. Purification by silica gel chromatography (100% EtOAc) gave 446 mg (44%) of the title compound as a white solid. ¹H NMR (400 MHz, MeOD-d₄) δ 7.40-7.48 (m, 2H), 7.21-7.28 (m, 2H), 4.30 (s, 2H), 3.29-3.41 (m, 4H). [M+H] calc'd for C₁₀H₁₁BrN₂O, 255, 257; found, 255, 257.

Example 23b 3-(2-Oxo-imidazolidin-1-ylmethyl)-phenylboronic acid, pinacol ester

The title compound was synthesized in 77% yield using 3-(3-bromo-benzyl)-imidazolidine-2-one following the procedure for the synthesis of Example 15b. ¹H NMR (400 MHz, MeOD-d₄) δ 7.63-7.69 (m, 2H), 7.31-7.39 (m, 2H), 4.32 (s, 2H), 3.24-3.36 (m, 4H), 1.32 (s, 12H). [M+H] calc'd for C₁₆H₂₃BN₂O₃, 317; found, 317.

Example 23 1-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-imidazolidin-2-one

The title compound was synthesized in 25% yield using 3-(2-oxo-imidazolidin-1-ylmethyl)-phenylboronic acid, pinacol ester following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.07 (s, 1H), 7.98-8.05 (m, 2H), 7.59 (s, 1H), 7.42-7.50 (m, 2H), 7.37 (s, 1H), 6.56 (s, 1H), 4.43 (s, 2H), 3.39 (s, 2H), 3.33 (s, 2H), 1.98-2.04 (m, 1H), 1.00-1.08 (m, 2H), 0.76-0.84 (m, 2H). [M+H] calc'd for C₂₂H₂₂N₈O, 415; found, 415.

Example 24 Cyclopropane carboxylic acid 3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide

The title compound was synthesized in 32% yield using 3-[(cyclopropanecarbonyl-amino)-methyl]-phenylboronic acid, pinacol ester following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.60 (d, J=2.0 Hz, 1H), 8.10-8.16 (m, 2H), 8.05 (d, J=7.6 Hz, 1H), 7.94 (s, 1H), 7.50-7.58 (m, 2H), 6.80 (s, 1H), 4.49 (s, 2H), 2.55 (s, 3H), 1.62-1.70 (m, 1H), 0.81-0.88 (m, 2H), 0.73-0.79 (m, 2H). [M+H] calc'd for C₂₁H₂₁N₇O, 388; found, 388.

Example 25 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 2-methoxyphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.57 (s, 1H) 8.06 (m, 2H) 7.83 (s, 1H) 7.51 (m, 1H) 7.24(d, J=8 Hz, 1H) 7.14 (m, 1H) 6.96 (s, 1H) 3.94 (s, 3H) 1.95 (m, 1H) 0.97 (m, 2H) 0.71 (m, 2H). [M+H] calc'd for C₁₉H₁₉N₆O, 347; found, 347.

Example 26 3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzonitrile

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-cyanophenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.59 (s, 1H) 8.55 (s, 1H) 8.48 (d, J=8.0 Hz, 1H) 7.97 (m, 2H) 7.87 (s, 1H) 7.76 (m, 1H) 7.11 (s, 1H) 6.48 (s, 1H) 1.97 (m, 1H) 1.02 (m, 2H) 0.77 (m, 2H). [M+H] calc'd for C₁₉H₁₆N₇, 342; found, 342.

Example 27 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3,5-dimethylphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.55 (s, 1H) 7.99 (s, 1H) 7.80 (s, 2H) 7.68 (s, 1H) 7.17 (s, 1H) 6.55 (s, 1H) 2.37 (s, 6H) 1.97 (m, 1H) 1.02 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆, 345; found, 345.

Example 28 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-p-tolylimidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 4-methylphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.55 (s, 1H) 8.06 (d, J=8.0 Hz, 2H) 8.00 (s, 1H) 7.66 (s, 1H) 7.38 (d, J=8.0 Hz, 2H) 6.52 (s, 1H) 2.38 (s, 3H) 1.98 (m, 1H) 1.01 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₁₉H₁₉N₆, 331; found, 331.

Example 29 7-(5-chloro-2-methoxyphenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 5-chloro-2-methoxyphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.58 (s, 1H) 8.18 (s, 1H) 8.07 (s, 1H), 7.94 (s, 1H) 7.56 (d, J=8.0 Hz, 1H) 7.28 (d, J=8.0 Hz, 1H) 6.40 (s, 1H) 3.97 (s, 3H) 1.97 (m, 1H) 1.02 (m, 2H) 0.75 (m, 2H). [M+H] calc'd for C₁₉H₁₈ClN₆O, 381; found, 381.

Example 30 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxy-5-methylphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 2-methoxy-5-methylphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.57 (s, 1H) 8.07 (s, 1H) 7.97 (s, 1H), 7.89 (s, 1H) 7.35 (d, J=8.0 Hz, 1H) 7.15 (d, J=8.0 Hz, 1H) 6.49 (s, 1H) 3.91 (s, 3H) 2.34 (s, 1H) 1.95 (m, 1H) 1.01 (m, 2H) 0.71 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆O, 361; found, 361.

Example 31 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3,5-dimethoxyphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.56 (s, 1H) 8.01 (s, 1H) 7.77 (s, 1H) 7.36 (s, 2H) 6.66 (s, 1H) 6.57 (s, 1H) 3.86 (s, 6H) 1.95 (m, 1H) 0.98 (m, 2H) 0.73 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆O₂, 377; found, 377.

Example 32 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-methoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 4-methoxyphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.55 (s, 1H) 8.13 (d, J=8.0 Hz, 2H) 8.02 (s, 1H) 7.62 (s, 1H) 7.11 (d, J=8.0 Hz, 2H) 6.52 (s, 1H) 3.85 (s, 3H) 1.98 (m, 1H) 1.01 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₁₉H₁₉N₆O, 347; found, 347.

Example 33 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(pyrimidin-5-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 5-pyrimidinylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 9.49 (s, 2H) 9.28 (s, 1H) 8.57 (s, 1H) 7.96 (s, 1H) 7.94 (s, 1H) 6.50 (s, 1H) 1.99 (m, 1H) 1.00 (m, 2H) 0.75 (m, 2H). [M+H] calc'd for C₁₆H₁₅N₈, 319; found, 319.

Example 34 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(pyridin-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-pyridineboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 9.37 (s, 1H) 8.75 (d, J=4.0 Hz, 1H) 8.62 (m, 2H) 8.08 (s, 1H) 7.88 (s, 1H) 7.69 (m, 1H) 6.51 (s, 1H) 1.99 (m, 1H) 1.00 (m, 2H) 0.75 (m, 2H). [M+H] calc'd for C₁₇H₁₆N₇, 318; found, 318.

Example 35 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,4-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3,4-dimethoxyphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.56 (s, 1H) 8.03 (s, 1H) 7.79 (m, 2H) 7.69 (s, 1H) 7.14 (d, J=8.0 Hz, 1H) 6.59 (s, 1H) 3.90 (s, 3H) 3.85 (s, 3H) 1.96 (m, 1H) 0.98 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆O₂, 377; found, 377.

Example 36 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,3-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 2,3-dimethylphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.58 (s, 1H) 8.05 (s, 1H) 7.30 (m, 2H) 7.23 (m, 2H) 6.35 (s, 1H) 2.32 (s, 3H) 2.27 (s, 3H) 1.90 (m, 1H) 0.93 (m, 2H) 0.64 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆, 345; found, 345.

Example 37 7-(benzo[d][1,3]dioxol-5-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3,4-methylenedioxyphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.53 (s, 1H) 8.00 (s, 1H) 7.75 (d, J=8.0 Hz, 1H) 7.71 (s, 1H) 7.62 (s, 1H) 7.10 (d, J=8.0 Hz, 1H) 6.46 (s, 1H) 6.14 (s, 2H) 3.90 (s, 3H) 3.85 (s, 3H) 1.96 (m, 1H) 1.01 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₁₉H₁₇N₆O₂, 361; found, 361.

Example 38 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,6-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 2,6-dimethylphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.58 (s, 1H) 8.07 (s, 1H) 7.24 (m, 2H) 7.15 (m, 2H) 6.21 (s, 1H) 2.15 (s, 3H) 2.07 (s, 3H) 1.80 (m, 1H) 0.90 (m, 2H) 0.61 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆, 345; found, 345.

Example 39 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,6-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 2,6-dimethoxyphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.48 (s, 1H) 7.99 (s, 1H) 7.43 (t, J=8.0 Hz, 1H) 7.07 (s, 1H) 6.81 (d, J=8.0 Hz, 2H) 6.29 (s, 1H) 3.74 (s, 3H) 3.67 (s, 3H) 1.87 (m, 1H) 0.92 (m, 2H) 0.61 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆O₂, 377; found, 377.

Example 40 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxypyridin-4-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 2-methoxypyridin-4-ylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.59 (s, 1H) 8.50 (d, J=8.0 Hz, 1H) 8.34 (d, J=4.0 Hz, 1H) 8.07 (s, 1H) 7.94 (s, 1H) 7.25 (m, 1H) 6.44 (s, 1H) 4.05 (s, 3H) 1.97 (m, 1H) 0.98 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₁₈H₁₈N₇O, 348; found, 348.

Example 41 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-phenoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 4-phenoxyphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.54 (s, 1H) 8.16 (d, J=8.0 Hz, 2H) 7.97 (s, 1H) 7.63 (s, 1H) 7.45 (m, 2H) 7.21 (m, 1H) 7.13 (m, 4H) 6.52 (s, 1H) 1.98 (m, 1H) 0.98 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₂₄H₂₁N₆O, 409; found, 409.

Example 42 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-biphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-biphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.61 (s, 1H) 8.48 (s, 1H) 8.16 (d, J=8.0 Hz, 1H) 8.06 (s, 1H) 7.87 (s, 1H) 7.82 (d, J=8.0 Hz, 1H) 7.75 (m, 2H) 7.66 (m, 1H) 7.53 (m, 2H) 7.43 (m, 1H) 6.60 (s, 1H) 1.96 (m, 1H) 0.96 (m, 2H) 0.69 (m, 2H). [M+H] calc'd for C₂₄H₂₁N₆, 393; found, 393.

Example 43 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-biphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 4-biphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.58 (s, 1H) 8.25 (d, J=8.0 Hz, 2H) 8.03 (s, 1H) 7.87-7.35 (m, 8H) 6.57 (s, 1H) 2.00 (m, 1H) 1.01 (m, 2H) 0.78 (m, 2H). [M+H] calc'd for C₂₄H₂₁N₆, 393; found, 393.

Example 44 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-biphenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 2-biphenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.48 (s, 1H) 7.93 (s, 1H) 7.57-7.17 (m, 10H) 5.63 (s, 1H) 1.12 (m, 1H) 0.93 (m, 2H) 0.64 (m, 2H). [M+H] calc'd for C₂₄H₂₁N₆, 393; found, 393.

Example 45 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-fluorophenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 2-flurophenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.59 (s, 1H) 8.09 (m, 1H) 8.01 (s, 1H) 7.57 (m, 2H) 7.42(m, 2H) 6.50 (s, 1H) 1.96 (m, 1H) 0.97 (m, 2H) 0.71 (m, 2H). [M+H] calc'd for C₁₈H₁₆FN₆, 335; found, 335.

Example 46 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-difluorophenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3,5-diflurophenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.52 (s, 1H) 7.90 (m, 3H) 7.38 (m, 2H) 6.44 (s, 1H) 1.96 (m, 1H) 1.01 (m, 2H) 0.72 (m, 2H). [M+H] calc'd for C₁₈H₁₅F₂N₆, 353; found, 353.

Example 47 3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-methylbenzamide

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-(N-methylaminocarbonyl)phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.61 (b, 2H) 8.29 (d, J=8.36 Hz, 1H) 8.04 (s, 1H) 7.93 (d, J=8.36 Hz, 1H) 7.78 (s, 1H) 7.65 (m, 1H) 6.58 (s, 1H) 2.84 (d, J=3.2 Hz, 3H) 1.96 (m, 1H) 1.00 (m, 2H) 0.79 (m, 2H). [M+H] calc'd for C₂₀H₂₀N₇O, 374; found, 374.

Example 48 3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-ethylbenzamide

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-(N-ethylaminocarbonyl)phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.65-8.60 (b, 2H) 8.29 (d, J=7.8 Hz, 1H) 8.04 (s, 1H) 7.93 (d, J=7.8 Hz, 1H) 7.78 (s, 1H) 7.65 (m, 1H) 6.57 (s, 1H) 3.33 (m, 2H) 1.96 (m, 1H) 1.16 (t, J=7.0 Hz, 3H) 0.99 (m, 2H) 0.79 (m, 2H). [M+H] calc'd for C₂₁H₂₂N₇O, 388; found, 388.

Example 49 N-cyclopropyl-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-(cyclopropylaminocarbonyl)phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.60 (s, 1H) 8.57 (s, 1H) 8.29 (d, J=8.6 Hz, 1H) 8.05 (s, 1H) 7.93 (d, J=8.6 Hz, 1H) 7.78 (s, 1H) 7.65 (m, 1H) 6.57 (s, 1H) 2.88 (m, 1H) 1.96 (m, 1H) 0.98 (m, 2H) 0.79 (m, 2H) 0.74 (m, 2H) 0.61 (m, 2H). [M+H] calc'd for C₂₂H₂₂N₇O, 400; found, 400.

Example 50 N-(2-cyanoethyl)-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-(2-cyanoethylaminocarbonyl)phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.64 (s, 1H) 8.61 (s, 1H) 8.33 (d, J=7.8 Hz, 1H) 8.05 (s, 1H) 7.97 (d, J=7.8 Hz, 1H) 7.78 (s, 1H) 7.68 (m, 1H) 6.57 (s, 1H) 3.55 (q, J=6.28 Hz, 2H) 2.82 (t, J=6.28 Hz, 2H) 1.96 (m, 1H) 0.98 (m, 2H) 0.81 (m, 2H). [M+H] calc'd for C₂₂H₂₁N₈O, 413; found, 413.

Example 51 (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(pyrrolidin-1-yl)methanone

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-(pyrrolidine-1-carbonyl)phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.61 (s, 1H) 8.31 (s, 1H) 8.25 (d, J=7.56 Hz, 1H) 8.09 (s, 1H) 7.83 (s, 1H) 7.64 (m, 2H) 6.48 (s, 1H) 3.52 (t, J=6.84 Hz, 2H) 3.39 (t, J=6.84 Hz, 2H) 1.90 (m, 1H) 0.98 (m, 2H) 0.73 (m, 2H). [M+H] calc'd for C₂₃H₂₄N₇O, 414; found, 414.

Example 52 Methyl 3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzoate

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-methoxycarbonylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.78 (s, 1H) 8.61 (s, 1H) 8.42 (d, J=8.08 Hz, 1H) 8.11 (d, J=8.08 Hz, 1H) 8.03 (s, 1H) 7.82 (s, 1H) 7.72 (m, 1H) 6.57 (s, 1H) 3.93 (s, 3H) 1.98 (m, 1H) 1.00 (m, 2H) 0.79 (m, 2H). [M+H] calc'd for C₂₀H₁₉N₆O₂, 375; found, 375.

Example 53 (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanol

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and 3-(hydroxymethyl)phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.61 (s, 1H) 8.17 (s, 1H) 8.07 (s, 1H) 8.03 (d, J=7.08 Hz, 1H) 7.73 (s, 1H) 7.50 (m, 2H) 6.57 (s, 1H) 4.62 (s, 2H) 1.97 (m, 1H) 1.00 (m, 2H) 0.78 (m, 2H). [M+H] calc'd for C₁₉H₁₉N₆O, 347; found, 347.

Example 54 (E)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-styrylimidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine and trans-2-phenylvinylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, DMSO) δ 8.58 (s, 1H) 8.02 (s, 1H) 7.73-7.65 (m, 3H) 7.49-7.41 (m, 4H) 7.25 (s, 1H) 6.60 (s, 1H) 2.02 (m, 1H) 1.00 (m, 2H) 0.78 (m, 2H). [M+H] calc'd for C₂₀H₁₉N₆, 343; found, 343.

Example 55 N-(5-methyl-1H-pyrazol-3-yl)-7-phenylimidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.35 (s, 1H) 8.17-8.14 (m, 2H) 7.95 (d, J=2.3 Hz, 1H) 7.62 (s, 1H) 7.55-7.54 (m, 3H) 6.61 (s, 1H) 2.39 (s, 3H). [M+H] calc'd for C₁₆H₁₄N₆, 291; found, 291.

Example 56 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)acetamide

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.32 (s, 1H) 8.12-8.10 (d, J=8.4 Hz, 2H) 7.94 (s, 1H) 7.76-7.74 (d, J=8.4 Hz, 2H) 7.58 (s, 1H) 6.47 (s, 1H) 2.11 (s, 1H) 2.02-1.99 (m, 1H) 1.29 (s, 3H) 1.09-1.05 (m, 1H) 0.82-0.78 (m, 1H). [M+H] calc'd for C₂₀H₁₉N₇O, 374; found, 374.

Example 57 7-(2-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.42 (s, 1H) 8.02 (s, 1H) 7.79-7.77 (d, J=9.3 Hz, 1H) 7.62-7.59 (d, J=8.8 Hz, 1H) 7.50 (s, 3H) 6.46 (s, 1H) 1.93 (m, 1H) 1.0-0.99 (m, 2H) 0.71-0.69 (m, 2H). [M+H] calc'd for C₁₈H₁₅ClN₆, 351; found, 351.

Example 58 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-o-tolylimidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.35 (s, 1H) 7.97 (s, 1H) 7.59-7.56 (d, J=12.0 Hz, 1H) 7.41-7.40 (d, J=6.0 Hz, 1H) 7.36-7.34 (d, J=1.1 Hz, 2H) 7.22 (s, 2H) 6.30 (s, 1H) 2.46 (s, 3H) 2.31 (s, 3H) 1.96-1.89 (m, 1H) 1.01-0.98 (m, 2H) 0.71-0.68 (m, 2H). [M+H] calc'd for C₁₉H₁₈N₆, 331; found, 331.

Example 59 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-m-tolylimidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.35 (s, 1H) 8.00 (s, 1H) 7.96-7.95 (d, J=2.28 Hz, 2H) 7.62 (s, 1H) 7.39 (m, 1H) 7.24-7.20 (m, 2H) 6.51 (s, 1H) 2.46 (s, 3H) 2.33 (s, 3H) 2.02-1.98 (m, 1H) 1.09-1.06 (m, 2H) 0.82-0.78 (m, 2H). [M+H] calc'd for C₁₉H₁₈N₆, 331; found, 331.

Example 60 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-(dimethylamino)phenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.23 (s, 1H) 8.02-8.00 (d, J=8.84 Hz, 2H) 7.84 (s, 1H) 7.35 (s, 1H) 6.85-6.83 (d, J=8.84 Hz, 2H) 6.45 (s, 1H) 3.08 (s, 6H) 2.00 (m, 1H) 1.09-1.05 (m, 2H) 0.82-0.78 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₇, 360; found, 360.

Example 61 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(1H-indol-5-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.40 (s, 1H) 8.23 (s, 1H) 7.89 (s, 1H) 7.86-7.85 (d, J=2.52 Hz, 1H) 7.50-7.49 (d, J=3.04 Hz, 2H) 7.3472 (m, 1H) 6.57 (s, 1H) 6.49 (s, 1H) 2.01 (m, 1H) 1.11-1.98 (m, 2H) 0.85-0.81 (m, 2H). [M+H] calc'd for C₂₀H₁₇N₇, 356; found, 356.

Example 62 7-(3-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.39 (s, 1H) 8.23 (s, 1H) 8.08 (m, 1H) 8.00-7.99 (d, J=2.28 Hz, 1H) 7.71 (s, 1H) 7.55 (m, 3H) 6.48 (s, 1H) 2.00 (m, 1H) 1.09-1.05 (m, 2H) 0.84-0.80 (m, 2H). [M+H] calc'd for C₁₈H₁₅ClN₆, 351; found, 351.

Example 63 7-(3-(1H-pyrazol-1-yl)phenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.67 (s, 1H) 8.41 (s, 1H) 8.33-8.32 (d, J=2.52 Hz, 1H) 8.12-8.10 (d, J=7.8 Hz, 1H) 8.01 (s, 1H) 7.92-7.91 (d, J=7.84 Hz, 1H) 7.81 (s, 1H) 7.78 (s, 1H) 6.60 (m, 2H) 1.99 (m, 1H) 1.07-1.02 (m, 2H) 0.85-0.82 (m, 2H). [M+H] calc'd for C₂₁H₁₈N₈, 383; found, 383.

Example 64 (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(morpholino)methanone

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.40 (s, 1H) 8.28-8.25 (d, J=10.6 Hz, 2H) 8.02-8.01 (d, J=2.56 Hz, 1H) 7.75 (s, 1H) 7.68-7.60 (m, 2H) 6.47 (s, 1H) 3.81 (s, 4H) 3.62 (s, 2H) 3.49 (s, 1H) 2.00 (m, 1H) 1.09-1.05 (m, 2H) 0.83-0.79 (m, 2H). [M+H] calc'd for C₂₃H₂₃N₇O₂, 430; found, 430.

Example 65 (4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(morpholino)methanone

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.40 (s, 1H) 8.28-8.26 (d, J=8.6 Hz, 2H) 8.01-8.01 (d, J=2.52 Hz, 1H) 7.73 (s, 1H) 7.62-7.61 (d, J=8.6 Hz, 2H) 6.49 (s, 1H) 3.79 (s, 4H) 3.65 (s, 1H) 3.48 (s, 1H) 2.01 (m, 1H) 1.09-1.04 (m, 2H) 0.82-0.78 (m, 2H). [M+H] calc'd for C₂₃H₂₃N₇O₂, 430; found, 430.

Example 66 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-morpholinophenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.27 (s, 1H) 8.08-8.05 (d, J=9.3 Hz, 2H) 7.89 (s, 1H) 7.46 (s, 1H) 7.09-7.07 (d, J=8.84 Hz, 2H) 6.47 (s, 1H) 3.85 (s, 4H) 3.30 (s, 4H) 2.01 (m, 1H) 1.08-1.05 (m, 2H) 0.81 (m, 2H). [M+H] calc'd for C₂₂H₂₃N₇O, 402; found, 402.

Example 67 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-morpholinophenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.35 (s, 1H) 7.97 (s, 1H) 7.81 (s, 1H) 7.63 (m, 2H) 7.42 (m, 1H) 7.18 (m, 1H) 6.52 (s, 1H) 3.88 (m, 4H) 3.24 (m, 4H) 1.99 (m, 1H) 1.08-1.04 (m, 2H) 0.80-0.76 (m, 2H). [M+H] calc'd for C₂₂H₂₃N₇O, 402; found, 402.

Example 68 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-(piperidin-1-yl)phenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.29 (s, 1H) 8.12-8.10 (d, J=8.84 Hz, 2H) 7.90 (s, 1H) 7.50 (s, 1H) 7.26-7.24 (d, J=8.84 Hz, 2H) 6.45 (s, 1H) 3.47 (m, 4H) 2.00 (m, 1H) 1.80 (s, 4H) 1.73 (s, 2H) 1.09-1.04 (m, 2H) 0.82-0.78 (m, 2H). [M+H] calc'd for C₂₃H₂₅N₇, 400; found, 400.

Example 69a 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-methylpiperazine

1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-4-methylpiperazine was prepared by reacting 2-(3-(bromomethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (100 mg, 0.35 mmol) with methyl piperazine (196 μl, 1.76 mmol) in THF at room temperature for 2 hours. The intermediate product was purified by flash chromatography to afford 68 mg of colorless oil.

Example 69 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-((4-methylpiperazin-1-yl)methyl)phenyl) imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized from Example 69a using the procedure as Example 12. ¹H NMR (400 MHz, MeOD) δ 8.38 (s, 1H) 8.19 (s, 1H) 8.16-8.14 (d, J=7.56 Hz, 1H) 8.00 (s, 1H) 7.72 (s, 1H) 7.60 (m, 2H) 6.49 (s, 1H) 5.48 (s, 2H) 3.94 (s, 2H) 3.38 (s, 4H) 3.34 (s, 2H) 2.99 (s, 3H) 2.90 (s, 4H) 2.03 (m, 1H) 1.10-1.06 (m, 2H) 0.83-0.79 (m, 2H). [M+H] calc'd for C₂₄H₂₈N₈, 429; found, 429.

Example 70 N-{3-[5-(5-Cyclopropyl-2H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-methanesulfonamide

The title compound was prepared following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.76-0.83 (m, 2H) 0.93-1.01 (m, 2H) 2.00 (ddd, J=13.52, 8.34, 4.93 Hz, 1H) 3.04 (s, 3H) 6.63 (s, 1H) 7.19 (d, J=8.34 Hz, 2H) 7.32 (m, 2H) 7.62 (s, 1H) 8.06 (d, J=7.33 Hz, 2H) 8.62 (s, 1H) 9.98 (s, 1H) 10.96 (s, 1H) 12.37 (s, 1H); ESI-MS: m/z 410.3 (M+H)⁺

Example 71 N-{3-[5-(5-Cyclopropyl-2H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-acetamide

The title compound was prepared following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.80 (ddd, J=6.13, 4.74, 4.55 Hz, 2H) 0.93-1.00 (m, 2H) 1.98-2.05 (m, 1H) 2.09 (s, 3H) 6.66 (s, 1H) 7.45-7.54 (m, 2H) 7.59 (s, 1H) 7.80 (d, J=7.33 Hz, 1H) 8.05 (s, 1H) 8.63 (d, J=10.36 Hz, 2H) 10.16 (s, 1H) 10.97 (s, 1H) 12.40 (s, 1H); ESI-MS: m/z 374.4 (M+H)⁺

Example 72 N-{3-[5-(5-Methyl-2H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-methanesulfonamide

The title compound was prepared following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.32 (s, 3H) 3.05 (s, 3H) 6.75 (s, 1H) 7.30 (dd, J=8.72, 1.39 Hz, 1H) 7.52 (t, J=7.83 Hz, 1H) 7.66 (s, 1H) 7.88 (d, J=7.83 Hz, 1H) 8.06 (d, J=1.77 Hz, 1H) 8.15 (s, 1H) 10.03 (s, 1H) 11.00 (s, 1H) 12.38 (s, 1H); ESI-MS: m/z 384.3 (M+H)⁺

Example 73 [7-(3-Ethanesulfonyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-2H-pyrazol-3-yl)-amine

The title compound was prepared following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 1.15 (t, J=7.33 Hz, 3H) 3.38 (q, J=7.33 Hz, 2H) 3.56 (s, 3H) 6.68 (s, 1H) 7.81-7.90 (m, 2H) 7.98-8.03 (m, 2H) 8.53 (d, J=7.83 Hz, 1H) 8.60 (s, 1H) 8.73 (s, 1H) 10.95 (s, 1H) 12.39 (s, 1H); ESI-MS: m/z 383.3 (M+H)⁺

Example 74 N-{3-[5-(5-Cyclopropyl-2H-pyrazol-3-ylamino)-2-hydroxymethyl-imidazo[1,2-]pyrimidin-7-yl]-phenyl}-methanesulfonamide

The title compound was prepared following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.78 (dd, J=4.93, 2.15 Hz, 2H) 0.97 (dd, J=8.34, 2.27 Hz, 2H) 1.95-2.03 (m, 1H) 3.04 (s, 3H) 4.68 (s, 2H) 6.61 (s, 1H) 7.32 (d, J=6.32 Hz, 1H) 7.48-7.55 (m, 2H) 7.86 (d, J=7.83 Hz, 1H) 8.05 (s, 1H) 8.52 (s, 1H) 9.96 (s, 1H) 10.87 (s, 1H) 12.35 (s, 1H); ESI-MS: m/z 440.3 (M+H)⁺

Example 75 (5-Cyclopropyl-2H-pyrazol-3-yl)-[7-(3-ethanesulfonyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-amine

The title compound was prepared following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.83 (ddd, J=6.76, 4.74, 4.42 Hz, 2H) 0.95-1.00 (m, 2H) 1.15 (t, J=7.33 Hz, 3H) 1.95 (ddd, J=13.39, 8.34, 5.05 Hz, 1H) 3.38 (q, J=7.33 Hz, 2H) 6.53 (s, 1H) 7.81-7.90 (m, 2H) 8.00-8.05 (m, 2H) 8.53 (d, J=8.08 Hz, 1H) 8.62 (d, J=1.52 Hz, 1H) 8.67 (s, 1H) 10.97 (s, 1H) 12.48 (s, 1H); ESI-MS: m/z 409.3 (M+H)⁺

Example 76 [7-(4-Methyl-piperazin-1-yl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

Referring to Scheme 6, (7-Chloro-imidazo[1,2-c]pyrimidin-5-yl)-(5-methyl-1H-pyrazol-3-yl)-amine (0.12 mol) and 1-methyl-piperazine (1.2 mol) were dissolved in DMF (0.3 mL). This solution was heated at between 150-200° C. for 1-25 minutes using a microwave reactor. Purification by preparative HPLC afforded the product as a solid. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.27 (s, 3H) 2.84 (s, 3H) 3.13 (bs, 2H) 3.32-3.49 (m, 4H) 4.41 (bs, 2H) 6.31 (s, 1H) 6.38 (s, 1H) 7.78 (d, J=2.53 Hz, 1H) 8.29 (d, J=2.27 Hz, 1H) 10.83 (s, 1H) 12.41 (s, 1H); ESI-MS: m/z 313.3 (M+H)⁺

Example 77 (5-Methyl-1H-pyrazol-3-yl)-(7-piperidin-1-yl-imidazo[1,2-c]pyrimidin-5-yl)-amine

The title compound was prepared following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, DMSO-D6) δ ppm 1.56-164 (m, 6H) 2.26 (s, 3H) 3.63 (bs, 4H) 6.17 (s, 1H) 6.31 (s, 1H) 7.65 (d, J=2.27 Hz, 1H) 8.19 (d, J=2.27 Hz, 1H) 10.64 (s, 1H) 12.38 (s, 1H); ESI-MS: m/z 298.3 (M+H)⁺

Example 78 (5-Cyclopropyl-1H-pyrazol-3-yl)-[7-(2,3-dihydro-indol-1-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine

The title compound was prepared following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.71 (td, J=5.37, 4.17 Hz, 2H) 0.94-1.03 (m, 2H) 1.91-2.02 (m, 1H) 3.22 (t, J=8.46 Hz, 2H) 4.05 (t, J=8.59 Hz, 2H) 6.16 (s, 1H) 6.22 (s, 1H) 6.92-7.04 (m, 2H) 7.24 (d, J=7.33 Hz, 1H) 7.81 (d, J=2.02 Hz, 1H) 8.02 (d, J=7.83 Hz, 1H) 8.22 (s, 1H) 10.59 (s, 1H) 12.61 (s, 1H); ESI-MS: m/z 358.4 (M+H)⁺

Example 79 (5-Cyclopropyl-1H-pyrazol-3-yl)-[7-(3,4-dihydro-1H-isoquinolin-2-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine

The title compound was prepared following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.71-0.79 (m, 2H) 0.98-1.05 (m, 2H) 1.98 (ddd, J=13.20, 8.53, 5.31 Hz, 1H) 2.95 (t, J=5.81 Hz, 2H) 3.86 (bs, 2H) 4.79 (s, 2H) 6.20 (s, 1H) 6.34 (s, 1H) 7.24 (s, 4H) 7.70 (d, J=1.77 Hz, 1H) 8.22 (d, J=1.77 Hz, 1H) 10.76 (s, 1H) 12.47 (s, 1H); ESI-MS: m/z 372.4 (M+H)⁺

Example 80 Ethyl 5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-7-(4-((2,5-dioxoimidazolidin-1-yl)methyl)phenyl)imidazo[1,2-f]pyrimidine-2-carboxylate

The title compound was prepared following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.77-0.87 (m, 2H) 0.94-1.03 (m, 2H) 1.27 (s, 1H) 1.35 (t, J=7.20 Hz, 2H) 1.99-2.10 (m, 1H) 4.00 (s, 2H) 4.33 (q, J=7.16 Hz, 2H) 4.63 (s, 2H) 6.64 (s, 1H) 7.33 (d, J=7.83 Hz, 1H) 7.47 (t, J=7.83 Hz, 1H) 7.55 (s, 1H) 8.01 (d, J=7.58 Hz, 1H) 8.06 (s, 1H) 8.15 (s, 1H) 9.13 (s, 1H) 10.54 (s, 1H) 12.28 (s, 1H). MS [m+H] calc'd for C₂₅H₂₄N₈O₄, 501.19; found 501.19.

Example 81 Ethyl 5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-7-(4-(pyrrolidine-1-carbonyl)phenyl)imidazo[1,2-f]pyrimidine-2-carboxylate

The title compound was prepared following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD) δ ppm 0.74-0.83 (m, 2H) 1.00-1.09 (m, 2H) 1.25-1.36 (m, 5H) 1.43 (t, J=7.07 Hz, 3H) 1.92-1.97 (m, 2H) 2.00-2.06 (m, 2H) 4.40-4.47 (m, 2H) 6.46 (s, 1H) 7.53-7.63 (m, 3H) 8.14-8.21 (m, 1H) 8.29 (s, 1H) 8.71 (s, 1H). MS [m+H] calc'd for C₂₆H₂₇N₇O₃, 486.18; found 486.18.

Example 82 Ethyl 5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-7-(4-(cyclopropylcarbamoyl)phenyl)imidazo[1,2-f]pyrimidine-2-carboxylate

The title compound was prepared following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD) δ ppm 0.67-0.72 (m, 2H) 0.76-0.79 (m, 2H) 0.84 (td, J=7.14, 4.93 Hz, 2H) 0.98 (td, J=7.45, 4.29 Hz, 2H) 1.42 (t, J=7.07 Hz, 3H) 1.91-1.99 (m, 1H) 2.85-2.95 (m, 1H) 4.41 (q, J=7.07 Hz, 2H) 6.21 (s, 1H) 7.30 (s, 1H) 7.57 (t, J=7.71 Hz, 1H) 7.85 (d, J=7.83 Hz, 1H) 8.20 (d, J=7.33 Hz, 1H) 8.46 (s, 1H) 8.60 (s, 1H). MS [m+H] calc'd for C₂₅H₂₅N₇O₃, 472.21; found 472.21.

Example 83a 3-[(Cyclopentanecarbonyl-amino)-methyl]-phenylboronic acid, pinacol ester

The title compound was synthesized in quantitative yield using cyclopentanecarbonyl chloride following the procedure described for the synthesis of Example 21a. ¹H NMR (400 MHz, MeOD-d₄) δ 7.67 (s, 1H), 7.62 (d, J=7.6 Hz, 1H), 7.37 (d, J=7.6 Hz, 1H), 7.31 (t, J=7.6 Hz, 1H), 4.36 (s, 2H), 2.62-2.71 (m, 1H), 1.53-1.90 (m, 8H), 1.33 (s, 12H). [M+H] calc'd for C₁₉H₂₈BNO₃, 330; found, 330.

Example 83 Cyclopentanecarboxylic acid 3-[5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide

The title compound was synthesized in 34% yield using 3-[(cyclopentanecarbonyl-amino)-methyl]-phenylboronic acid, pinacol ester following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.51 (d, J=2.0 Hz, 1H), 8.01-8.11 (m, 3H), 7.84 (s, 1H), 7.45-7.53 (m, 2H), 6.73 (s, 1H), 4.47 (s, 2H), 2.62-2.72 (m, 1 H), 2.51 (s, 3H), 1.80-1.90 (m, 2H), 1.52-1.76 (m, 6H). [M+H] calc'd for C₂₃H₂₅N₇O, 416; found 416.

Example 84 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-phenylimidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 3-(morpholine-4-carbonyl)phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, CD₃OD) 8.39 (s, 1H) 8.27 (d, J=7.56 Hz, 2H) 8.01 (s, 1H) 7.75 (s, 1H) 7.62 (m, 2H) 6.48 (s, 1H) 3.97 (s, 1H) 3.81 (s, 4H) 3.62 (s, 2H) 3.50 (s, 2H) 2.01 (m, 1H) 1.08 (m, 2H) 0.81 (m, 2H). [M+H] calc'd for C₂₃H₂₃N₇O₂, 429; found, 429.

Example 85 N-cyclopropyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide

The title compound was synthesized using 3-(cyclopropylcarbamoyl)phenylboronic acid following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, CD₃OD) 8.64 (s, 1H) 8.41 (s, 1H) 8.35 (d, J=6.8 Hz, 1H) 8.02 (s, 1H) 7.92 (d, J=6.84 Hz, 1H) 7.76 (s, 1H) 7.65 (t, 1H) 6.67 (s, 1H) 5.50 (s, 1H) 2.92 (m, 1H) 2.42 (s, 3H) 0.86 (m, 2H) 0.69 (m, 2H). [M+H] calc'd for C₂₀H₁₉N₇O, 374; found, 374.

Example 86 (3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(4-methylpiperazin-1-yl)methanone

The title compound was synthesized using (4-methylpiperazin-1-yl)(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanone following the procedure described in the synthesis of Example 12. ¹H NMR (400 MHz, CD₃OD) 8.41 (s, 1H) 8.29 (m, 2H) 8.02 (s, 1H) 7.79 (s, 1H) 7.67 (s, 2H) 6.60 (s, 1H) 3.99 (s, 1H) 3.53 (s, 3H) 3.36 (d, J=5.4 Hz 4H) 3.18 (s, 2H) 2.96 (s, 3H) 2.40 (s, 3H). [M+H] calc'd for C₂₂H₂₄N₈O, 417; found, 417.

Example 87 (4-aminopiperidin-1-yl)(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanone

The title compound was synthesized using tert-butyl 1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperidin-4-ylcarbamate following the procedure described in the synthesis of Example 12. The protecting group was then removed by stirring in trifluoroacetic acid for 30 minutes before purification. ¹H NMR (400 MHz, CD₃OD) 8.40 (s, 1H) 8.30 (d, J=7.84 Hz 1H) 8.24 (s, 1H) 8.01 (s, 1H) 7.77 (s, 1H) 7.67 (t, 1H) 7.61 (d, J=7.84 Hz 1H) 6.60 (s, 1H) 3.45 (m, 1H) 3.31 (s, 4H) 2.39 (s, 3H) 1.62 (s, 2H). [M+H] calc'd for C₂₂H₂₄N₈O, 417; found, 417.

Example 88 3-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-(piperidin-4-yl)benzamide

The title compound was synthesized using tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamido)piperidine-1-carboxylate following the procedure described in the synthesis of Example 12. The protecting group was then removed by stirring in trifluoroacetic acid for 30 minutes before purification. ¹H NMR (400 MHz, CD₃OD) 8.64 (s, 1H) 8.40 (s, 1H) 8.35 (d, J=8.0 Hz, 1H) 8.00 (s, 1H) 7.99 (d, J=8.0 Hz, 1H) 7.77 (s, 1H) 7.65 (t, J=8.0 Hz, 1H) 6.64 (s, 1H) 4.19-4.26 (m, 1H) 3.31-3.52 (m, 2H) 3.14-3.22 (m, 2H) 2.40 (s, 3H) 2.15-2.30 (m, 2H) 1.80-2.00 (m, 2H). [M+H] calc'd for C₂₂H₂₄N₈O, 417; found, 417.

Example 89 (3-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(piperazin-1-yl)methanone

The title compound was synthesized using tert-butyl tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperazine-1-carboxylate following the procedure described in the synthesis of Example 12. The protecting group was then removed by stirring in trifluoroacetic acid for 30 minutes before purification. ¹H NMR (400 MHz, CD₃OD) 8.40 (s, 1H) 8.27-8.31 (m, 2H) 8.02 (s, 1H) 7.79 (s, 1H) 7.66-7.68 (m, 2H) 6.48 (s, 1H) 3.70-4.20 (m, 2H) 3.20-3.40 (m, 2H) 1.94-2.03 (m, 1H) 1.06-1.10 (m, 2H) 0.75-0.90 (m, 2H). [M+H] calc'd for C₂₃H₂₅N₈O, 429; found, 429.

Example 90a (S)-3-{[(N-(tert-butylcarbonyl-pyrrolidine-2-carbonyl)-amino)-methyl]-phenylboronic acid, pinacol ester

(3-Aminomethylphenyl)boronic acid pinacol ester, hydrochloride (200 mg, 0.74 mmol) and BOC-L-proline (160 mg, 0.74 mmol) were stirred with DIEA (260 mL, 1.48 mmol) in CH₂Cl₂ (5 mL). PyBOP (578 mg, 1.11 mmol) was added, and the reaction stirred at r.t for 16 h. The solution was washed with 1N HCl and brine, dried (MgSO₄), and concentrated in vacuo. Purification by silica gel chromatography (33% to 100% EtOAc/hexanes) gave 222 mg (70%) of the title compound as a clear oil. ¹H NMR (400 MHz, MeOD-d₄) δ 7.72 (s, 1H), 7.62 (d, J=7.6 Hz, 1H), 7.40 (d, J=7.6 Hz, 1H), 7.31 (t, J=7.6 Hz, 1H), 4.330-4.45 (m, 2H), 4.15-4.20 (m, 1H), 3.49-3.46 (m, 1H), 3.37-4.13 (m, 1H), 2.16-2.24 (m, 1H), 1.82-1.98 (m, 3H), 1.33 (s, 12H), 1.28 (s, 4.5H), 1.19 (s, 4.5H). [M+H] calc'd for C₂₃H₃₅BN₂O₅, 431; found, 431.

Example 90 (S)-Pyrrolidine-2-carboxylic acid 3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide

The title compound was synthesized in 34% yield using (S)-3-{[(N-(tert-butylcarbonyl-pyrrolidine-2-carbonyl)-amino)-methyl]-phenylboronic acid, pinacol ester following the procedure described in the synthesis of Example 12, followed by deprotection using 50% TFA/CH₂Cl_(2.) ¹H NMR (400 MHz, MeOD-d₄) δ 8.38 (d, J=2.0 Hz, 1H), 8.13 (s, 1H), 8.09 (d, J=7.6 Hz, 1H), 7.99 (s, 1H), 7.68 (s, 1H), 7.49-7.56 (m, 2H), 6.61 (s, 1H), 4.54 (d, J=5.6 Hz, 2H), 4.26-4.31 (m, 1H), 3.30-3.40 (m, 2H), 2.39-2.45 (m, 1H), 2.39 (s, 3H), 1.98-2.08 (m, 3H). [M+H] calc'd for C₂₂H₂₄N₈O, 417; found, 417.

Example 91 N-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-(4-methyl-piperazin-1-ylmethyl)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-methanesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.74-0.81 (m, 2H) 0.96 (dd, J=8.46, 2.15 Hz, 2H) 1.99 (ddd, J=13.52, 8.46, 5.05 Hz, 1H) 2.66 (bs, 2H) 2.81 (s, 3H) 3.04 (s, 3H) 3.21 (bs, 2H) 3.45 (bs, 2H) 3.55 (bs, 2H) 3.96 (s, 2H) 6.61 (s, 1H) 7.24-7.34 (m, 1H) 7.45-7.55 (m, 2H) 7.83 (d, J=7.83 Hz, 1H) 8.04 (s, 1H) 8.49 (s, 1H) 9.96 (s, 1H) 10.72 (bs, 1H); ESI-MS: m/z 522.4 (M+H)⁺

Example 92 [7-(3-Methanesulfonyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.32 (s, 3H) 3.31 (s, 3H) 6.69 (s, 1H) 7.85 (t, J=7.83 Hz, 1H) 7.91 (s, 1H) 8.04-8.10 (m, 2H) 8.53 (d, J=7.83 Hz, 1H) 8.63 (d, J=1.77 Hz, 1H) 8.78 (s, 1H) 11.03 (s, 1H) 12.40 (bs, 1H); ESI-MS: m/z 369.3 (M+H)⁺

Example 93 [5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-7-(3-ethanesulfonyl-phenyl)-imidazo[1,2-c]pyrimidin-2-yl]-methanol

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.82 (ddd, J=6.69, 4.67, 4.29 Hz, 2H) 0.94-1.00 (m, 2H) 1.15 (t, J=7.33 Hz, 3H) 1.95 (ddd, J=13.58, 8.40, 5.31 Hz, 1H) 3.38 (q, J=7.49 Hz, 2H) 4.69 (s, 3H) 6.51 (s, 1H) 7.77-7.86 (m, 2H) 8.02 (d, J=8.08 Hz, 1H) 8.52-8.53 (m, 2H) 8.66 (s, 1H) 10.90 (s, 1H) 12.45 (bs. 1H); ESI-MS: m/z 439.3 (M+H)⁺

Example 94 (5-Cyclopropyl-1H-pyrazol-3-yl)-[7-(3-ethanesulfonyl-phenyl)-2-(4-methyl-piperazin-1-ylmethyl)-imidazo[1,2-c]pyrimidin-5-yl]-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.82 (ddd, J=6.57, 4.67, 4.42 Hz, 2H) 0.94-1.00 (m, 2H) 1.16 (t, J=7.33 Hz, 3H) 1.94 (ddd, J=13.39, 8.34, 5.05 Hz, 1H) 2.66 (bs, 2H) 2.79 (s, 3H) 3.05 (bs, 2H) 3.21 (bs, 3H) 3.37 (q, J=7.33 Hz, 2H) 3.55 (bs, 2H) 3.95 (s, 2H) 6.52 (s, 1H) 7.73-7.83 (m, 2H) 7.96 (d, J=7.83 Hz, 1H) 8.42-8.50 (m, 2H) 8.65 (s, 1H) 10.57 (s, 1H) 12.37 (bs, 1H); ESI-MS: m/z 521.4 (M+H)⁺

Example 95 [7-(3-Ethanesulfonyl-phenyl)-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-2-yl]-methanol

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 1.14 (t, J=7.33 Hz, 3H) 2.31 (s, 3H) 3.38 (q, J=7.16 Hz, 2H) 4.68 (s, 2H) 6.66 (s, 1H) 7.78 (s, 1H) 7.83 (t, J=7.83 Hz, 1H) 8.00 (d, J=8.08 Hz, 1H) 8.47-8.56 (m, 2H) 8.72 (s, 1H) 10.87 (s, 1H) 12.35 (bs, 1H); ESI-MS: m/z 413.3 (M+H)⁺

Example 96 [7-(3-Ethanesulfonyl-phenyl)-2-(4-methyl-piperazin-1-ylmethyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 1.15 (t, J=7.45 Hz, 3H) 2.30 (s, 3H) 2.78 (s, 3H) 3.03 (bs, 2H) 3.20 (bs, 2H) 3.37 (q, J=7.33 Hz, 2H) 3.45 (s, 2H) 3.64 (s, 2H) 3.91 (s, 2H) 6.67 (s, 1H) 7.72-7.83 (m, 2H) 7.95 (d, J=7.83 Hz, 1H) 8.42 (s, 1H) 8.48 (d, J=8.08 Hz, 1H) 8.71 (s, 1H) 10.56 (s, 1H) 12.30 (s, 1H); ESI-MS: m/z 495.4 (M+H)⁺

Example 97 N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(2-(piperidin-1-yl)ethyl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.22 (s, 1H) 7.22 (d, J=1.768 Hz, 1H) 6.50 (s, 1H) 3.72 (t, J=6.3 Hz, 2H) 3.51 (d, J=12.4 Hz, 2H) 3.24 (t, J=6.6 Hz, 2H) 2.80 (d, J=10.1 Hz, 2H) 2.34 (s, 3H) 1.85 (s, 5H). MS (ES) [m+H] calc'd for C₁₇H₂₄N₈, 341; found 341.

Example 98 N⁷-(2-(diethylamino)ethyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.38 (s, 1H) 7.26 (s, 1H) 6.57 (s, 1H) 3.72-3.78 (m, 3H) 3.26 (t, J=7.3 Hz, 4H) 3.18 (m, 2H) 2.39 (s, 3H) 1.32 (t, J=7.3 Hz, 6H). MS (ES) [m+H] calc'd for C₁₆H₂₅N₈, 329; found 329.

Example 99 N⁷-(2,5-difluorobenzyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.08 (s, 1H) 7.24 (m, 1H) 6.96 (m, 2H) 6.88 (s, 1H) 6.24 (s, 1H) 4.46 (s, 2H) 2.30 (s, 3H). MS (ES) [m+H] calc'd for C₁₇H₁₆F₂N₇, 356; found 356.

Example 100 N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(thiophen-2-ylmethyl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.04 (s, 1H) 7.21 (d, J=2.5 Hz, 1H) 7.13-7.17 (dd, J=1.0 and 5.1 Hz, 1H) 6.96 (s, 1H) 6.88 (dd, J=5.1, 3.5 Hz, 1H) 6.30 (s, 1H) 5.23 (s, 1H) 4.59 (s, 2H) 2.29 (s, 3H). MS (ES) [m+H] calc'd for C₁₅H₁₆N₇S, 326; found 326.

Example 101 N⁷-(2-chlorophenethyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.08 (s, 1H) 7.27-7.32 (m, 1H) 7.17-7.22 (m, 2H) 7.08-7.16 (m, 3H) 6.31 (s, 1H) 3.38-3.40 (m, 2H) 2.91 (t, J=7.2 Hz, 2H) 2.31 (s, 3H). MS (ES) [m+H] calc'd for C₁₆H₂₅N₈, 368; found 368.

Example 102 N⁷-(3-chlorophenethyl)-N-5-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 7.99 (s, 1H) 7.11-7.22 (m, 5H) 6.31 (s, 1H) 3.45 (s, 2H) 2.80-2.91 (m, 2H) 2.30 (s, 3H). MS (ES) [m+H] calc'd for C₁₆H₂₅N₈, 368; found 368.

Example 103 N⁷-(4-chlorophenethyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 7.98 (s, 1H) 7.16-7.21 (m, 4H) 7.06-7.11 (m, 2H) 6.28 (s, 1H) 3.40 (m, 2H) 2.84 (m, 2H) 2.31 (s, 3H). MS (ES) [m+H] calc'd for C₁₈H₁₉ClN₇, 368; found 368.

Example 104 N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-phenethylimidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.05 (s, 1H) 7.24-7.14 (m, 7H) 6.29 (s, 1H) 3.33 (m, 2H) 2.89 (t, J=7.5 Hz, 2H) 2.31 (s, 3H). MS (ES) [m+H] calc'd for C₁₈H₂₀N₇, 334; found 334.

Example 105 N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(3-phenylpropyl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.04 (s, 1H) 7.19 (m, 3H) 7.07-7.14 (m, 3H) 6.28 (s, 1H), 5.23 (1s, 1H) 3.60 (m, 2H) 3.32 (s, 2H) 2.66 (t, J=7.2 Hz, 2H) 2.30 (s, 3H) 1.88-1.97 (m, 2H). MS (ES) [m+H] calc'd for C₁₉H₂₂N₇, 348; found 348.

Example 106 N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(2-phenoxyethyl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.04 (s, 1H) 7.14-7.23 (m, 3H) 6.88 (t, J=7.3 Hz, 1H) 6.81 (d, J=7.8 Hz, 2H) 6.31 (s, 1H) 6.03 (s, 1H) 4.08 (t, J=5.3 Hz, 2H) 3.55 (m, 2H) 2.28 (s, 3H). MS (ES) [m+H] calc'd for C₁₈H₂₀N₇O, 350; found 350.

Example 107 (R)-2-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylamino)-1-phenylethanol

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 7.97 (s, 1H) 7.20-7.37 (m, 6H) 7.12 (d, J=2.3 Hz, 1H) 6.27 (s, 1H) 4.86 (s, 1H) 3.36 (m, 2H) 2.26 (s, 3H). MS (ES) [m+H] calc'd for C₁₈H₂₀N₇O, 350; found 350.

Example 108 (S)-2-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylamino)-1-phenylethanol

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 7.96 (s, 1H) 7.2-7.37 (m, 6H) 7.16 (d, J=2.3 Hz, 1H) 6.32 (s, 1H) 4.86 (s, 1H) 3.41 (m, 2H) 2.27 (s, 3H). MS (ES) [m+H] calc'd for C₁₈H₂₀N₇O, 350; found 350.

Example 109 2-(methyl(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)amino)-1-phenylethanol

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 7.88 (s, 1H) 7.08-7.20 (m, 6H) 6.22 (s, 1H) 3.75 (dd, J=12.8, 2.7 Hz, 1H) 3.54-3.61 (m, 2H) 2.28 (s, 3H). MS (ES) [m+H] calc'd for C₁₉H₂₂N₇O, 364; found 364.

Example 110 (R)-2-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylamino)-4-phenylbutan-1-ol

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 7.77 (s, 1H) 7.16-7.30 (m, 6H) 6.28 (s, 1H) 4.60 (s, 1H) 3.56 (s, 1H) 3.05-3.11 (m, 1H) 3.01 (m, 3H) 2.26 (s, 3H) 1.95 (m, 2H). MS (ES) [m+H] calc'd for C₂₀H₂₃N₇O, 378; found 378.

Example 111 N⁵-(5-methyl-1H-pyrazol-3-yl)-N⁷-(pyridin-2-ylmethyl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, DMSO-D6) δ ppm 1.99 (s, 3H) 3.17 (s, 2H) 7.27-7.39 (m, 4H) 7.71-7.83 (m, 3H) 8.15-8.28 (m, 2H) 8.51-8.62 (m, 2H). MS [m+H] calc'd for C₁₆H₁₆N₈, 321.3; found 321.3.

Example 112 N⁷-(3-fluorobenzyl)-N⁷-methyl-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.14 (s, 3H) 3.18 (s, 3H) 4.89 (s, 2H) 6.05 (s, 2H) 7.03-7.13 (m, 3H) 7.34-7.44 (m, 1H) 7.69 (d, J=2.27 Hz, 1H) 8.23 (d, J=2.27 Hz, 1H) 10.71 (s, 1H) 12.31 (s, 1H) 12.87 (s, 1H). MS [m+H] calc'd for C₁₈H₁₈FN₇, 352.4; found 352.4.

Example 113 N⁷-(3-chlorobenzyl)-N⁷-methyl-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.16 (s, 3H) 3.18 (s, 3H) 4.88 (s, 2H) 6.06 (s, 2H) 7.18 (d, J=7.33 Hz, 1H) 7.29-7.40 (m, 3H) 7.70 (d, J=2.27 Hz, 1H) 8.24 (d, J=2.27 Hz, 1H) 10.71 (s, 1H) 12.32 (s, 1H) 12.92 (s, 1H). MS [m+H] calc'd for C₁₈H₁₈ClN₇, 368.3; found 368.3.

Example 114 N⁷-(3,4-dimethoxybenzyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.22 (s, 3H) 3.72 (s, 8H) 6.81-6.93 (m, 4H) 6.97 (s, 2H) 7.63 (d, J=2.53 Hz, 2H) 8.20 (b, 4H) 10.68 (b, 2H) 12.32 (s, 2H). MS [m+H] calc'd for C₁₉H₂₁N₇O₂, 380.17; found 380.17.

Example 115 N⁷-(2-Methoxy-benzyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)-imidazo[1,2-c]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.15 (s, 3H) 3.84 (s, 3H) 3.85 (s, 2H) 6.07 (s, 1H) 6.85-6.96 (m, 1H) 7.05 (d, J=7.58 Hz, 1H) 7.17 (s, 1H) 7.21-7.31 (m, 1H) 7.63 (d, J=2.53 Hz, 1H) 8.19 (s, 2H) 10.68 (s, 1H) 12.27 (s, 1H) 12.58 (s, 1H). MS [m+H] calc'd for C₁₈H₁₉N₇O, 350.3; found 350.3.

Example 116 N⁷-(4-Methoxy-benzyl)-N⁵-(5-methyl-1H-pyrazol-3-yl)-imidazo[1,2-c]pyrimidine-5,7-diamine

The title compound was synthesized following a procedure analogous to that described in Example 76. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.22 (s, 3H) 3.72 (s, 3H) 3.735 (s, 2H) 6.91 (d, J=8.59 Hz, 2H) 6.99 (d, J=8.59 Hz, 1H) 7.25 (s, 2H) 7.32-7.41 (m, 1H) 7.62 (d, J=2.53 Hz, 1H) 8.20 (s, 1H) 8.25 (s, 1H) 10.67 (s, 1H) 12.31 (s, 1H).). MS [m+H] calc'd for C₁₈H₁₉N₇O, 350.3; found 350.3.

Example 117 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)thiophene-2-sulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.13 (s, 1H) 7.73 (dd, J=3.9, 1.4 Hz, 1H) 7.70 (dd, J=5.1, 1.3 Hz, 1H) 7.61 (s, 1H) 7.28 (d, J=8.3 Hz, 2H) 7.08 (dd, J=4.9, 3.9 Hz, 1H) 6.75 (d, J=7.8 Hz, 2H) 6.62 (s, 1H) 6.49 (s, 1H) 2.51 (s, 3H). MS (ES) [m+H] calc'd for C₂₀H₁₈N₇O₂S₃, 484; found 484.

Example 118 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.10 (d, J=2.0 Hz, 1H) 7.61 (d, J=2.3 Hz, 1H) 7.26-7.31 (m, 2H) 6.72-6.77 (m, 2H) 6.65 (s, 1H) 6.50 (s, 1H) 2.64-2.71 (m, 1H) 2.46 (s, 3H) 2.40 (d, J=5.1 Hz, 1H) 1.33-1.38 (m, 2H) 1.11 (m, J=8.0, 1.9 Hz, 3H). MS (ES) [m+H] calc'd for C₁₉H₂₀N₇O₂S₂, 442; found 442.

Example 119 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)propane-2-sulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.06 (s, 1H) 7.45 (d, J=2.0 Hz, 1H) 7.35 (d, J=8.6 Hz, 2H) 7.17-7.22 (d, J=8.6 Hz, 2H) 6.47 (s, 1H) 5.89 (s, 1H) 3.15-3.20 (m, 1H) 2.11 (s, 3H) 1.20 (d, J=6.8 Hz, 6H). MS (ES) [m+H] calc'd for C₁₉H₂₁N₇O₂S₂, 444; found 444.

Example 120 1-amino-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.02 (s, 1H) 7.56-7.61 (m, 2H) 7.38-7.42 (m, 3H) 6.37 (s, 1H) 5.99 (s, 1H) 2.09 (m, 4H) 1.49-1.55 (m, 2H) 1.27-1.33 (m, 2H). MS (ES) [m+H] calc'd for C₂₀H₂₁N₈OS, 421; found 421.

Example 121 (R)-2-amino-3-methyl-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)butanamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 7.94 (d, J=1.8 Hz, 1H) 7.52 (d, J=8.6 Hz, 2H) 7.36 (d, J=2.3 Hz, 1H) 7.31 (d, J=8.6 Hz, 2H) 6.30 (s, 1H) 5.85 (s, 1H) 3.61 (d, J=5.8 Hz, 1H) 1.97 (s, 4H) 0.82 (dd, J=13.0, 6.9 Hz, 6H). MS (ES) [m+H] calc'd for C₂₁H₂₅N₈OS, 437; found 437.

Example 122 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-methoxyacetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 7.96 (d, J=2.0 Hz, 1H) 7.52 (ddd, J=8.9, 2.5, 2.2 Hz, 2H) 7.37 (d, J=2.5 Hz, 1H) 7.32-7.36 (m, 2H) 6.32 (s, 1H) 5.78 (s, 1H) 3.80 (s, 2H) 3.25 (s, 3H) 1.59 (ddd, J=13.5, 8.3, 4.9 Hz, 1H) 0.70-0.76 (m, 2H) 0.46 (dt, J=6.8, 4.7 Hz, 2H). MS (ES) [m+H] calc'd for C₂₁H₂₂N₇O₂S, 436; found 436.

Example 123 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)picolinamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.43 (d, J=4.3 Hz, 1H) 7.96-8.04 (m, 2H) 7.70-7.77 (m, 3H) 7.37-7.44 (m, 3H) 7.34 (ddd, J=7.6, 4.8, 1.0 Hz, 1H) 6.44 (s, 1H) 5.73 (s, 1H) 1.95 (s, 3H). MS (ES) [m+H] calc'd for C₂₂H₁₉N₈OS, 443; found 433.

Example 124 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)morpholine-4-carboxamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.09 (s, 1H) 7.47 (d, J=2.3 Hz, 1H) 7.16-7.21 (d, J=6.6 Hz, 2H) 6.64-6.69 (d, J=6.6 Hz, 2H) 6.27 (s, 1H) 6.23 (s, 1H) 3.60-3.68 (m, 4H) 3.56 (m, 4H) 2.07 (m, 1H) 0.87-0.98 (m, 2H) 0.59-0.66 (m, 2H). MS (ES) [m+H] calc'd for C₂₃H₂₅N₈O₂S, 477; found 477.

Example 125 2-methoxyethyl 4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.15 (s, 1H) 7.60 (s, 1H) 7.27 (s, 2H) 6.73 (d, J=8.1 Hz, 2H) 6.63 (s, 1H) 6.37 (s, 1H) 4.49 (m, 2H) 4.47 (s, 3H) 3.64-3.72 (m, 2H) 3.34 (s, 3H) 3.25 (s, 1H) 2.47 (s, 3H). MS (ES) [m+H] calc'd for C₂₀H₂₂N₇O₃S, 440; found 440.

Example 126 Ethyl 4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.07 (d, J=1.5 Hz, 1H) 7.44-7.50 (m, 3H) 7.38-7.44 (m, 2H) 6.53 (s, 1H) 5.96 (s, 1H) 4.10 (q, J=7.1 Hz, 2H) 2.13 (s, 3H) 1.20 (t, J=7.1 Hz, 3H). MS (ES) [m+H] calc'd for C₁₉H₂₀N₇O₂S, 410; found 410.

Example 127 Isobutyl 4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.12 (d, J=2.0 Hz, 1H) 7.53 (d, J=2.3 Hz, 1H) 7.25 (d, J=8.3 Hz, 2H) 6.75 (d, J=8.6 Hz, 2H) 6.55 (s, 1H) 6.41 (s, 1H) 4.08-4.14 (d, J=6.8 Hz, 2H) 2.42 (s, 3H) 1.95-2.06 (m, 1H) 0.88-0.96 (d, J=6.8, Hz, 6H). MS (ES) [m+H] calc'd for C₂₁H₂₃N₇O₂S, 438; found 438.

Example 128 Ethyl 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio) phenylcarbamate

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.94 (s, 1H) 8.35 (s, 1H) 7.52 (d, J=8.6 Hz, 2H) 7.33-7.40 (d, J=8.6 Hz, 2H) 6.58 (s, 1H) 5.97 (s, 1H) 4.09 (q, J=7.2 Hz, 2H) 1.74 (s, 1H) 1.19 (t, J=7.1 Hz, 3H) 0.83 (dd, J=8.3, 1.8 Hz, 2H) 0.56-0.68 (m, 2H). MS (ES) [m+H] calc'd for C₂₁H₂₂N₇O₂S, 436; found 436.

Example 129 {4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl}-carbamic acid but-2-ynyl ester

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.05 (d, J=2.3 Hz, 1H) 7.47 (d, J=2.3 Hz, 1H) 7.17 (d, J=8.1 Hz, 2H) 6.63 (d, J=8.3 Hz, 2H) 6.49 (s, 1H) 6.30 (s, 1H) 4.82-4.86 (m, 2H) 2.25 (m, 1H) 1.71 (t, J=2.0 Hz, 3H) 0.91-0.99 (m, 2H) 0.58-0.65 (m, 2H). MS (ES) [m+H] calc'd for C₂₁H₂₂N₇O₂S, 460; found 460.

Example 130 {4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl}-carbamic acid allyl ester

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.15 (s, 1H) 7.49-7.55 (m, 3H) 7.40-7.48 (m, 2H) 6.60 (s, 1H) 6.09 (s, 1H) 5.84-5.94 (m, 1H) 5.29 (dd, J=17.2, 1.5 Hz, 1H) 5.18 (d, J=10.4 Hz, 1H) 4.59 (d, J=5.6 Hz, 2H) 3.32 (s, 2H) 1.74-1.84 (m, 1H) 1.17 (s, 2H) 0.90-1.00 (m, 2H) 0.65-0.74 (m, 2H). MS (ES) [m+H] calc'd for C₂₂H₂₂N₇O₂S, 448; found 448.

Example 131 Propyl 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenylcarbamate

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CDCl₃/CD₃OD 10:1) δ ppm 8.09 (s, 1H) 7.49 (m, 3H) 7.39-7.45 (d, J=8.6 Hz, 2H) 6.52 (s, 1H) 6.02 (s, 1H) 4.02 (t, J=6.7 Hz, 2H) 1.71-1.81 (m, 1H) 1.54-1.65 (m, 2H) 1.13 (s, 3H) 0.83-0.93 (m, 5H) 0.61-0.68 (m, 2H). MS (ES) [m+H] calc'd for C₂₂H₂₄N₇O₂S, 450; found 450.

Example 132 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)pyrrolidine-2-carboxamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 1.94 (s, 3H) 2.11-2.23 (m, 4H) 2.36-2.45 (m, 2H) 4.79-4.80 (m, 1H) 6.04 (s, 1H) 6.23 (s, 1H) 7.22 (d, J=7.83 Hz, 2H) 7.34 (s, 2H) 7.54 (s, 1H) 7.95 (s, 1H). MS [m+H] calc'd for, C₂₁H₂₂N₈OS 435.3; found 435.3.

Example 133 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)butyramide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 1.02 (t, J=7.45 Hz, 3H) 1.68-1.79 (m, 2H) 2.21 (s, 3H) 2.40 (t, J=7.45 Hz, 2H) 5.95 (s, 1H) 6.72 (s, 1H) 7.51-7.62 (m, 2H) 7.71-7.82 (m, 3H) 8.24 (s, 1H). MS [m+H] calc'd for C₂₀H₂₁N₇OS, 408.3; found 408.3.

Example 134 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclobutanecarboxamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, DMSO-D6) δ ppm 1.79-1.88 (m, 2H) 1.98 (dt, J=17.49, 8.81 Hz, 2H) 2.12 (s, 3H) 2.16-2.27 (m, 4H) 3.25-3.32 (m, 1H) 5.85 (s, 1H) 6.67 (s, 1H) 7.58 (d, J=8.08 Hz, 2H) 7.83 (d, J=8.84 Hz, 3H) 8.46 (s, 1H) 10.09 (s, 1H) 10.98 (s, 1H) 12.32 (s, 1H). MS [m+H] calc'd for C₂₁H₂₁N₇OS, 420.4; found 420.4.

Example 135 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)isobutyramide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, DMSO-D6) δ ppm 1.12 (s, 3H) 1.13 (s, 3H) 2.12 (s, 3H) 2.59-2.71 (m, 2H) 5.84 (s, 1H) 6.70 (s, 1H) 7.58 (d, J=8.08 Hz, 2H) 7.82-7.93 (m, 3H) 8.48 (s, 1H) 10.20 (s, 1H) 11.06 (s, 1H) 12.36 (s, 1H). MS [m+H] calc'd for C₂₀H₂₁N₇OS, 408.15; found 408.15.

Example 136 2-methoxy-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.14 (s, 3H) 3.39 (s, 3H) 4.05 (s, 2H) 5.90 (s, 1H) 6.65 (s, 2H) 7.60 (d, J=7.58 Hz, 3H) 7.85-7.95 (m, 5H) 8.46 (s, 2H) 10.15 (s, 1H) 10.99 (s, 1H) 12.30 (s, 1H). MS [m+H] calc'd for C₁₉H₁₉N₇O₂S, 410.3; found 410.3.

Example 137 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-propoxyacetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 1.00 (t, J=7.45 Hz, 3H) 1.66-1.76 (m, 2H) 2.22 (s, 3H) 3.58 (t, J=6.69 Hz, 2H) 4.12 (s, 2H) 5.96 (s, 1H) 6.73 (s, 1H) 7.63 (d, J=8.59 Hz, 2H) 7.78-7.88 (m, 3H) 8.24 (d, J=2.02 Hz, 1H). MS [m+H] calc'd for C₂₁H₂₃N₇O₂S 438.3; found 438.3.

Example 138 2-ethoxy-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 1.30 (t, J=7.07 Hz, 3H) 2.21 (s, 3H) 3.67 (q, J=6.91 Hz, 3H) 4.11 (s, 2H) 6.00 (s, 1H) 6.53 (s, 1H) 7.41 (s, 2H) 7.60 (d, J=8.8 Hz, 2H) 7.80 (d, J=8.8, 2H) 7.93 (s, 1H). MS [m+H] calc'd for C₂₀H₂₁N₇O₂S, 424.82; found 424.82.

Example 139 2-(allyloxy)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 2.22 (s, 3H) 4.13 (s, 3H) 4.17 (d, J=5.81 Hz, 2H) 5.27 (d, J=10.8 Hz, 1H) 5.37 (d, J=17.18, 1H) 5.97 (s, 1H) 6.72 (s, 1H) 7.62 (d, J=8.59 Hz, 2H) 7.81-7.86 (m, 3H) 8.24 (s, 1H). MS [m+H] calc'd for C₂₁H₂₁N₇O₂S, 436.3; found 436.3.

Example 140 2-(dimethylamino)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 2.24 (s, 3H) 3.02 (s, 6H) 4.22 (s, 2H) 6.02 (s, 1H) 6.72 (s, 1H) 7.66 (d, J=8.59 Hz, 2H) 7.80-7.89 (m, 3H) 8.25 (s, 1H). MS [m+H] calc'd for C₂₀H₂₂N₈OS, 423; found 423.3.

Example 141 2-(cyclopropylamino)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.91-0.98 (m, 4H) 2.24 (s, 3H) 2.83-2.90 (m, 1H) 4.15 (s, 2H) 6.01 (s, 1H) 6.72 (s, 1H) 7.66 (d, J=8.34 Hz, 2H) 7.76-7.86 (m, 3H) 8.25 (s, 1H). MS [m+H] calc'd for C₂₁H₂₂N₈OS, 435.8; found 435.8.

Example 142 2-(1H-imidazol-1-yl)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 2.22 (s, 3H) 5.16 (s, 2H) 6.08 (s, 1H) 6.53 (s, 1H) 7.38 (s, 1H) 7.50 (d, J=11.87 Hz, 2H) 7.61 (d, J=8.84 Hz, 2H) 7.76 (d, J=8.84 Hz, 2H) 8.01 (s, 1H) 8.51 (s, 1H). MS [m+H] calc'd for C₂₁ H₁₉N₉OS, 446.3; found 446.3.

Example 143 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-(ethyl(methyl)amino)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.62-0.71 (m, 2H) 0.94 (q, J=6.32 Hz, 2H) 1.14 (t, J=7.20 Hz, 3H) 1.75-1.89 (m, 1H) 2.38 (s, 3H) 2.60 (q, J=7.07 Hz, 2H) 3.20 (s, 2H) 3.34 (s, 3H) 5.99 (s, 1H) 6.53 (s, 1H) 7.42 (s, 1H) 7.57 (d, J=8.59 Hz, 2H) 7.76 (d, J=8.34 Hz, 2H) 7.93 (s, 1H). MS [m+H] calc'd for C₂₃ H₂₆N₈OS, 463.43; found 463.43.

Example 144 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-(dimethylamino)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.67 (ddd, J=6.76, 4.74, 4.42 Hz, 2H) 0.99 (ddd, J=8.40, 6.51, 4.29 Hz, 2H) 1.86-1.91 (m, 1H) 2.69 (s, 3H) 3.02 (s, 6H) 4.20 (s, 2H) 6.07 (s, 1H) 6.64 (s, 1H) 7.66 (d, J=8.59 Hz, 2H) 7.78-7.88 (m, 3H) 8.24 (d, J=2.27 Hz, 1H). MS [m+H] calc'd for C₂₂ H₂₄N₈OS, 449.1; found 449.1.

Example 145 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-(cyclopropylamino)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.63-0.70 (m, 2H) 0.91-1.02 (m, 6H) 1.84-1.93 (m, 1H) 3.48 (td, J=7.39, 6.19 Hz, 1H) 4.14 (s, 2H) 6.08 (s, 1H) 6.63 (s, 1H) 7.65 (d, J=8.84 Hz, 2H) 7.82 (d, J=8.59 Hz, 3H) 8.24 (s, 1H). MS [m+H] calc'd for C₂₃ H₂₄N₈OS, 461.2; found 461.2.

Example 146 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-ethoxyacetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.68 (dd, J=4.93, 1.89 Hz, 2H) 0.98 (dd, J=8.34, 2.02 Hz, 2H) 1.30 (t, J=7.2 Hz, 3H) 1.79-1.91 (m, 1H) 3.67 (q, J=6.99 Hz, 2H) 4.11 (s, 2H) 6.02 (s, 1H) 6.67 (s, 1H) 7.63 (d, J=8.84 Hz, 2H) 7.79-7.90 (m, 3H) 8.24 (s, 1H). MS [m+H] calc'd for C₂₂ H₂₃N₇O₂S, 450.1; found 450.1.

Example 147 2-(ethyl(methyl)amino)-N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 1.07 (t, J=7.33 Hz, 3H) 2.20 (s, 3H) 2.38 (s, 3H) 2.60 (q, J=7.07 Hz, 2H) 3.20 (s, 2H) 5.94 (s, 1H) 6.44 (s, 1H) 7.37 (s, 1H) 7.58 (d, J=8.59 Hz, 2H) 7.75 (d, J=8.59 Hz, 2H) 7.89 (s, 1H). MS [m+H] calc'd for C₂₁ H₂₄N₈OS, 437.46; found 437.46.

Example 148 N-(4-(2-(hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-methoxyacetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.67 (ddd, J=6.76, 4.74, 4.42 Hz, 2H) 0.95-1.00 (m, 2H) 1.82-1.89 (m, 1H) 3.50 (s, 3H) 4.07 (s, 2H) 4.74 (d, J=1.01 Hz, 2H) 6.00 (s, 1H) 6.61 (s, 1H) 7.62 (d, J=8.84 Hz, 2H) 7.86 (d, J=8.84 Hz, 2H) 8.08 (s, 1H). MS [m+H] calc'd for C₂₂ H₂₃N₇O₃S, 466.42; found 466.42.

Example 149 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio) phenyl)nicotinamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.63-0.73 (m, 2H) 0.90-0.93 (m, 2H) 1.82-1.90 (m, 1H) 6.04 (s, 1H) 6.71 (s, 1H) 7.69-7.7 (m, 3H) 7.98 (d, J=8.84 Hz, 2H) 8.24 (s, 2H) 8.40 (d, J=7.33 Hz, 1H) 8.78 (s, 1H) 9.11 (s, 1H). MS [m+H] calc'd for C₂₄ H₂₀N₈OS, 469.09; found 469.09.

Example 150 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-2-methylcyclopropanecarboxamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.66-0.76 (m, 3H) 0.91-1.03 (m, 2H) 1.17 (s, 3H) 1.28-1.39 (m, 2H) 1.53 (dt, J=8.15, 4.14 Hz, 1H) 1.81-1.88 (m, 1H) 5.97 (s, 1H) 6.68 (s, 1H) 7.59 (d, J=8.59 Hz, 2H) 7.76 (s, 3H) 8.21 (s, 1H). MS [m+H] calc'd for C₂₃ H₂₃N₇OS, 446.16; found 446.16.

Example 151 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)pyrrolidine-1-carboxamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.68-0.77 (m, 3H) 1.03-1.06 (m, 2H) 1.93-2.05 (m, 5H) 3.51-3.57 (m, 4H) 6.19 (s, 1H) 6.79 (d, J=8.4 Hz, 2H) 7.32 (d, J=8.84 Hz, 3H) 8.09 (s, 1H) 8.31 (s, 1H). MS [m+H] calc'd for C₂₃ H₂₄N₈OS, 461.17; found 461.17.

Example 152 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)-3-methylbutanamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.66-0.71 (m, 2H) 0.94-1.00 (m, 2H) 1.02 (s, 3H) 1.3 (s, 3H) 1.83-1.90 (m, 1H) 2.11-2.21 (m, 1H) 2.27-2.30 (m, 2H) 6.06 (s, 1H) 6.63 (s, 1H) 7.61 (d, J=8.84 Hz, 2H) 7.78-7.82 (m, 3H) 8.24 (s, 1H). MS [m+H] calc'd for C₂₃ H₂₅N₇OS, 448.09; found 448.09.

Example 153 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-(methoxymethyl)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.65-0.70 (m, 2H) 0.95-1.04 (m, 2H) 1.82-1.91 (m, 1H) 2.17 (s, 3H) 3.45 (s, 3H) 4.62 (s, 2H) 6.01 (s, 1H) 6.60 (s, 1H) 7.61 (d, J=8.84 Hz, 2H) 7.79 (d, J=8.59 Hz, 2H) 8.14 (s, 1H). MS [m+H] calc'd for C₂₂ H₂₃N₇O₂S, 450.13; found 450.13.

Example 154 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)isonicotinamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.67 (ddd, J=6.69, 4.80, 4.67 Hz, 2H) 0.91-1.00 (m, 2H) 1.84-1.91 (m, 1H) 6.03 (s, 1H) 6.72 (s, 1H) 7.66-7.74 (m, 3H) 7.82 (d, J=2.27 Hz, 1H) 7.98-8.00 (m, 3H) 8.25 (s, 1H) 8.82 (s, 2H). MS [m+H] calc'd for C₂₄ H₂₀N₈OS, 469.35; found 469.35.

Example 155 6-chloro-N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)nicotinamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD) δ ppm 0.67-0.68 (m, 2H) 0.93-0.95 (m, 2H) 1.84-1.94 (m, 1H) 6.05 (s, 1H) 6.71 (s, 1H) 7.63-7.72 (m, 3H) 7.81 (s, 1H) 7.96 (d, J=8.0 Hz, 2H) 8.24 (s, 1H) 8.33 (dd, J=8.34, 2.53 Hz, 1H) 8.93 (s, 1H). MS [m+H] calc'd for C₂₄ H₁₉CNl₈OS, 503.34, 505.24; found 503.34.

Example 156a Ethyl 7-chloro-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidine-2-carboxylate

2,6-Dichloro-pyrimidin-4-ylamine and 3-bromo-2-oxo-propionic acid ethyl ester were reacted to provide 5,7-dichloro-imidazo[1,2-c]pyrimidine-2-carboxylic acid ethyl ester. The title compound was prepared from 5,7-dichloro-imidazo[1,2-c]pyrimidine-2-carboxylic acid ethyl ester and 5-methyl-1H-pyrazol-3-ylamine according to the procedure described in Scheme 7. ¹H NMR (400 MHz, DMSO) 10.81 (s, 1H) 9.10 (s, 1H) 7.10 (s, 1H) 6.48 (s, 1H) 4.37 (q, J=7.2 Hz 2H) 2.28 (s, 3H) 1.33 (t, J=7.2 Hz, 3H). [M+H] calc'd for C₁₃ H₁₄ClN₆O₂, 321; found, 321.

Example 156b Ethyl 7-(4-acetamidophenylthio)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidine-2-carboxylate

The title compound was synthesized following a procedure analogous to that described in Scheme 1. ¹H NMR (400 MHz, CD₃OD) 8.60 (s, 1H) 7.71-7.74 (m, 2H) 7.56-7.58 (m, 2H) 6.54 (s, 1H) 6.03 (s, 1H) 4.38 (q, J=7.2 Hz 2H) 2.21 (s, 3H) 2.16 (s, 3H) 1.38 (t, J=7.2 Hz, 3H). [M+H] calc'd for C₂₁ H₂₂N₇O₃S, 452; found, 452.

Example 156 N-(4-(2-(Hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

Ethyl 7-(4-acetamidophenylthio)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidine-2-carboxylate (10 mg, 0.022 mmol, 1 eq) was dissolved in anhydrous THF under nitrogen at 0° C. 1.0M lithium aluminum hydride in THF (220 μl) was added dropwise. Upon completion of addition the solution was stirred for 2 hours. Reaction was seen to be complete by LCMS. Sodium sulfate decahydrate was slowly added until bubbling stopped and the reaction mixture was filtered. The solid was triturated in 20% methanol in methylene chloride and filtered. This was repeated a further two times. The solvent was removed in vacuo to leave a brown oil which was purified by flash chromatography to leave the desired as an off-white solid. [M+H] calc'd for C₁₉ H₂₀N₇O₂S, 410; found, 410.

Example 157a Ethyl 7-(4-(Cyclopropanecarboxamido)phenylthio)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidine-2-carboxylate

The title compound was synthesized following a procedure analogous to that described in Example 156b. ¹H NMR (400 MHz, DMSO) 10.51 (s, 1H) 9.05 (s, 1H) 7.76-7.79 (m, 2H) 7.54-7.57 (m, 2H) 6.52 (s, 1H) 5.86 (s, 1H) 4.30 (q, J=7.2 Hz, 2H) 2.12 (s, 3H) 1.80-1.84 (m, 1H) 1.32 (t, J=7.2 Hz, 3H), 0.82-0.84 (m, 4H). [M+H] calc'd for C₂₃ H₂₃N₇O₃S, 478; found, 478.

Example 157 N-(4-(2-(Hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

The title compound was synthesized following a procedure analogous to that described in Example 156. ¹H NMR (400 MHz, CD₃OD) 8.09 (s, 1H) 7.76-7.80 (m, 2H) 7.57-7.60 (m, 2H) 6.68 (s, 1H) 5.90 (s, 1H) 4.74 (s, 2H) 2.20 (s, 3H) 1.80-1.84 (m, 1H) 0.95-1.00 (m, 2H), 0.87-0.92 (m, 2H). [M+H] calc'd for C₂₁ H₂₂N₇O₂S, 436; found, 436.

Example 158 N-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-dimethylaminomethyl-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl} acetamide

Referring to Scheme 11, ethyl 7-chloro-5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidine-2-carboxylate (3.59 g, 10.4 ml 1 eq) was dissolved in anhydrous THF under nitrogen at 0° C. 1.0M lithium aluminum hydride in THF (15.5 ml, 15.5 mmol, 1.5 eq) was added dropwise. Upon completion of addition the solution was stirred for 2 hours. Reaction was seen to be complete by LCMS. Sodium sulfate decahydrate was slowly added until bubbling stopped and the reaction mixture was filtered. The solid was triturated in 20% methanol in methylene chloride and filtered. This was repeated a further two times. The solvent was removed in vacuo to leave a brown oil which was purified by flash chromatography to leave (7-chloro-5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-2-yl) methanol as an off-white solid. 1.4 g (41%). [M+H] calc'd for C₁₃ H₁₃ClN₆O, 305; found, 305.

(7-chloro-5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-2-yl)methanol (928 mg, 30.5 mmol, 1 eq), N-(4-mercaptophenyl)acetamide (1.02 g, 61 mmol, 2 eq) and potassium carbonate (421 mg, 30.5 mmol, 1 eq) were dissolved in DMF. The mixture was placed in a microwave reactor at 160° C. for 15 minutes. LCMS confirmed the product. The solvent was evaporated and the residue purified by flash chromatography to leave N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-(hydroxymethyl)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide, 383 mg (29%). ¹H NMR (400 MHz, CDCl₃) 7.75 (s, 1H) 7.68-7.70 (m, 2H) 7.55-7.58 (m, 2H) 6.55 (br.s., 1H) 4.70 (s, 2H) 2.18 (s, 3H) 1.84-1.87 (m, 1H) 0.93-0.98 (m, 2H), 0.70-0.73 (m, 2H). [M+H] calc'd for C₂₁ H₂₂N₇O₂S, 436; found, 436.

N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-(hydroxymethyl)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide (50 mg, 0.11 mmol, 1 eq) and 2.0M methylamine in THF (1 ml, 22 mmol, 180 eq) were mixed in DMF and stirred at room temperature. The reaction was followed by LCMS. Upon completion the reaction mixture was evaporated and the residue purified by high-performance liquid chromatography to leave the title compound as an off-white solid. 4 mg (8%). ¹H NMR (400 MHz, CD₃OD) 7.87 (s, 1H) 7.72 (d, J=8.84 Hz, 2H) 7.56 (d, J=8.84 Hz, 2H) 6.50 (s, 1H) 5.99 (s, 1H) 4.67 (s, 2H) 2.15 (s, 2H) 1.85 (m, 1H) 1.29 (s, 6H) 0.96 (m, 3H) 0.66 (m, 2H). [M+H] calc'd for C₂₃ H₂₆N₈OS, 463; found, 463.

Example 159 N-(4-(5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-((4-methylpiperazin-1-yl)methyl)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 158. [M+H] calc'd for C₂₆ H₃₂N₉OS, 518; found, 518.

Example 160 N-(5-methyl-1H-pyrazol-3-yl)-7-(o-tolylthio)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 2-methylbenzenethiol following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, CD₃OD) 8.25 (s, 1H) 7.80 (s, 1H) 7.66 (d, J=7.84 Hz, 1H) 7.54 (m, 1H) 7.49 (m, 1H) 7.37 (m, 1H) 6.67 (s, 1H) 5.86 (s, 1H) 2.44 (s, 3H) 2.24 (s, 3H). [M+H] calc'd for C₁₇ H₁₆N₆S, 337; found, 337.

Example 161 ((5-fluoro-2-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)methanol

The title compound was synthesized using (5-fluoro-2-mercaptophenyl)methanol following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, DMSO) 7.64 (m, 1H) 7.42 (m, 1H) 7.22 (m, 1H) 5.45 (s, 1H) 4.60 (s, 2H) 3.61 (s, 1H) 2.08 (s, 3H). [M+H] calc'd for C₁₇ H₁₅FN₆OS, 371; found, 371.

Example 162 7-(3-aminophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 3-aminobenzenethiol following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, CD₃OD) 8.25 (s, 1H) 7.81 (s, 1H) 7.38 (t, 1H) 7.09 (d, J=9.08 Hz, 1H) 6.72 (s, 1H) 6.09 (s, 1H) 3.34 (s, 2H) 2.66 (s, 1H) 2.28 (s, 3H). [M+H] calc'd for C₁₆ H₁₅N₇S, 338; found, 338.

Example 163 Methyl 3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzoate

The title compound was synthesized using methyl 3-mercaptobenzoate following the procedure described in the synthesis of Example 1. However, the reaction mixture contained the intended (example 8) and the corresponding carboxylic acid (example 9). The two compounds were separated by HPLC. ¹H NMR (400 MHz, CD₃OD) 8.2 (m, 3H) 7.91 (d, J=8.84 Hz, 1H) 7.81 (m, 1H) 7.67 (t, 1H) 6.87 (s, 1H) 5.68 (s, 1H) 3.91 (s, 3H) 3.29 (s, 1H) 2.17 (s, 3H). [M+H] calc'd for C₁₈ H₁₆N₆O₂S, 381; found, 381.

Example 164 3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzoic acid

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CD₃OD) 8.2 (m, 3H) 7.89 (d, J=7.8 Hz, 1H) 7.82 (s, 1H) 7.66 (t, 1H) 6.86 (s, 1H) 5.71 (s, 1H) 2.19 (s, 3H). [M+H] calc'd for C₁₇ H₁₄N₆O₂S, 367; found, 367.

Example 165 Methyl 4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzoate

The title compound was synthesized using methyl 3-mercaptobenzoate following the procedure described in the synthesis of Example 1. The two compounds were separated by HPLC. ¹H NMR (400 MHz, CD₃OD) 8.26 (m, 1H) 8.11-8.26 (m, 2H) 7.84 (s, 1H) 7.76-7.78 (m, 2H) 6.94 (s, 1H) 5.73 (s, 1H) 3.96 (s, 3H) 2.13 (s, 3H). [M+H] calc'd for C₁₈ H₁₇N₆O₂S, 381; found, 381.

Example 166 4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzoic acid

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, CD₃OD) 8.27 (s, 1H) 8.13-8.15 (m, 2H) 7.84 (s, 1H) 7.75-7.78 (m, 2H) 7.33 (m, 1H) 6.94 (s, 1H) 5.73 (s, 1H) 2.15 (s, 3H). [M+H] calc'd for C₁₇ H₁₅N₆O₂S, 367; found, 367.

Example 167 (E)-methyl 3-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acrylate

The title compound was synthesized using (E)-methyl 3-(4-mercaptophenyl)acrylate following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, CD₃OD) 8.2 (s, 1H) 7.79 (m, 4H) 7.71 (d, J=8.32 Hz, 2H) 6.83 (s, 1H) 6.71 (d, J=16.2 Hz, 1H) 5.87 (s, 1H) 3.81 (s, 3H) 2.15 (s, 1H). [M+H] calc'd for C₂₀ H₁₈N₆O₂S, 407; found, 407.

Example 168 3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzamide

The title compound was synthesized using 3-mercaptobenzamide following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, CD₃OD) 8.2 (s, 1H) 8.19 (m, 1H) 8.10 (m, 1H) 7.82 (m, 2H) 7.62 (m, 1H) 6.81 (s, 1H) 5.79 (s, 1H) 2.65 (s, 1H) 2.20 (s, 3H). [M+H] calc'd for C₁₇ H₁₅N₇OS, 366; found, 366.

Example 169 7-(2-Amino-4-chlorophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 2-amino-4-chlorobenzenethiol following the procedure described in the synthesis of Example 1. [M+H] calc'd for C₁₆ H₁₅ClN₇S, 372; found, 372.

Example 170 2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetic acid

The title compound was synthesized using 2-(3-mercaptophenyl)acetic acid following the procedure described in the synthesis of Example 1. ¹H NMR (400 MHz, CD₃OD) 8.46 (s, 1H) 7.86 (s, 1H) 7.58 (s, 1H) 7.53 (m, 3H) 6.66 (s, 1H) 5.89 (s, 1H) 3.67 (s, 2H) 2.89 (s, 1H) 2.73 (s, 1H) 2.17 (s, 3H). [M+H] calc'd for C₁₈ H₁₆N₆O₂S, 381; found, 381.

Example 171 N-cyclopropyl-2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

Referring to Scheme 8, 2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetic acid (30 mg, 0.078 mmol, 1 eq), hydroxybenzotriazole (11 mg, 0.078 mmol, 1 eq), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (16 mg, 0.078 mmol, 1 eq), triethylamine (16 μl, 0.15 mmol, 2 eq) and cyclopropylamine (27 μl, 0.39 mmol, 5 eq) were stirred in DMF (2 ml) for 8 hours. The solvent was removed and the residue purified by high-performance liquid chromatography to leave N-cyclopropyl-2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide, 29 mg (88% yield). ¹H NMR (400 MHz, CD₃OD) 8.24 (s, 1H) 7.81 (s, 1H) 7.61 (s, 1H) 7.58 (m, 1H) 7.51 (m, 2H) 6.70 (s, 1H) 5.89 (s, 1H) 3.98 (s, 1H) 3.51 (s, 1H) 3.34 (s, 1H) 2.61 (m, 1H) 2.25 (s, 3H) 0.69 (m, 2H) 0.44 (m, 2H). [M+H] calc'd for C₂₁ H₂₁N₇OS, 420; found, 420.

Example 172 N-methyl-2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 171. ¹H NMR (400 MHz, CD₃OD) 8.24 (s, 1H) 7.81 (s, 1H) 7.62 (s, 1H) 7.58 (s, 1H) 7.52 (s, 2H) 6.70 (s, 1H) 5.97 (s, 1H) 3.98 (s, 1H) 3.55 (s, 2H) 3.34 (s, 1H) 2.68 (s, 3H) 2.25 (s, 3H). [M+H] calc'd for C₁₉ H₁₉N₇OS, 394; found, 394.

Example 173 N-ethyl-2-(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 171. ¹H NMR (400 MHz, CD₃OD) 8.24 (s, 1H) 7.80 (s, 1H) 7.62 (s, 1H) 7.57 (s, 1H) 7.52 (s, 2H) 6.70 (s, 1H) 5.97 (s, 1H) 3.54 (s, 2H) 3.17 (m, 2H) 2.24 (s, 2H) 2.14 (s, 3H) 1.07 (m, 3H). [M+H] calc'd for C₂₀ H₂₁N₇OS, 408; found, 408.

Example 174 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-ethylbenzamide

Referring to Scheme 9, 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzoic acid (40 mg, 0.1 mmol, 1 eq), hydroxybenzotriazole (14 mg, 0.1 mmol, 1 eq), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (19.5 mg, 0.1 mmol, 1 eq), triethylamine (29 μl, 0.2 mmol, 2 eq) and ethanamine (50 μl, 0.15 mmol, 1.5 eq) were stirred in DMF (2 ml) for 8 hours. The solvent was removed and the residue purified by high-performance liquid chromatography to leave 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-ethylbenzamide. 21 mg (51% yield). ¹H NMR (400 MHz, DMSO) 8.66 (s, 1H) 8.51 (s, 1H) 8.03 (d, J=8.32 Hz, 1H) 7.93 (s, 1H) 7.74 (d, J=8.36 Hz, 1H) 6.88 (s, 1H) 5.78 (s, 1H) 3.31 (m, 3H) 3.17 (s, 2H) 1.13 (m, 1H) 0.86 (m, 2H) 0.54 (m, 2H). [M+H] calc'd for C₂₁ H₂₁N₇OS, 420; found, 420.

Example 175 (4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)(piperazin-1-yl)methanone

The title compound was synthesized using tert-butyl piperazine-1-carboxylate following the procedure described in the synthesis of Example 174. The protecting group was then removed by stirring in trifluoroacetic acid for 30 minutes before purification. ¹ H NMR (400 MHz, CD₃OD) 8.23 (s, 1H) 7.79 (m, 2H) 7.66 (m, 2H) 6.71 (s, 1H) 6.12 (s, 1H) 3.98 (s, 1H) 3.34 (s, 2H) 1.93 (m, 1H) 0.99 (m, 2H) 0.70 (m, 2H). [M+H] calc'd for C₂₃ H₂₄N₈OS, 461; found, 461.

Example 176 N-cyclopropyl-4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzamide

The title compound was synthesized using cyclopropanamine following the procedure described in the synthesis of Example 174. ¹H NMR (400 MHz, CD₃OD) 8.52 (s, 1H) 8.34 (s, 2H) 7.89 (m, 2H) 7.60 (s, 2H) 7.53 (s, 1H) 6.87 (s, 1H) 5.76 (s, 1H) 2.84 (m, 1H) 1.68 (m, 2H) 0.82 (m, 2H) 0.69 (m, 2H) 0.57 (m, 2H) 0.43 (m, 2H). [M+H] calc'd for C₂₂ H₂₁N₇OS, 432; found, 432.

Example 177 Azetidin-1-yl(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)methanone

The title compound was synthesized using azetidine following the procedure described in the synthesis of Example 174. ¹H NMR (400 MHz, CD₃OD) 8.26 (s, 1H) 7.77 (m, 4H) 6.80 (s, 1H) 5.95 (s, 1H) 4.42 (m, 2H) 4.23 (m, 2H) 3.98 (s, 1H) 2.99 (s, 1H) 2.86 (s, 2H) 2.40 (m, 2H) 1.86 (m, 1H) 0.98 (m, 2H) 0.66 (m, 2H). [M+H] calc'd for C₂₂ H₂₁N₇OS, 432; found, 432.

Example 178 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(pyrrolidin-3-yl)benzamide

The title compound was synthesized using tert-butyl 3-aminopyrrolidine-1-carboxylate following the procedure described in the synthesis of Example 174. The protecting group was then removed by stirring in trifluoroacetic acid for 30 minutes before purification. ¹H NMR (400 MHz, CD₃OD) 8.27 (s, 1H) 8.01 (m, 2H) 7.85 (s, 1H) 7.77 (m, 2H) 6.85 (s, 1H) 5.91 (s, 1H) 4.65 (m, 1H) 3.61 (m, 2H) 3.39 (m, 1H) 2.42 (m, 2H) 2.19 (m, 2H) 1.81 (m, 1H) 1.29 (s, 1H) 0.96 (m, 2H) 0.60 (m, 2H). [M+H] calc'd for C₂₃ H₂₄N₈OS, 461; found, 461.

Example 179 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(piperidin-4-yl)benzamide

The title compound was synthesized using tert-butyl 4-aminopiperidine-1-carboxylate following the procedure described in the synthesis of Example 174. The protecting group was then removed by stirring in trifluoroacetic acid for 30 minutes before purification. ¹H NMR (400 MHz, CD₃OD) 8.27 (s, 1H) 7.99 (m, 2H) 7.84 (s, 1H) 7.77 (m, 2H) 6.87 (s, 1H) 5.87 (s, 1H) 4.21 (m, 1H) 3.47 (m, 2H) 3.17 (m, 2H) 2.65 (s, 2H) 2.20 (m, 2H) 1.81 (m, 3H) 0.94 (m, 2H) 0.60 (s, 2H). [M+H] calc'd for C₂₄ H₂₆N₈OS, 475; found, 475.

Example 180 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(piperidin-3-yl)benzamide

The title compound was synthesized using tert-butyl 3-aminopiperidine-1-carboxylate following the procedure described in the synthesis of Example 174. The protecting group was then removed by stirring in trifluoroacetic acid for 30 minutes before purification. ¹H NMR (400 MHz, CD₃OD) 8.27 (s, 1H) 8.00 (m, 2H) 7.85 (s, 1H) 7.77 (m, 2H) 6.87 (s, 1H) 5.88 (s, 1H) 4.29 (m, 1H) 3.98 (s, 1H) 3.53 (m, 1H) 3.34 (s, 2H) 2.95 (m, 2H) 2.07 (m, 2H) 1.80 (m, 3H) 0.94 (m, 2H) 0.60 (s, 2H). [M+H] calc'd for C₂₄ H₂₆N₈OS, 475; found, 475.

Example 181 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-methoxybenzamide

The title compound was synthesized using methoxyamine following the procedure described in the synthesis of Example 174. ¹H NMR (400 MHz, CD₃OD) 8.28 (s, 1H) 7.92 (d, J=8.08 Hz, 2H) 7.85 (s, 1H) 7.76 (d, J=8.32 Hz, 2H) 6.91 (s, 1H) 5.83 (s, 1H) 3.83 (s, 3H) 3.31 (s, 2H) 1.80 (m, 1H) 0.98 (m, 2H) 0.61 (m, 2H). [M+H] calc'd for C₂₀ H₁₉N₇O₂S, 422; found, 422.

Example 182 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N′,N′-di methylbenzohydrazide

The title compound was synthesized using 1,1-dimethylhydrazine following the procedure described in the synthesis of Example 174. ¹H NMR (400 MHz, CD₃OD) 8.27 (s, 1H) 7.97 (d, J=7.56 Hz, 2H) 7.85 (s, 1H) 7.77 (d, J=7.78 Hz, 2H) 6.89 (s, 1H) 5.85 (s, 1H) 2.77 (s, 4H) 1.80 (m, 1H) 0.96 (m, 2H) 0.60 (m, 2H). [M+H] calc'd for C₂₁ H₂₂N₈OS, 435; found, 435.

Example 183 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(2-(dimethylamino)ethyl)benzamide

The title compound was synthesized using N1,N1-dimethylethane-1,2-diamine following the procedure described in the synthesis of Example 174. ¹H NMR (400 MHz, CD₃OD) 8.27 (s, 1H) 8.03 (d, J=8.32 Hz, 2H) 7.85 (s, 1H) 7.79 (d, J=8.36 Hz, 2H) 6.85 (s, 1H) 5.92 (s, 1H) 3.79 (m, 2H) 3.40 (m, 2H) 3.00 (s, 6H) 1.81 (m, 1H) 0.95 (m, 2H) 0.60 (m, 2H). [M+H] calc'd for C₂₃ H₂₆N₈OS, 463; found, 463.

Example 184 4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)-N-(2-hydroxyethyl)benzamide

The title compound was synthesized using 2-aminoethanol following the procedure described in the synthesis of Example 174. ¹H NMR (400 MHz, CD₃OD) 8.26 (s, 1H) 7.99 (m, 2H) 7.84 (s, 1H) 7.74 (d, J=8.36 Hz, 2H) 6.85 (s, 1H) 5.87 (s, 1H) 3.98 (m, 1H) 3.72 (m, 2H) 3.53 (m, 2H) 1.80 (m, 1H) 0.95 (m, 2H) 0.59 (m, 2H). [M+H] calc'd for C₂₁ H₂₁N₇O₂S, 436; found, 436.

Example 185 (4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)(morpholino)methanone

The title compound was synthesized using morpholine following the procedure described in the synthesis of Example 174. ¹H NMR (400 MHz, CD₃OD) 8.23 (s, 1H) 7.89 (s, 1H) 7.79 (d, J=8.32 Hz, 2H) 7.61 (d, J=8.32 Hz, 2H) 6.67 (s, 1H) 6.14 (s, 1H) 3.78-3.65 (d, J=50.7 Hz, 6H) 3.48 (s, 2H) 1.94 (m, 1H) 1.00 (m, 2H) 0.72 (m, 2H). [M+H] calc'd for C₂₃ H₂₃N₇O₂S, 462; found, 462.

Example 186 N-cyclopropyl-4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzamide

The title compound was synthesized using cyclopropanamine following the procedure described in the synthesis of Example 174. ¹H NMR (400 MHz, CD₃OD) 8.26 (s, 1H) 7.79 (d, J=7.84 Hz, 2H) 7.84 (s, 1H) 7.76 (d, J=8.08 Hz, 2H) 6.89 (s, 1H) 5.75 (s, 1H) 2.88 (m, 1H) 2.15 (s, 3H) 0.85 (m, 2H) 0.66 (m, 2H). [M+H] calc'd for C₂₃ H₂₃N₇O₂S, 462; found, 462.

Example 187 N-ethyl-4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)benzamide

The title compound was synthesized using ethanamine following the procedure described in the synthesis of Example 174. ¹H NMR (400 MHz, CD₃OD) 8.27 (s, 1H) 8.00 (d, J=8.56 Hz, 2H) 7.84 (s, 1H) 7.78 (d, J=8.6 Hz, 2H) 6.89 (s, 1H) 5.78 (s, 1H) 3.47 (m, 2H) 2.16 (s, 3H) 1.26 (m, 3H). [M+H] calc'd for C₁₉ H₁₉N₇OS, 394; found, 394.

Example 188 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-(5-ethyl-1,3,4-oxadiazol-2-yl)phenylthio)imidazo[1,2-f]pyrimidin-5-amine

Referring to Scheme 10, 4 4-(tritylthio)benzohydrazide (407 mg, 0.99 mmol, 1 eq), is reacted with Triethyl orthopropionate (2 ml, 10.0 ml 10 eq) in a microwave reactor at 120° C. for 20 minutes. LCMS confirmed the product. Excess propionate was removed under a stream of nitrogen to leave Compound D that was used without further purification. Compound D was dissolved in dioxane (2 ml) and 3 drops of acetic acid was added. This mixture was reacted in a microwave reactor at 170° C. for 20 minutes. TLC and LCMS confirmed the intended product. The solvent was removed and the residue purified by flash chromatography to leave 2-ethyl-5-(4-(tritylthio)phenyl)-1,3,4-oxadiazole-Compound E. 220 mg (49% yield). [M+H] calc'd for C₂₉ H₂₄N₂OS, 449; found, 449.

2-Ethyl-5-(4-(tritylthio)phenyl)-1,3,4-oxadiazole was dissolved in trifluoroacetic acid (5 ml) and a large excess of triethyl silane (500 μl) was added. The solution was stirred for 10 minutes then the solvent was removed under a stream of nitrogen to leave 4-(5-ethyl-1,3,4-oxadiazol-2-yl)benzenethiol-Compound F 98 mg (99%).

4-(5-Ethyl-1,3,4-oxadiazol-2-yl)benzenethiol (53 mg, 0.26 mmol, 1.3 eq) and 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine (50 mg, 0.20 mmol, 1 eq) were dissolved in DMF (2 ml) and reacted in a microwave reactor at 190° C. for 15 minutes. The solvent was removed in vacuo and the residue purified by high-performance liquid chromatography to leave N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-(5-ethyl-1,3,4-oxadiazol-2-yl)phenylthio)imidazo[1,2-f]pyrimidin-5-amine as a tan solid, 30 mg (37%). ¹H NMR (400 MHz, CD₃OD) 8.27 (s, 1H) 8.17 (d, J=8.6 Hz, 2H) 7.85 (m, 3H) 6.98 (s, 1H) 5.81 (s, 1H) 3.03 (m, 2H) 1.69 (m, 1H) 1.44 (m, 3H) 0.78 (m, 2H) 0.51 (m, 2H). [M+H] calc'd for C₂₂ H₂₀N₈OS, 445; found, 445.

Example 189 7-(4-(5-ethyl-1,3,4-oxadiazol-2-yl)phenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine following the procedure described in the synthesis of Example 188. ¹H NMR (400 MHz, CD₃OD) 8.27 (s, 1H) 8.19 (d, J=8.56 Hz, 2H) 7.86 (m, 3H) 6.97 (s, 1H) 5.83 (s, 1H) 3.05 (m, 2H) 2.06 (s, 3H) 1.46 (m, 3H). [M+H] calc'd for C₂₀ H₁₈N₈OS, 419; found, 419.

Example 190 7-(4-(1,3,4-Oxadiazol-2-yl)phenylthio)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine following the procedure described in the synthesis of Example 188. ¹H NMR (400 MHz, CD₃OD) 9.10 (s, 1H) 8.28 (s, 1H) 8.19-8.21 (m, 2H) 7.84-7.87 (m, 3H) 7.00 (s, 1H) 5.81 (s, 1H) 1.64-1.69 (m, 1H) 0.76-0.80 (m, 2H) 0.40-0.60 (m, 2H). [M+H] calc'd for C₂₀ H₁₇N₈OS, 417; found, 417.

Example 191 7-(4-(1,3,4-oxadiazol-2-yl)phenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine following the procedure described in the synthesis of Example 188. ¹H NMR (400 MHz, CD₃OD) 9.07 (s, 1H) 8.12-8.15 (m, 2H) 8.01 (s, 1H) 7.78-7.80 (m, 2H) 7.51 (s, 1H) 6.88 (s, 1H) 5.90 (s, 1H) 5.49 (s, 1H) 2.03 (s, 3H). [M+H] calc'd for C₁₈ H₁₅N₈OS, 391; found, 391.

Example 192 7-(4-(5-Methyl-1,3,4-oxadiazol-2-yl)phenylthio)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine following the procedure described in the synthesis of Example 188. ¹H NMR (400 MHz, CD₃OD) 8.27 (br.s., 1H) 8.15-8.27 (m, 2H) 7.83-7.86 (m, 3H) 6.95 (s, 1H) 5.84 (s, 1H) 2.65 (s, 3H) 2.07 (s, 3H). [M+H] calc'd for C₁₉ H₁₇N₈OS, 405; found, 405.

Example 193 N-(5-Cyclopropyl-1H-pyrazol-3-yl)-7-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenylthio)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized using 7-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine following the procedure described in the synthesis of Example 188. ¹H NMR (400 MHz, CD₃OD) 8.28 (br.s., 1H) 8.13-8.16 (m, 2H) 7.82-7.87 (m, 3H) 6.98 (s, 1H) 5.83 (s, 1H) 2.66 (s, 3H) 1.68-1.72 (m, 1H), 0.80-0.83 (m, 2H), 0.45-0.60 (m, 2H). [M+H] calc'd for C₂₁ H₁₉N₈OS, 431; found, 431.

Example 194 N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yloxy)phenyl)acetamide

Referring to Scheme 12, a mixture of (7-Chloro-imidazo[1,2-c]pyrimidin-5-yl)-(5-cyclopropyl-1H-pyrazol-3-yl)-amine (125 mg, 0.46 mmol), N-(4-Hydroxy-phenyl)-acetamide (689 mg, 4.56 mmol) and K₂CO₃ (630 mg) was mixed in DMF (1 ml) was heated at 200° C. in microwave for 15 minutes. The reaction mixture was then purified with HPLC to give the title compound (30 mg) as a solid. ¹H NMR (400 MHz, CD₃OD) 7.97 (s, 1H) 7.68-7.70 (m, 2H) 7.45 (s, 1H) 7.10-7.12 (m, 2H) 6.35 (s, 1H) 5.74 (s, 1H) 2.15 (s, 3H) 1.75 (m, 1H) 0.87-0.89 (m, 2H) 0.49 (m, 2H). [M+H] calc'd for C₂₀ H₂₀N₇O₂S, 390; found, 390.

Example 195 2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-phenylimidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.15 (m, 2H) 8.05 (s, 1H) 7.58 (s, 1H) 7.54 (m, 3H) 6.60 (s, 1H) 2.55 (s, 3H) 2.39 (s, 3H). [M+H] calc'd for C17H16N6, 304; found, 304.

Example 196 N-cyclopropyl-2-(3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 7.99 (m, 2H) 7.75 (s, 1H) 7.44 (s, 1H) 7.40 (d, J=32.84 Hz, 3H) 6.64 (s, 1H) 3.55 (s, 2H) 3.34 (s, 1H) 2.67 (m, 1H) 2.40 (d, J=17.44 Hz, 6H) 1.28 (s, 2H) 0.70 (m, 2H) 0.49 (m, 2H). [M+H] calc'd for C22H18N7O, 402; found, 402.

Example 197 7-(3-(ethylsulfonyl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.80 (s, 1H) 8.49 (d, J=7.56 Hz, 1H) 8.10 (s, 1H) 8.06 (d, J=6.84 Hz 1H) 7.82 (m, 1H) 7.76 (s, 1H) 6.65 (s, 1H) 2.57 (s, 3H) 2.40 (s, 3H) 1.25 (m, 3H). [M+H] calc'd for C₁₉ H₂₀N₆O₂S, 396; found, 397.

Example 198 2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-methylsulfonyl)phenyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.84 (s, 1H) 8.47 (s, 1H) 8.09 (s, 1H) 7.80 (m, 2H) 6.65 (s, 1H) 3.19 (s, 3H) 2.57 (s, 3H) 2.40 (s, 3H). [M+H] calc'd for C₁₈ H₁₈N₆O₂S, 383; found, 383.

Example 199 2-methoxy-N-methyl-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.76 (s, 1H) 8.37 (d, J=8.6 Hz, 1H) 8.03 (s, 1H) 7.57 (m, 1H) 7.35 (d, J=8.84 Hz, 1H) 6.69 (s, 1H) 4.06 (s, 3H) 2.53 (s, 6H) 2.40 (s, 3H). [M+H] calc'd for C₁₉ H₂₁N₇O₃S, 428; found, 428.

Example 200 2-methoxy-N-methyl-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.57 (s, 1H) 8.24 (s, 1H) 8.04 (s, 1H) 7.56 (s, 1H) 6.66 (s, 1H) 2.98 (m, 2H) 2.54 (s, 3H) 2.39 (s, 3H) 1.08 (m, 3H). [M+H] calc'd for C₂₁ H₂₃N₇O₃S, 454; found, 454.

Example 201 N-ethyl-N-methyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.58 (s, 1H) 8.32 (d, J=8.08 Hz, 1H) 8.05 (s, 1H) 7.87 (d, J=8.56 Hz, 1H) 7.72 (d, J=7.84 Hz, 1H) 7.67 (s, 1H) 6.57 (s, 1H) 3.31 (s, 3H) 3.09 (m, 2H) 2.73 (s, 3H) 2.56 (s, 3H) 2.38 (s, 3H) 1.10 (m, 3H). [M+H] calc'd for C₂₀ H₂₃N₇O₂S, 426; found, 426.

Example 202 N-ethyl-N-methyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-yl amino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.35 (s, 1H) 8.06 (s, 1H) 7.88 (d, J=7.84 Hz, 1H) 7.56 (s, 1H) 7.42 (d, J=8.36 Hz, 1H) 6.77 (s, 1H) 3.17 (m, 2H) 2.55 (s, 3H) 2.43 (d, J=13.12 Hz, 6H) 1.36 (m, 3H). [M+H] calc'd for C₂₀ H₂₃N₇O₂S, 426; found, 426.

Example 203 N-(3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)cyclopropanesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.19 (br.s., 1H) 7.80 (br.d., 1H) 7.24-7.44 (m, 4H) 6.75 (br.s., 1H) 2.56-2.62 (m, 1H) 2.43 (s, 3H) 2.38 (s, 3H) 1.06-1.09 (m, 2H), 0.94-0.97 (m, 2H). [M+H] calc'd for C₂₀ H₂₂N₇O₂S, 424; found, 424.

Example 204 N-Ethyl-2-methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.68 (d, J=2.4, 1H) 8.27 (dd, J=8.8, 2.4, 1H) 7.97 (s., 1H) 7.52 (s, 1H) 7.28 (d, J=8.8, 1H) 6.61 (s, 1H) 4.05 (s, 3H) 2.91 (q, J=7.2, 2H) 2.53 (s, 3H) 2.38 (s, 3H) 1.05 (t, J=7.2, 3H). [M+H] calc'd for C₂₀ H₂₃N₇O₃S, 442; found, 442.

Example 205 N-(3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)ethanesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.21 (s, 1H) 8.04 (s, 1H) 7.80 (d, J=7.6, 1H) 7.55 (s, 1H) 7.45 (t, J=8.0, 1H) 7.24-7.26 (m, 1H) 6.72 (s, 1H) 3.98 (s, 1H) 3.14 (q, J=7.6, 2H) 2.54 (s, 3H) 2.39 (s, 3H) 1.31 (t, J=7.6, 3H). [M+H] calc'd for C₁₉ H₂₂N₇O₂S, 412; found, 412.

Example 206 N-(2-Methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)cyclopropanesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.83 (d, J=2.4, 1H) 8.39 (dd, J=8.8, 2.4, 1H) 8.05 (s, 1H) 7.59 (s, 1H) 7.37 (d, J=8.8, 1H) 6.69 (s, 1H) 4.07 (s, 3H) 2.55 (s, 3H) 2.41 (s, 3H) 2.11-2.15 (m, 1H) 0.43-0.65 (m, 4H). [M+H] calc'd for C₂₁ H₂₄N₇O₃S, 454; found, 454.

Example 207 N-(3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.26 (m, 1H) 8.07 (s, 1H) 7.87 (d, J=8.0, 1H) 7.58 (s, 1H) 7.49 (t, J=8.0, 1H) 6.74 (s, 1H) 3.01 (s, 3H) 2.57 (s, 3H) 2.40 (s, 3H). [M+H] calc'd for C₁₈ H₂₀N₇O₂S, 398; found, 398.

Example 208 N-(4-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, CD₃OD) 8.14 (d, J=8.8, 2H) 8.03 (s, 1H) 7.54 (s, 1H) 7.39 (d, J=8.8, 2H) 6.58 (s, 1H) 3.05 (s, 3H) 2.54 (s, 3H) 2.39 (s, 3H). [M+H] calc'd for C₁₈ H₂₀N₇O₂S, 398; found, 398.

Example 209 Cyclopropane carboxylic acid 4-fluoro-3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.39 (s, 1H), 8.15 (d, J=7.2 Hz, 1H), 7.99 (s, 1H), 7.67 (s, 1H), 7.45-7.51 (m, 1H), 7.25-7.31 (m, 1H), 6.62 (s, 1H), 4.45 (s, 2H), 2.39 (s, 3H), 1.57-1.62 (m, 1H), 0.82-0.88 (m, 2H), 0.71-0.78 (m, 2H). [M+H] calc'd for C₂₁ H₂₀FN₇O, 406; found, 406.

Example 210 Cyclopropane carboxylic acid 4-fluoro-3-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.14 (d, J=7.2 Hz, 1H), 8.09 (s, 1H), 7.58 (s, 1H), 7.45-7.51 (m, 1H), 7.24-7.30 (m, 1H), 6.61 (s, 1H), 4.43 (s, 2H), 2.55 (s, 3H), 2.38 (s, 3H), 1.54-1.61 (m, 1H), 0.82-0.88 (m, 2H), 0.70-0.77 (m, 2H). [M+H] calc'd for C₂₂ H₂₂FN₇O, 420; found, 420.

Example 211 5-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-1,3-dihydro-benzoimidazol-2-one

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-d₆) δ 12.39 (s, 1H), 10.97 (s, 1H), 10.94 (s, 1H), 10.77 (s, 1H), 8.29 (s, 1H), 7.82 (d, J=7.6 Hz, 1H), 7.75 (s, 1H), 7.55 (s, 1H), 7.07 (d, J=7.6 Hz, 1H), 6.60 (s, 1H), 2.43 (s, 3H), 2.34 (s, 3H). [M+H] calc'd for C₁₈ H₁₆N₈O, 361; found, 361.

Example 212 Cyclopropanesulfonic acid methyl-{3-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-amide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.28 (s, 1H), 7.96 (s, 1H), 7.76 (s, 1H), 7.45-7.51 (m, 2H), 7.40 (s, 1H), 6.69 (s, 1H), 3.41 (s, 3H), 2.51-2.60 (m, 1H), 2.42 (s, 3H), 2.35 (s, 3H), 0.90-0.98 (m, 4H). [M+H] calc'd for C₂₁ H₂₃N₇O₂S, 438; found, 438.

Example 213 (5-Methyl-1H-pyrazol-3-yl)-(2-methyl-7-pyridin-2-yl-imidazo[1,2-c]pyrimidin-5-yl]-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.63 (s, 1H), 8.20-8.33 (m, 2H), 7.91 (t, J=7.6 Hz, 1H), 7.79 (s, 1H), 7.38-7.45 (m, 1H), 6.51 (s, 1H), 2.42 (s, 3H), 2.35 (s, 3H). [M+H] calc'd for C₁₆ H₁₅N₇, 306; found, 306.

Example 214 [7-(1-Ethanesulfonyl-1H-indol-6-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-(5-methyl-1H-pyrazol-3-yl)-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.89 (s, 1H), 7.96 (d, J=8.4 Hz, 1H), 7.79 (s, 1H), 7.71 (d, J=8.4 Hz, 1H), 7.59 (d, J=3.6 Hz, 1H), 7.46 (s, 1H), 6.86 (s, 1H), 6.79 (d, J=3.6 Hz, 1H), 3.48 (q, J=7.2 Hz, 2H), 2.42 (s, 6H), 1.15 (t, J=7.2 Hz, 3H). [M+H] calc'd for C₂₁ H₂₁N₇O₂S, 436; found, 436.

Example 215 Ethanesulfonic acid methyl-{3-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzyl}-amide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.09 (s, 1H), 7.92 (s, 1H), 7.71 (s, 1H), 7.26-7.45 (m, 3H), 6.61 (s, 1H), 4.40 (s, 2H), 3.11 (q, J=7.2 Hz, 2H), 2.80 (s, 3H), 2.39 (s, 3H), 2.36 (s, 3H), 1.36 (t, J=7.2 Hz, 3H). [M+H] calc'd for C₂₁ H₂₅N₇O₂S, 440; found, 440.

Example 216 Ethanesulfonic acid {5-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-1H-indol-7-yl}-amide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d₄) δ 8.14 (s, 1H), 7.97 (s, 1H), 7.72 (s, 1H), 7.30-7.39 (m, 2H), 6.75 (s, 1H), 6.59 (s, 1H), 3.16 (q, J=7.2 Hz, 2H), 2.41 (s, 3H), 2.38 (s, 3H), 1.35 (t, J=7.2 Hz, 3H). [M+H] calc'd for C₂₁ H₂₂N₈O₂S, 451; found, 451.

Example 217 N-ethyl-2-methoxy-N-methyl-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO) δ 8.72 (s, 1H) 8.41 (d, J=9.1 Hz, 1H) 8.36 (s, 1H) 7.71 (s, 1H) 7.41(d, J=9.1 Hz, 1H) 6.66 (s, 1H) 3.98 (s, 3H) 3.16 (q, J=6.8 Hz, 2H) 2.78 (s, 3H) 2.44 (s, 3H) 2.29 (s, 3H) 1.03 (t, J=6.8 Hz, 3H). [M+H] calc'd for C₂₁ H₂₅N₇O₃S, 455; found, 456.

Example 218 N-(cyclopropylmethyl)-2-methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO) δ 8.71 (s, 1H) 8.40 (d, J=8.8 Hz, 1H) 8.36 (s, 1H) 7.69 (s, 1H) 7.38(d, J=8.8 Hz, 1H) 6.67 (s, 1H) 3.99 (s, 3H) 2.72 (br, 2H) 2.45 (s, 3H) 2.31 (s, 3H) 0.71 (m, 1H) 0.24 (m, 2H) 0.02 (m, 2H). [M+H] calc'd for C₂₂ H₂₅N₇O₃S, 467; found, 468.

Example 219 N-cyclopropyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO) δ 8.69 (s, 1H) 8.44 (d, J=8.0 Hz, 1H) 8.32 (s, 1H) 7.90 (d, J=8.0 Hz, 1H) 7.77 (m, 1H) 7.73 (s, 1H) 6.67 (s, 1H) 2.42 (s, 3H) 2.29 (s, 3H) 2.12 (m, 1H) 0.46 (m, 2H), 0.38 (m, 2H). [M+H] calc'd for C₂₀ H₂₁N₇O₂S, 423; found, 424.

Example 220 N-ethyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO) δ 8.65 (s, 1H) 8.43 (d, J=7.6 Hz, 1H) 8.37 (s, 1H) 7.92 (d, J=8.0 Hz, 1H) 7.77 (m, 1H) 7.67 (s, 1H) 6.65 (s, 1H) 2.83 (q, J=6.8 Hz, 2H) 2.45 (s, 3H) 2.30 (s, 3H) 0.97 (t, J=6.8 Hz, 3H). [M+H] calc'd for C₁₉ H₂₁N₇O₂S, 411; found, 412.

Example 221 7-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(isopropoxymethyl)imidazo [1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD) δ ppm 0.69 (m, 2H) 0.81-0.92 (m, 4H) 1.02-1.10 9m, 2H) 1.24 (m, 7H) 2.44 s, 2H) 2.72-2.81 (m, 1H) 2.86-2.96 (m, 1H) 6.67 s, 1H) 7.50 (s, 1H) 7.62 (t, J=7.83 Hz, 1H) 7.90 (d, J=8.08 Hz, 1H) 8.27 (d, J=7.33 Hz, 1H) 8.59 (s, 1H). MS [m+H] calc'd, 472.4 and 473.4; found 472.4 and 473.4.

Example 222 7-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(isopropoxymethyl)imidazo [1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD) δ ppm 0.89 (s, 2H) 1.04 (s, 2H) 1.23-1.31 (m, 3H) 2.00 (s, 1H) 2.54 (s, 3H) 3.25-3.30 (m, 2H) 6.50 (s, 1H) 7.70 (s, 1H), 7.79 (s, 1H) 8.04 (s, 2H) 8.46 (s, 1H) 8.75 (s, 1H). MS [m+H] calc'd for C₂₁ H₂₂N₆O₂S, 423.3 and 424.3; found 423.3 and 424.3.

Example 223 7-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(isopropoxymethyl)imidazo [1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD) δ ppm 0.82 (ddd, J=6.63, 4.74, 4.55 Hz, 2H) 1.01-1.11 (m, 2H) 1.27 (t, J=7.20 Hz, 3H) 1.93-2.04 (m, 1H) 2.56 (s, 3H) 3.47 (q, J=7.24 Hz, 2H) 6.52 (s, 1H) 7.61-7.69 (m, 2H) 7.94 (d, J=7.58 Hz, 1H) 8.06 (s, 1H) 8.30(d, J=8.08 Hz, 1H) 8.61 (s, 1H). MS [m+H] calc'd C₂₂ H₂₃N₇O, 402.3; and 403.3; found 402.3 and 403.3.

Example 224 N-{3-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl}-acetamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD) δ ppm 0.63-0.70 (m 2H) 0.94-1.02 (m, 2H) 1.82-1.88 (m, 1H) 2.16 (s, 3H) 2.44 (s, 3H) 5.98 (s, 1H) 6.57 (s, 1H) 7.20 (d, J=8.8 Hz, 1H) 7.41 (d, J=8.59 Hz, 1H) 7.59 (d, J=8.59 Hz, 1H), 7.77 (d, J=8.59 Hz, 1H) 7.9 (s, 1H). MS [m+H] calc'd C₂₁ H₂₁N₇OS, 420.3; and 421.3; found 420.3 and 421.3.

Example 225 N-(5-methyl-1H-pyrazol-3-yl)-7-phenyl-2-(trifluoromethyl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 2.31 (s, 3H) 6.65 (s, 1H) 7.45 (t, J=7.20 Hz, 1H) 7.52 (t, J=7.58 Hz, 2H) 7.64 (s, 1H) 8.13 (d, J=7.58 Hz, 2H) 8.98 (s, 1H) 10.48 (bs, 1H); ESI-MS: m/z 359.3 (M+H)⁺.

Example 226 3-(2-(Chloromethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl0-N-cyclopropylbenzamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 0.56-0.63 (m, 2H) 0.69-0.77 (m, 2H) 2.31 (s, 3H) 2.88 (td, J=7.45, 3.79 Hz, 1H) 4.90 (s, 2H) 6.68 (s, 1H) 7.58 (t, J=7.71 Hz, 1H) 7.66 (s, 1H) 7.86 (d, J=7.58 Hz, 1H) 8.25 (d, J=7.83 Hz, 1H) 8.52 (d, J=8.84 Hz, 2H) 8.59 (d, J=3.79 Hz, 1H) 10.51 (s, 1H); ESI-MS: m/z 422.4 (M+H)⁺

Example 227 2-Ethyl-7-(3-(ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ ppm 1.14 (t, J=7.07 Hz, 3H) 1.32 (t, J=7.20 Hz, 3H) 2.31 (s, 3H) 2.83 (q, J=6.74 Hz, 2H) 3.35-3.43 (m, 2H) 6.66 (s, 1H) 7.82-7.89 (m, 2H) 8.03 (d, J=7.58 Hz, 1H) 8.46 (s, 1H) 8.55 (d, J=7.33 Hz, 1H) 8.73 (s, 1H) 10.95 (s, 1H) 12.42 (bs, 1H); ESI-MS: m/z 411.4 (M+H)⁺.

Example 228 7-(3-(ethylsulfonyl)phenyl)-2-isopropyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) 12.46 (bs, 1H) 10.94 (bs, 1H) 8.72 (s, 1H) 8.56 (d, J=7.56 Hz, 1H) 8.45 (s, 1H) 8.04 (d, J=7.04 Hz 1H) 7.88 (t, J=7.14 Hz 1H) 7.82 (s, 1H) 6.66 (s, 1H) 3.34 (t, J=7.12 Hz 2H) 3.18 (m, 1H) 2.32 (s, 3H) 1.36 (d, J=6.82 Hz 6H) 1.16 (t, J=7.33 Hz 2H) 1.09 (t, J=7.07 Hz 3H). [M+H] calc'd for C₂₁ H₂₄N₆O₂S, 425.17; found, 425.40.

Example 229 N-(5-ethyl-1H-pyrazol-3-yl)-7-(3-(ethylsulfonyl)phenyl)-2-methylimidazo [1,2-f]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) 12.42 (bs, 1H) 10.92 (bs, 1H) 8.73 (s, 1H) 8.56 (d, J=7.56 Hz, 1H) 8.45 (s, 1H) 8.03 (d, J=8.59 Hz 1H) 7.86 (t, J=3.92 Hz 1H) 7.82 (s, 1H) 6.68 (s, 1H) 3.38 (q, J=7.41 Hz 2H) 2.68 (q, J=7.41 Hz 2H) 2.47 (s, 3H) 1.29 (t, J=7.58 Hz 3H) 1.14 (t, J=7.33 Hz 3H). [M+H] calc'd for C₂₀ H₂₂₂N₆O₂S, 411.15; found, 411.20.

Example 230 N-(methyl-N-(3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino) imidazo[1,2-f]pyrimidin-7-yl)phenyl)cyclopropanesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, DMSO-D6) δ 12.40 (bs, 1H) 10.96 (bs, 1H) 8.51 (s, 1H), 8.21 (s, 1H), 8.06-8.16 (m, 1H), 7.70 (s, 1H), 7.60-7.65 (m, 2H), 6.72 (s, 1H), 3.38 (s, 3H), 3.10-3-20 (m, 1H). 2.70-2.78 (m, 1H), 2.30 (s, 3H), 1.36 (d, J=6.82 Hz 6H), 0.92-0.98 (m, 2H) 0.80-0.86 (m, 2H). [M+H] calc'd for C₂₃ H₂₇N₇O₂S, 466.19; found, 466.30.

Example 231 2-(3-(ethylsulfonyl)phenyl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.15 (t, J=7.33 Hz, 3H) 2.27 (s, 3H) 2.31 (s, 3H) 3.35-3.39 (m, 2H) 6.76 (s, 1H) 7.12 (s, 1H) 7.69 (s, 1H) 7.81 (t, J=7.83 Hz, 1H) 7.98 (d, J=7.83 Hz, 1H) 8.55 (d, J=7.83 Hz, 1H) 8.75 (s, 1H) 10.60 (s, 1H) 12.25 (s, 1H); ESI-MS: m/z calc'd for C19H20N6O2S 396.47; found 397.4 (M+H)⁺.

Example 232 2-(3-(ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.16 (t, J=7.33 Hz, 3H) 2.31 (s, 3H) 3.37 (q, J=7.24 Hz, 2H) 6.73-6.82 (m, 2H) 7.33 (s, 1H) 7.80-7.89 (m, 2H) 8.00 (d, J=7.58 Hz, 1H) 8.57 (d, J=7.83 Hz, 1H) 8.77 (s, 1H) 10.77 (s, 1H); ESI-MS: m/z calc'd for C18H18N6O2S 382.44; found 383.3 (M+H)⁺.

Example 233 N-(5-methyl-1H-pyrazol-3-yl)-2-(3-(methylsulfonyl)phenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.32 (s, 3H) 3.29 (s, 3H) 6.76 (dd, J=4.42, 2.65 Hz, 1H) 6.78 (s, 1H) 7.33 (s, 1H) 7.79-7.89 (m, 2H) 8.05 (d, J=8.34 Hz, 1H) 8.56 (d, J=7.83 Hz, 1H) 8.83 (s, 1H) 10.76 (s, 1H); ESI-MS: m/z calc'd for C17H16N6O2S 368.41; found 369.3 (M+H)⁺.

Example 234 N-(5-methyl-1H-pyrazol-3-yl)-2-phenylpyrrolo[1,2-f][1,2,4]triazin-4-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.32 (s, 3H) 6.71 (dd, J=4.17, 2.65 Hz, 1H) 6.76 (s, 1H) 7.29 (s, 1H) 7.46-7.56 (m, 3H) 7.79 (d, J=2.27 Hz, 1H) 8.26 (d, J=7.07 Hz, 2H) 10.60 (s, 1H) 12.25 (s, 1H); ESI-MS: m/z calc'd for C16H14N6 290.32; found 291.4 (M+H)⁺.

Example 235 2-(1-(Ethylsulfonyl)-1H-indol-6-yl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.14 (t, J=7.33 Hz, 3H) 2.35 (s, 3H) 3.76 (q, J=7.24 Hz, 2H) 6.73 (dd, J=4.29, 2.53 Hz, 1H) 6.94 (s, 1H) 7.33 (s, 1H) 7.83 (dd, J=2.53, 1.52 Hz, 1H) 8.00 (s, 1H) 8.06 (d, J=8.59 Hz, 1H) 8.33 (d, J=9.09 Hz, 1H) 8.97 (s, 1H) 9.77 (s, 1H) 10.71 (s, 1H) 12.25 (bs. 1H); ESI-MS: m/z calc'd for C20H196N7O2S 421.13; found 422.2 (M+H)⁺.

Example 236 2-(1-(Ethylsulfonyl)-1H-indol-6-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.14 (t, J=7.30 Hz, 3H) 2.27 (s, 3H) 2.35 (s, 3H) 3.76 (q, J=7.24 Hz, 2H) 6.75 (dd, J=4.29, 2.55 Hz, 1H) 6.96 (s, 1H) 7.36 (s, 1H) 8.02 (s, 1H) 8.08 (d, J=8.59 Hz, 1H) 8.34 (d, J=9.10 Hz, 1H) 8.98 (s, 1H) 9.78 (s, 1H) 10.70 (s, 1H) 12.30 (bs. 1H); m/z calc'd for C21H21N7O2S 435.15; found 435.3 (M+H)⁺.

Example 237 2-(3-((dimethylamino)methyl)-1-(ethylsulfonyl)-1H-indol-6-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl) pyrrolo[1,2-f][1,2,4]triazin-4-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.16 (t, J=7.33 Hz, 3H) 2.27 (s, 3H) 2.30 (s, 3H) 2.80 (d, J=4.55 Hz, 6H) 3.76 (q, J=7.24 Hz, 2H) 6.73 (dd, J=4.29, 2.53 Hz, 1H) 6.94 (s, 1H) 7.33 (s, 1H) 8.00 (s, 1H) 8.06 (d, J=8.59 Hz, 1H) 8.33 (d, J=9.09 Hz, 1H) 8.97 (s, 1H) 9.77 (s, 1H) 10.71 (s, 1H) 12.25 (bs. 1H); ESI-MS: m/z calc'd for C24H28N8O2S 492.21; found 493.3 (M+H)⁺.

Example 238 Cyclobutanecarboxylic acid 3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide, TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 7.90-8.07 (m, 3H), 7.57 (s, 1H), 7.39-7.49 (m, 2H), 7.28-7.34 (m, 1H), 6.61 (s, 1H), 4.42 (s, 2H), 3.10-3.20 (m, 2H), 2.39 (s, 3H), 1.80-2.32 (m, 6H). [M+H] calc'd for C₂₂ H₂₃N₇O, 402; found, 402.

Example 239 Azetidine-3-carboxylic acid 3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.70 (s, 1H), 8.37 (s, 1H), 8.06-8.11 (m, 2H), 7.98 (s, 1H), 7.49-7.53 (m, 2H), 6.61 (s, 1H), 4.51 (s, 2H), 4.18-4.23 (m, 4H), 3.56-3.63 (m, 1H), 2.40 (s, 3H). [M+H] calc'd for C₂₁ H₂₂N₈O, 403; found, 403.

Example 240 [7-(3-Aminomethyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 7.90-8.01 (m, 3H), 7.53 (s, 1H), 7.39-7.46 (m, 2H), 7.28 (s, 1H), 6.39 (s, 1H), 4.12 (s, 2H), 2.29 (s, 3H). [M+H] calc'd for C₁₇ H₁₇N₇, 320; found, 320.

Example 241 Cyclopropanesulfonic acid 3-[5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-benzylamide, TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 7.95-8.18 (m, 3H), 7.58 (s, 1H), 7.39-7.49 (m, 3H), 6.62 (s, 1H), 4.36 (s, 2H), 2.30-2.42 (m, 4H), 0.80-1.06 (m, 4H). [M+H] calc'd for C₂₀ H₂₁N₇O₂S, 424; found, 424.

Example 242 (7-{3-[(Cyclopropylmethyl-amino)-methyl]-phenyl}-imidazo[1,2-c]pyrimidin-5-yl)-(5-methyl-1H-pyrazol-3-yl)-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.01-8.13 (m, 3H), 7.38-7.59 (m, 4H), 6.52 (s, 1H), 4.17 (s, 2H), 2.85 (d, 2 H, J=7.6 Hz), 2.35 (s, 3H), 1.05-1.12 (m, 1H), 0.60-0.68 (m, 2H), 0.30-0.36 (m, 2H). [M+H] calc'd for C₂₁ H₂₃N₇, 374; found, 374.

Example 243 [7-(3-Methylaminomethyl-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.40 (s, 1H), 8.26-8.30 (m, 2H), 8.00 (s, 1H), 7.74 (s, 1H), 7.64-7.69 (m, 2H), 6.59 (s, 1H), 4.12 (s, 2H), 2.29 (s, 3H). [M+H] calc'd for C₁₈ H₁₉N₇, 334; found, 334.

Example 244 (5-Methyl-1H-pyrazol-3-yl)-[7-(1,2,3,4-tetrahydro-isoquinolin-7-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.37 (s, 1H), 7.98-8.12 (m, 3H), 7.70 (s, 1H), 7.44 (d, 1 H, J=8.4 Hz), 6.58 (s, 1H), 4.48 (s, 2H), 3.50-3.58 (m, 2H), 3.12-3.20 (m, 2H), 2.39 (s, 3H). [M+H] calc'd for C₁₉ H₁₉N₇, 346; found, 346.

Example 245 [7-(2-Methanesulfonyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.33 (s, 1H), 7.90-8.01 (m, 3H), 7.61 (s, 1H), 7.36 (d, 1 H, J=8.4 Hz), 6.57 (s, 1H), 4.53 (s, 2H), 3.58 (t, 2 H, J=6.0 Hz), 3.06 (t, 2 H, J=6.0 Hz), 2.93 (s, 3H), 2.39 (s, 3H). [M+H] calc'd for C₂₀ H₂₁N₇O₂S, 424; found, 424.

Example 246 [7-(3-Ethanesulfonylmethyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine, TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.21 (s, 1H), 8.02 (s, 1H), 7.74 (s, 1H), 7.45-7.51 (m, 2H), 7.34 (s, 1H), 6.68 (s, 1H), 4.46 (s, 2H), 3.04 (q, 2 H, J=7.6 Hz), 2.40 (s, 3H), 2.35 (s, 3H), 1.17 (t, 3 H, J=7.6 Hz). [M+H] calc'd for C₂₀ H₂₂N₆O₂S, 411; found, 411.

Example 247 [7-(3-Ethanesulfonylmethyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine, TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.13 (s, 1H), 7.95 (s, 1H), 7.70 (d, 1 H, J=7.6 Hz), 7.38-7.49 (m, 2H), 7.24 (d, 1 H, J=7.6 Hz), 6.67 (s, 1H), 3.82 (t, 2 H, J=6.4 Hz), 3.51 (t, 2 H, J=7.2 Hz), 2.50-2.59 (m, 2H), 2.49 (s, 3H), 2.35 (s, 3H). [M+H] calc'd for C₂₀ H₂₁N₇O₂S, 424; found, 424.

Example 248 {2-Methyl-7-[3-(3-methyl-pyridin-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.85 (s, 1H), 8.77 (d, 1 H, J=7.5 Hz), 8.31-8.36 (m, 2H), 8.08 (s, 1H), 7.99 (d, 1 H, J=7.5 Hz), 7.68-7.80 (m, 3H), 6.54 (s, 1H), 2.56 (s, 3H), 2.54 (s, 3H), 2.35 (s, 3H). [M+H] calc'd for C₂₃ H₂₁N₇, 396; found, 396.

Example 249 {7-[3-(3,5-Dimethyl-1H-pyrazol-4-yl)-phenyl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.10-8.14 (m, 2H), 8.06 (s, 1H), 7.69 (s, 2H), 7.66 (t, 1 H, J=8.0 Hz), 7.53 (d, 1 H, J=8.0 Hz), 6.52 (s, 1H), 2.56 (s, 3H), 2.41 (s, 6H), 2.35 (s, 3H). [M+H] calc'd for C₂₂ H₂₂N₈, 399; found, 399.

Example 250 {2-Methyl-7-[3-(3-methyl-3H-imidazol-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine, TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 9.05 (s, 1H), 8.30-8.41 (m, 2H), 8.09 (s, 1H), 7.70-7.79 (m, 4H), 6.59 (s, 1H), 3.95 (s, 3H), 2.56 (s, 3H), 2.37 (s, 3H). [M+H] calc'd for C₂₁ H₂₀N₈, 385; found, 385.

Example 251 (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[3-(1,3,5-trimethyl-1H-pyrazol-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine, TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.06-8.12 (m, 3H), 7.58-7.65 (m, 2H), 7.46 (d, 1H, J=8.0 Hz), 6.55 (s, 1H), 3.84 (s, 3H), 2.55 (s, 3H), 2.35 (s, 3H), 2.32 (s, 3H), 2.26 (s, 3H). [M+H] calc'd for C₂₃ H₂₄N₈, 413; found, 413.

Example 252 {7-[3-(3,5-Dimethyl-isoxazol-4-yl)-phenyl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.10-8.18 (m, 2H), 8.05 (s, 1H), 7.62-7.69 (m, 2H), 7.52 (d, 1H, J=7.6 Hz), 6.52 (s, 1H), 2.56 (s, 3H), 2.45 (s, 3H), 2.34 (S, 3H), 2.29 (s, 3H). [M+H] calc'd for C₂₂ H₂₂N₇O, 400; found, 4008.

Example 253 {7-[3-(5-Cyclopropyl-3-methyl-1H-pyrazol-4-yl)-phenyl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.23 (s, 1H), 8.04-8.10 (m, 2H), 7.59-7.65 (m, 3H), 6.54 (s, 1H), 2.55 (s, 3H), 2.34 (s, 3H), 2.32 (s, 3H), 1.88-1.95 (m, 1H), 0.78-0.94 (m, 4H). [M+H] calc'd for C₂₄ H₂₄N₈, 425; found, 425.

Example 254 (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[3-(thiazole-2-sulfonyl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 9.01 (s, 1H), 8.49 (d, 1 H, J=7.6 Hz), 8.19 (d, 1H, J=7.6 Hz), 8.10 (s, 1H), 8.02-8.09 (m, 2H), 7.80 (t, 1 H, J=7.6 Hz), 7.75 (s, 1H), 6.70 (s, 1H), 2.56 (s, 3H), 2.44 (s, 3H). [M+H] calc'd for C₂₀ H₁₇N₇O₂S₂, 438; found, 438.

Example 255 [7-(3-Dimethylaminomethyl-1-ethanesulfonyl-1H-indol-6-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine, TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.88 (s, 1H), 7.92-8.10 (m, 4H), 7.67 (s, 1H), 6.74 (s, 1H), 4.58 (s, 2H), 3.50-3.58 (m, 2H), 3.12-3.20 (m, 2H), 2.39 (s, 3H). [M+H] calc'd for C₁₉ H₁₉N₇, 346; found, 346.

Example 256 (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.62 (s, 1H), 8.28 (d, 1 H, J=3.2 Hz), 8.13 (d, 1H, J=5.4 Hz), 7.72-7.81 (m, 2H), 7.63 (t, 1 H, J=5.4 Hz), 7.47-7.50 (m, 2H), 7.29 (d, 1H, J=3.2 Hz), 6.72 (s, 1H), 6.63 (s, 1H), 2.43 (s, 3H), 2.22 (s, 3H). [M+H] calc'd for C₂₄ H₂₀N₈, 421; found, 421.

Example 257 (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[3-(S)-(pyrrolidine-3-sulfonyl)-phenyl]-imidazo[1,2-c]pyrimidin-5-yl}-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.79 (s, 1H), 8.51 (d, 1 H, J=7.6 Hz), 8.07-8.12 (m, 2H), 7.78-7.87 (m, 2H), 6.60 (s, 1H), 4.26-4.34 (m, 1H), 3.40-3.79 (m, 4H), 2.57 (s, 3H), 2.42-2.53 (m, 1H), 2.39 (s, 3H), 2.31-2.48 (m, 1H). [M+H] calc'd for C₂₁ H₂₃N₇O₂S, 438; found, 438.

Example 258 {7-[3-(3-Amino-propane-1-sulfonyl)-phenyl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine, bis-TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.81 (s, 1H), 8.10 (s, 1H), 8.8.50 (d, 1 H, J=6.0 Hz), 8.05-8.10 (m, 2H), 7.77-7.84 (m, 2H), 6.64 (s, 1H), 3.41 (t, 2 H, J=7.2 Hz), 3.09 (t. 2 H, J=7.2 Hz), 2.57 (s, 3H), 2.39 (s, 3H), 2.06-2.11 (m, 2H). [M+H] calc'd for C₂₀ H₂₃N₇O₂S, 426; found, 426.

Example 259 [7-(3-Ethylsulfanyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine, TFA salt

¹H NMR (400 MHz, DMSO-d₆) δ 12.20 (s, 1H), 10.09 (s, 1H), 8.10 (s, 1H), 8.07 (s, 1H), 7.87 (d, 1H, J=5.4 Hz), 7.51 (s, 1H), 7.29-7.40 (m, 2H), 6.64 (s, 1H), 3.07 (q, 2H, J=7.2 Hz), 2.32 (s, 3H), 2.29 (s, 3H), 1.29 (t, 3H, J=7.2 Hz). [M+H] calc'd for C₁₉ H₂₀N₆S, 365; found, 365.

Example 260 [7-(3-Ethanesulfinyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine, TFA salt

¹H NMR (400 MHz, MeOD-d₄) δ 8.45 (s, 1H), 8.24 (s, 1H), 7.78 (s, 1H), 7.63-7.71 (m, 2H), 7.47 (m, 1H), 6.64 (s, 1H), 3.01-3.11 (m, 1H), 2.88-2.98 (m, 1H), 2.43 (s, 3H), 2.30 (s, 3H), 1.22 (t, 3 H, J=7.2 Hz). [M+H] calc'd for C₁₉ H₂₀N₆OS, 381; found, 381.

Example 261 7-(3-(ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-5-amine

The title compound was synthesized following a procedure analogous to that described in Example 6. ¹H NMR (400 MHz, MeOD-d4) δ 8.72 (s, 1H) 8.63 (s, 1H) 8.52 (d, J=11.64 Hz, 1H) 8.01 (m, 2H) 7.81 (m, 1H) 6.60 (s, 1H) 2.49 (m, 2H) 2.30 (s, 3H) 1.15 (s, 3H). [M+H] calc'd for C₁₇ H₁₇N₇O₂S, 384; found, 384.

Example 262 N-(5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-2-(2-morpholinoethoxy)phenyl)cyclopropanesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.44 (d, J=2.28 Hz, 1H) 8.05 (m, 2H) 7.56 (s, 1H) 7.29 (d, J=8.6 Hz, 2H) 6.69 (s, 1H) 4.56 (m, 2H) 3.74 (m, 2H) 2.65 (s, 2H) 2.54 (s, 3H) 2.39 (s, 3H) 1.07 (m, 2H) 0.98 (s, 2H). [M+H] calc'd for C₂₆ H₃₂N₈O₄S, 553; found, 553.

Example 263 4-methyl-5-(3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)thiazol-2-amine

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.29 (s, 1H) 8.22 (d, J=7.72 Hz, 1H) 8.08 (s, 2H) 7.71 (d, J=5.8 Hz, 1H) 7.67 (d, J=7.8 Hz, 1H) 7.63 (d, J=7.84 Hz, 1H) 6.57 (s, 1H) 2.57 (s, 3H) 2.38 (d, J=8.08 Hz, 2H)). [M+H] calc'd for C₂₁ H₂₀N₈S, 417; found, 417.

Example 264 3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-phenylbenzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.63 (s, 1H) 8.29 (d, J=7.84 Hz, 1H) 8.06 (s, 1H) 7.87 (d, J=6.84 Hz, 1H) 7.63 (t, 1H) 7.59 (s, 1H) 7.10 (m, 4H) 6.99 (t, 1H) 6.61 (s, 1H) 2.69 (s, 1H) 2.55 (s, 3H) 2.42 (s, 6H). [M+H] calc'd for C₂₃ H₂₁N₇O₂S, 460; found, 460.

Example 265 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-((dimethylamino)methyl)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)acetamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD-d4) δ 7.87 (s, 1H) 7.72 (d, J=8.84 Hz, 2H) 7.56 (d, J=8.84 Hz, 2H) 6.50 (s, 1H) 4.66 (s, 2H) 2.15 (s, 3H) 1.28 (, 6H) 0.96 (d, J=6.32 Hz 3H) 0.66 (d, J=7.04 Hz, 2H). [M+H] calc'd for C₂₃ H₂₆N₀₈S, 463; found, 463.

Example 266 (4-hydroxypiperidin-1-yl)(3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)methanone

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.39 (s, 1H) 8.27 (d, J=7.8 Hz, 1H) 8.23 (s, 1H) 8.01 (s, 1H) 7.74 (s, 1H) 7.65 (t, 1H) 7.59 (d, J=7.6 Hz, 1H) 6.58 (s, 1H) 4.20 (s, 1H) 3.93 (s, 1H) 3.66 (s, 1H) 2.39 (s, 3H) 1.97 (s, 1H) 1.81 (s, 1H) 1.60 (s, 1H) 1.47 (s, 1H). [M+H] calc'd for C₂₂ H₂₃N₇O₂, 418; found, 418.

Example 267 N-isobutyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.62 (s, 1H) 8.40 (s, 1H) 8.35 (d, J=9.84 Hz, 1H) 8.01 (d, J=2.52 Hz, 1H) 7.97 (d, J=6.84 Hz, 1H) 7.73 (s, 1H) 7.65 (t, 1H) 6.64(s, 1H) 3.25 (d, J=7.08 Hz, 2H) 2.39 (s, 3H) 1.96 (m, 1H) 1.00 (d, J=6.56 6H). [M+H] calc'd for C₂₁ H₂₃N₇O, 389; found, 389.

Example 268 N-cyclopentyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.61 (s, 1H) 8.40 (d, J=2.28 Hz, 1H) 8.34 (d, J=8.08 Hz, 1H) 8.01 (d, J=2.28 Hz, 1H) 7.96 (d, J=8.32 Hz, 1H) 7.74 (s, 1H) 7.64 (t, 1H) 6.65(s, 1H) 4.36 (m, 1H) 2.40 (s, 3H) 2.07 (m, 2H) 1.80 (m, 2H) 1.65 (m, 4H). [M+H] calc'd for C₂₂ H₂₃N₇O, 402; found, 402.

Example 269 3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(pyrrolidin-3-ylmethyl)benzamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.66 (s, 1H) 8.40 (s, 1H) 8.37 (d, J=7.84 Hz, 1H) 8.01 (m, 2H) 7.77 (s, 1H) 7.66 (t, 1H) 6.66(s, 1H) 3.53 (m, 2H) 3.44 (m, 2H) 3.08 (m, 1H) 2.74 (m, 1H) 2.40 (s, 3H) 2.21 (m, 1H) 1.85 (m, 1H). [M+H] calc'd for C₂₂ H₂₄N₈O, 417; found, 417.

Example 270 3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(pyrrolidin-2-ylmethyl)benzamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.69 (s, 1H) 8.40 (s, 1H) 8.37 (d, J=7.84 Hz, 1H) 8.03 (d, J=9.32 Hz, 2H) 7.78 (s, 1H) 7.66 (t, 1H) 6.64(s, 1H) 3.84 (m, 1H) 3.75 (d, J=5.28 Hz, 2H) 3.39 (m, 1H) 2.39 (s, 3H) 2.23 (m, 1H) 2.09 (m, 2H) 1.86 (m, 1H). [M+H] calc'd for C₂₂ H₂₄N₈O, 417; found, 417.

Example 271 N-isopropyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.60 (s, 1H) 8.40 (d, J=2.52 Hz, 1H) 8.33 (d, J=7.84 Hz, 1H) 8.0 (d, J=2.52 Hz, 1H) 7.96 (d, J=15.8 Hz, 1H) 7.74 (s, 1H) 7.63 (t, 1H) 6.64(s, 1H) 4.25 (m, 1H) 2.39 (s, 3H) 1.30 (d, J=6.56 Hz, 6H). [M+H] calc'd for C₂₀ H₂₁N₇O, 376; found, 376.

Example 272 3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-phenylbenzamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.72 (s, 1H) 8.38 (s, 1H) 8.35 (d, J=7.8 Hz, 1H) 8.06 (d, J=7.84 Hz, 1H) 7.99 (s, 1H) 7.76 (s, 1H) 7.69 (m, 4H) 7.38 (m, 3H) 7.17 (m, 1H) 6.65 (s, 1H) 4.25 (m, 1H) 2.30 (s, 3H). [M+H] calc'd for C₂₃ H₁₉N₇O, 410; found, 410.

Example 273 N-benzyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.67 (s, 1H) 8.39 (s, 1H) 8.35 (d, J=9.88 Hz, 1H) 8.00 (s, 2H) 7.73 (s, 1H) 7.65 (t, 1H) 7.33 (m, 4H) 7.26 (m, 1H) 6.64 (s, 1H) 4.63 (m, 2H) 2.34 (s, 3H). [M+H] calc'd for C₂₄ H₂₁N₇O, 424; found, 424.

Example 274 N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

The title compound was synthesized following a procedure analogous to that described in Example 1. ¹H NMR (400 MHz, MeOD-d4) δ 7.72 (d, J=8.84 Hz, 2H) 7.63 (s, 1H) 7.55 (d, J=8.56 Hz 2H) 6.46 (s, 1H) 5.96 (s, 1H) 2.33 (s, 3H) 2.20 (s, 2H) 2.15 (s, 2 H) 1.80 (m, 1H) 0.97 (m, 2H) 0.86 (m, 2H). [M+H] calc'd for C₂₁ H₂₁N₇OS, 420; found, 420.

Example 275 3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(thiazol-2-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.82 (s, 1H) 8.33 (d, J=7.56 Hz, 1H) 8.08 (s, 1H) 8.01 (d, J=7.32 Hz 1H) 7.68 (s, 2H) 7.10 (d, J=4.8 Hz, 1H) 6.71 (d, J=4.96 Hz, 1H) 6.69 (s, 1H) 2.65 (s, 3H) 2.56 (s, 3H) 2.42 (s, 3H). [M+H] calc'd for C₂₀ H₁₈N₈O₂S₂, 467; found, 467.

Example 276 N-(2-aminoethyl)-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzenesulfonamide

The title compound was synthesized following a procedure analogous to that described in Example 12. ¹H NMR (400 MHz, MeOD-d4) δ 8.76 (s, 1H) 8.43 (d, J=8.6 Hz, 1H) 8.09 (s, 1H) 8.02 (d, J=9.6 Hz 1H) 7.79 (d, J=7.84 Hz, 1H) 7.75 (s, 1H) 6.64 (s, 1H) 3.13 (m, 2H) 3.07 (m, 2H) 2.56 (s, 3H) 2.39 (s, 3H). [M+H] calc'd for C₁₉ H₂₂N₈O₂S, 427; found, 427.

Example 277 N-(4-(2-ethyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

7-chloro-2-ethyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine 0.22 mmol, 0.06 g) was dissolved in DMF (1 mL). N-(4-mercaptophenyl)cyclopropanecarboxamide (0.24 mmol, 0.046 g) and K₂CO₃ (0.24 mmol, 0.033 g) was added. The reaction mixture was heated to 160° C. using a microwave reactor for 20 minutes. The mixture was then concentrated and purified by LC-MS to give the title compound. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.83-0.84 (m, 4H) 1.25 (t, J=7.45 Hz, 3H) 1.79-1.86 (m, 1H) 2.12 (s, 3H) 2.73 (q, J=7.24 Hz, 2H) 5.80 (s, 1H) 6.65 (s, 1H) 7.58 (d, J=8.59 Hz, 2H) 7.81 (d, J=8.59 Hz, 2H) 8.31 (s, 1H) 10.55 (s, 1H) 10.97 (s, 1H) 12.30 (s, 1H); ESI-MS: m/z calc'd for C22H23N7OS 433.53; found 434.4 (M+H)⁺.

Example 278 N-ethyl-N-(3-(2-isopropyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)methanesulfonamide

7-chloro-2-isopropyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine (0.17 mmol, 0.05 g), 3-(N-ethylmethylsulfonamido)phenylboronic acid (0.35 mmol) and (Ph₃)₄ Pd (O) (0.086 mmol, 0.1 g) were stirred in dioxane (3 mL) and sat. K₂CO₃ (1.5 mL). The reaction mixture was heated to 150° C. using a microwave reactor for 20 minutes. The mixture was then concentrated and purified by LC-MS to give the title compound. ¹ H NMR (400 MHz, DMSO-d₆) δ ppm 1.06 (t, J=7.07 Hz, 3H) 1.35 (d, J=6.82 Hz, 6H) 2.29 (s, 3H) 3.04 (s, 3H) 3.76 (q, J=7.07 Hz, 2H) 6.70 (s, 1H) 7.57 (s, 1H) 7.59-7.67 (m, 2H) 8.11 (d, J=7.58 Hz, 1H) 8.17 (s, 1H) 8.45 (s, 1H) 10.80 (s, 1H) 12.35 (s, 1H); ESI-MS: m/z calc'd for C22H27N7O2S 453.56; found 454.4 (M+H)⁺.

Example 279 N-isopropyl-3-(5-(5-methyl-1H-pyrazol-3-ylamino)-2-(trifluoromethyl)imidazo[1,2-c]pyrimidin-7-yl)benzamide

Title compound was synthesized from 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(trifluoromethyl)imidazo[1,2-c]pyrimidin-5-amine and 3-(isopropylcarbamoyl)phenyl boronic acid using the procedure described in Example 278. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.21 (d, J=6.57 Hz, 6H) 2.32 (s, 3H) 4.15 (td, J=13.45, 6.69 Hz, 2H) 6.74 (s, 1H) 7.60 (t, J=7.71 Hz, 1H) 7.78 (s, 1H) 7.90 (d, J=7.83 Hz, 1H) 8.27 (d, J=8.08 Hz, 1H) 8.38 (d, J=7.58 Hz, 1H) 8.57 (s, 1H) 9.03 (s, 1H) 10.55 (s, 1H); ESI-MS: m/z calc'd for C21H20F3N7O 443.43; found 444.3 (M+H)⁺.

Example 280 N-(5-methyl-1H-pyrazol-3-yl)-2,7-diphenylimidazo[1,2-c]pyrimidin-5-amine

5-(methylthio)-2,7-diphenylimidazo[1,2-c]pyrimidines (0.13 mmol, 0.04 g), 3-amino-5-methylpyrazol (0.38 mmol, 0.037 g) and NaHCO3 (0.25 mmol, 0.021 g) were dissolved in DMF (1 mL). The reaction mixture was heated to 200° C. using a microwave reactor for 1 hour. The mixture was then concentrated and purified by LC-MS to give the title compound. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.33 (s, 3H) 6.71 (s, 1H) 7.35-7.50 (m, 6H) 7.63 (s, 1H) 7.93 (d, J=7.07 Hz, 2H) 8.15 (d, J=7.33 Hz, 2H) 8.90 (s, 1H) 10.22 (s, 1H) 12.24 (s, 1H); ESI-MS: m/z calc'd for C22H18N6 366.42; found 367.3 (M+H)⁺.

Example 281 N-(4-(2-(hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

The title compound was synthesized using (7-chloro-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-2-yl)methanol and 3-(cyclopropylcarbamoyl)phenyl boronic acid using the procedure described in Example 278. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.61 (d, J=6.57 Hz, 2H) 0.74 (d, J=6.57 Hz, 2H) 2.33 (s, 3H) 2.84-2.95 (m, 1H) 4.70 (s, 2H) 6.70 (s, 1H) 7.60-7.71 (m, 2H) 7.93 (d, J=7.33 Hz, 1H) 8.30 (d, J=7.07 Hz, 1H) 8.54 (d, J=17.68 Hz, 2H) 8.64 (s, 1H) 10.89 (s, 1H) 12.40 (s, 1H); ESI-MS: m/z calc'd for C21H21N7O2 403.44; found 404.4 (M+H)⁺.

Example 282 N-(3-(2-(hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)methanesulfonamide

The title compound was synthesized using (7-chloro-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-2-yl)methanol and 3-(methylsulfonamido)phenyl boronic acid using the procedure described in Example 278. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.32 (s, 3H) 3.06 (s, 3H) 4.70 (s, 2H) 6.75 (s, 1H) 7.31 (dd, J=7.96, 1.64 Hz, 1H) 7.50-7.61 (m, 2H) 7.89 (d, J=8.08 Hz, 1H) 8.15 (s, 1H) 8.57 (s, 1H) 10.02 (s, 1H) 10.97 (s, 1H) 12.37 (s, 1H); ESI-MS: m/z calc'd for C18H19N7O3S 413.45; found 414.3 (M+H)⁺.

Example 283 N-(4-(2-((dimethylamino)methyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

N-(4-(2-(hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide (0.18 mmol, 0.089 g) was treated with thionyl chloride (0.5 mL) at ambient temperature for 1 hour. After reaction mixture was concentrated in vacuo, excess dimethylamine in THF (1.5 mL) was added and heated to 60° C. Reaction mixture was concentrated and purified by LC-MS to give the title compound. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.82 (d, J=6.57 Hz, 4H) 1.81 (dt, J=12.19, 6.16 Hz, 1H) 2.12 (s, 3H) 3.17 (d, J=5.31 Hz, 6H) 4.10 (s, 1H) 5.89 (s, 1H) 6.42 (s, 1H) 7.52 (d, J=8.34 Hz, 2H) 7.74 (d, J=8.34 Hz, 2H) 8.17 (s, 1H) 10.21 (s, 1H) 10.46 (s, 1H) 12.09 (s, 1H); ESI-MS: m/z calc'd for C23H26N8OS 462.57; found 463.4 (M+H)⁺.

Example 284 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)-2-((methylamino)methyl)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

The title compound was synthesized using N-(4-(2-(hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide and methyl amine using the procedure described in Example 283. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.82 (d, J=5.56 Hz, 4H) 1.82 (dt, J=12.06, 5.97 Hz, 1H) 2.11 (s, 3H) 3.28 (s, 3H) 4.03 (s, 2H) 5.84 (s, 1H) 6.49 (s, 1H) 7.53 (d, J=8.08 Hz, 2H) 7.75 (d, J=8.08 Hz, 2H) 8.27 (s, 1H) 10.48 (s, 1H) 12.12 (s, 1H); ESI-MS: m/z calc'd for C22H24N8OS 448.54; found 449.4 (M+H)⁺.

Example 285 N-(4-(2-((2-hydroxyethylamino)methyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide

The title compound was synthesized using N-(4-(2-(hydroxymethyl)-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide and ethanol amine using the procedure described in Example 283. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.82 (d, J=6.32 Hz, 4H) 1.82 (dt, J=12.44, 6.28 Hz, 1H) 2.11 (s, 3H) 2.83-2.92 (m, 2H) 3.53-3.62 (m, 2H) 4.01 (s, 2H) 4.90 (s, 1H) 5.86 (s, 1H) 6.47 (s, 1H) 7.53 (d, J=8.08 Hz, 2H) 7.75 (d, J=7.83 Hz, 2H) 8.26 (s, 1H) 10.36 (s, 1H) 10.48 (s, 1H) 12.12 (s, 1H); ESI-MS: m/z calc'd for C23H26N8O2S 478.57; found 479.4 (M+H)⁺.

Example 286 [7-(3-Ethanesulfonyl-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.16 (t, J=7.33 Hz, 3H) 2.31 (s, 3H) 2.35 (s, 3H) 4.10 (q, J=5.22 Hz, 2H) 6.70 (s, 1H) 7.67 (s, 1H) 7.76 (t, J=7.83 Hz, 1H) 7.89 (d, J=7.83 Hz, 1H) 8.15 (s, 1H) 8.46 (d, J=7.83 Hz, 1H) 8.71 (s, 1H) 10.23 (s, 1H) 12.22 (s, 1H) MS [m+H] calc'd C₁₉ H₂₀N₆O₂S 397.14 and 398.15; found 397.14 and 398.15.

Example 287 N⁷-(1-Benzyl-piperidin-4-yl)-2-methyl-N⁵-(5-methyl-1H-pyrazol-3-yl)-imidazo[1,2-c]pyrimidine-5,7-diamine

¹H NMR (400 MHz, MeOD) δ ppm 1.59-1.88 (m, 2H) 1.95-2.26 (m, 2H) 2.25-2.44 (m, 7H) 2.98-3.22 (m, 2H) 3.47-3.69 (m, 2H) 4.36 (s, 2H) 5.93 (s, 1H) 6.35 (s, 1H) 7.40-7.55 (m, 5H) 7.59 (s, 1H) MS [m+H] calc'd C₂₃ H₂₈N₈ 417.25 and 418.26; found 417.25 and 418.26.

Example 288 [7-(3-Isopropoxy-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 1.29 (d, J=6.06 Hz, 3H) 1.37 (d, J=6.06 Hz, 3H) 2.40 (s, 3H) 2.55 (s, 3H) 4.49-4.65 (m, 1H) 6.86-6.97 (m, 1H) 7.04-7.16 (m, 2H) 7.27 (d, J=16.67 Hz, 2H) 7.38-7.51 (m, 1H) 8.05 (s, 1H) MS [m+H] calc'd C₂₀ H₂₂N₆O 363.20, and 363.21; found 363.20, and 364.21.

Example 289 [2-Methyl-7-(3-propoxy-phenyl)-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 1.04 (t, J=7.45 Hz, 3H) 1.71-1.85 (m, 2H) 2.39 (s, 3H) 2.55 (s, 3H) 3.92 (t, J=6.57 Hz, 2H) 6.93 (dd, J=8.08, 2.02 Hz, 2H) 7.36-7.51 (m, 1H) 7.59 (s, 1H) 7.69 (d, J=7.83 Hz, 1H) 7.75 (d, J=2.02 Hz, 1H) 8.04 (s, 1H) MS [m+H] calc'd C₂₀ H₂₂N₆O 363.20 and 364.22; found 363.20 and 364.22.

Example 290 [7-(3-Ethanesulfonyl-phenyl)-2-imidazol-1-ylmethyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 1.22-1.30 (m, 3H) 2.34 (s, 2H) 2.54 (s, 3H) 4.02-4.18 (m, 2H) 5.50-5.67 (s, 1H)) 7.16 (s, 1H) 7.59 (s, 1H) 7.76-7.82 (m, 2H) 8.06-8.7 (m, 2H) 8.24 (s, 1H) 8.41 (s, 1H) 9.08 (s, 1H) MS [m+H] calc'd C₂₂ H₂₂N₈O₂S 463.17 and 464.17; found 463.17 and 464.17.

Example 291 3-{3-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-propionic acid methyl ester

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.34 (s, 3H) 2.46 (s, 3H) 2.75 (t, J=7.45 Hz, 2H) 2.98 (t, J=7.71 Hz, 2H) 3.58 (s, 3H) 6.66 (s, 1H) 7.40 (d, J=8.08 Hz, 1H) 7.48 (t, J=7.71 Hz, 1H) 7.66 (s, 1H) 8.01 (d, J=9.60 Hz, 1H) 8.07 (s, 1H) 8.35 (s, 1H) 10.83 (s, 1H) 12.38 (s, 1H) MS [m+H] calc'd C₂₁ H₂₂N₆O₂ 391.19 and 392.18; found 391.19 and 392.18.

Example 292 3-{3-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-propionic acid

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.33 (s, 3H) 2.44 (s, 3H) 2.65 (t, J=7.58 Hz, 2H) 2.91-3.02 (m, 2H) 6.68 (s, 1H) 7.39 (d, J=8.08 Hz, 1H) 7.47 (t, J=7.33 Hz, 1H) 7.65 (s, 1H) 8.00 (d, J=7.33 Hz, 1H) 8.08 (s, 1H) 8.32 (s, 1H) 10.78 (s, 1H) 12.26 (s, 2H) MS [m+H] calc'd C₂₀ H₂₀N₆O₂ 377.16 and 378.17; found 377.16 and 378.17.

Example 293 5-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-thiophene-2-carboxylic acid cyclopropylamide

¹H NMR (400 MHz, MeOD) δ ppm 0.54-0.72 (m, 2H) 0.74-0.96 (m, 2H) 1.81-1.90 (m, 1H) 2.40 (s, 3H) 2.51 (s, 3H) 5.49 (s, 1H) 7.53 (s, 1H) 7.68 (s, 1H) 7.83 (s, 1H) 8.04 (s, 1H) MS [m+H] calc'd C₁₉ H₁₉N₇OS 394.15 and 395.15; found 394.15 and 395.15.

Example 294 [7-(1-Benzyl-1H-pyrazol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-cyclopropyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.60-0.87 (m, 2H) 0.91-1.14 (m, 2H) 1.84-2.10 (m, 1H) 3.31 (s, 3H) 3.35 (s, 2H) 5.39 (s, 2H) 6.35 (s, 1H) 7.10-7.56 (m, 6H) 7.92 (s, 1H) 8.07 (s, 1H) 8.27 (s, 1H) MS [m+H] calc'd C₂₃ H₂₂N₈ 411.2 and 412.2; found 411.2 and 412.2.

Example 295 [7-(1-Benzyl-1H-pyrazol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 2.35 (s, 3H) 2.48 (s, 3H) 3.35 (s, 2H) 5.40 (s, 2H) 6.49 (s, 1H) 7.22-7.58 (m, 6H) 7.93 (s, 1H) 8.10 (s, 1H) 8.30 (s, 1H) MS [m+H] calc'd C₂₁ H₂₀N₈ 385.19 and 386.19; found 385.19 and 386.19.

Example 296 N-{2-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-methanesulfonamide

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.26 (s, 3H) 2.47 (s, 3H) 2.87 (s, 3H) 6.23 (s, 1H) 7.33 (t, J=7.33 Hz, 1H) 7.40-7.63 (m, 2H) 7.78 (d, J=7.83 Hz, 1H) 8.27 (s, 1H) 10.30 (s, 1H) 10.70 (s, 1H) 12.36 (s, 1H) MS [m+H] calc'd C₁₈ H₁₉N₇O₂S 398.13 and 399.13; found 398.13 and 399.13.

Example 297 N-{2-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-phenyl}-acetamide

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.82 (s, 3H) 2.26 (s, 3H) 2.47 (s, 3H) 6.29 (s, 1H) 7.25 (t, J=7.45 Hz, 1H) 7.39 (s, 1H) 7.42-7.51 (m, 1H) 7.72 (d, J=7.83 Hz, 1H) 8.03 (d, J=8.08 Hz, 1H) 8.27 (s, 1H) 10.63 (s, 1H) 10.75 (s, 1H) 12.47 (s, 1H) MS [m+H] calc'd C₁₉ H₁₉N₇O 362.18 and 363.18; found 362.18 and 363.18.

Example 298 [7-(1H-Indol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.17 (t, J=7.20 Hz, 2H) 2.27 (s, 3H) 2.42-2.50 (m, 3H) 6.62 (s, 1H) 6.94 (s, 1H) 7.28 (t, J=7.83 Hz, 1H) 7.49-7.64 (m, 2H) 7.68-7.77 (m, 1H) 8.37 (s, 1H) 10.82 (s, 1H) 11.46 (s, 1H) 12.40 (s, 1H) MS [m+H] calc'd C₁₉ H₁₇N₇ 344.15 and 345.15; found 344.15 and 345.15.

Example 299 N-{4-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-ylsulfanyl]-phenyl}-acetamide

¹H NMR (400 MHz, MeOD) δ ppm 2.17 (s, 3H) 2.21 (s, 3H) 2.45 (s, 3H) 5.92 (s, 1H) 6.64 (s, 1H) 7.60 (d, J=7.58 Hz, 2H) 7.78 (d, J=9.85 Hz, 2H) 7.91 (s, 1H) MS [m+H] calc'd C₁₉ H₁₉N₇OS 394.15 and 395.15; found 394.15 and 395.15.

Example 300 [7-(2-Amino-phenyl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 2.36 (s, 3H) 2.55 (s, 3H) 6.22 (s, 1H) 6.99 (t, J=8.97 Hz, 2H) 7.33 (t, J=7.71 Hz, 1H) 7.49 (s, 1H) 7.80 (d, J=8.08 Hz, 1H) 7.99 (s, 1H) MS [m+H] calc'd C17H17N7 320.17 and 321.18; found 320.17 and 321.18.

Example 301 [7-(1-Isobutyl-1H-pyrazol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.69-0.79 (m, 3H) 0.94-1.04 (m, 3H) 2.41 (s, 3H) 3.74 (s, 3H) 5.40 (d, J=7.5 Hz 2H) 6.49 (s, 1H) 6.79-6.99 (m, 2H) 7.22 (s, 1H) 8.27 (s, 1H) 8.47 (s, 1H) 10.74 (s, 1H) MS [m+H] calc'd C₁₈ H₂₂N₈ 351.2 and 352.2; found 351.2 and 352.2.

Example 302 4-{4-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzoic acid methyl ester

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.36 (s, 3H) 2.40 (s, 3H) 3.84 (s, 3H) 5.53 (s, 2H) 6.50 (s, 1H) 7.33 (s, 1H) 7.49-7.69 (m, 2H) 7.91 (s, 2H) 8.16 (s, 1H) 8.28 (s, 1H) 8.51 (s, 1H) 10.72 (s, 1H) 12.36 (s, 1H) MS [m+H] calc'd C₂₃ H₂₂N₈O₂ 443.20 and 444.20; found 443.20 and 444.20.

Example 303 (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(3-methoxy-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.69-0.79 (m, 2H) 0.94-1.04 (m, 2H) 1.91-2.06 (m, 1H) 2.41 (s, 3H) 3.74 (s, 3H) 5.40 (s, 2H) 6.49 (s, 1H) 6.79-6.99 (m, 2H) 7.22-7.38 (m, 2H) 8.15 (s, 1H) 8.27 (s, 1H) 8.47 (s, 1H) 10.74 (s, 1H) MS [m+H] calc'd C₂₄ H₂₄N₈O 441.22 and 442.22; found 441.22 and 442.22.

Example 304 (5-Cyclopropyl-1H-pyrazol-3-yl)-[2-methyl-7-(1-quinolin-8-ylmethyl-1H-pyrazol-4-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.67-0.79 (m, 2H) 0.92-1.04 (m, 2H) 1.88-2.04 (m, 1H) 2.40 (s, 3H) 6.06 (s, 2H) 6.48 (s, 1H) 7.34 (s, 1H) 7.48 (d, J=6.82 Hz, 1H) 7.52-7.70 (m, 2H) 8.00 (d, J=8.08 Hz, 1H) 8.17 (s, 1H) 8.26 (s, 1H) 8.44 (d, J=9.09 Hz, 1H) 8.53 (s, 1H) 8.92-9.06 (m, 1H) MS [m+H] calc'd C₂₆ H₂₃N₉ 462.23 and 463.23; found 462.23 and 463.23.

Example 305 3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzoic acid methyl ester

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.67-0.80 (m, 2H) 0.92-1.05 (m, 2H) 1.89-2.08 (m, 1H) 2.40 (s, 3H) 3.84 (s, 3H) 5.53 (s, 2H) 6.50 (s, 1H) 7.33 (s, 1H) 7.55 (t, J=7.20 Hz, 1H) 7.58-7.65 (m, 1H) 7.89-7.97 (m, 2H) 8.16 (s, 1H) 8.27 (s, 1H) 8.51 (s, 1H) MS [m+H] calc'd C₂₅ H₂₄N₈O₂ 469.2 and 470.2; found 469.2 and 470.2.

Example 306 (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(4-methanesulfonyl-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.70-0.81 (m, 2H) 0.93-1.03 (m, 2H) 1.90-2.08 (m, 1H) 2.42 (s, 3H) 3.20 (s, 3H) 5.59 (s, 2H) 6.50 (s, 1H) 7.34 (s, 1H) 7.53 (d, J=8.34 Hz, 2H) 7.94 (d, J=8.34 Hz, 2H) 8.19 (s, 1H) 8.28 (s, 1H) 8.57 (s, 1H). MS [m+H] calc'd C₂₄ H₂₄N₈O₂S 489.18 and 490.18; found 489.18 and 490.18.

Example 307 (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(4-methoxy-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.60-0.87 (m, 2H) 0.92-1.22 (m, 2H) 1.80-2.18 (m, 1H) 2.49 (s, 3H) 3.79 (s, 3H) 5.33 (s, 2H) 6.94 (d, J=8.34 Hz, 3H) 7.29 (d, J=8.84 Hz, 3H) 7.95 (s, 1H) 8.11 (s, 1H) 8.23 (s, 1H) MS [m+H] calc'd C₂₄ H₂₄N₈O 441.21 and 442.21; found 441.21 and 442.21.

Example 308 (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(2,3-dimethoxy-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.67-0.89 (m, 2H) 0.97-1.15 (m, 2H) 1.88-2.13 (m, 1H) 2.49 (s, 3H) 3.79 (s, 3H) 3.86 (s, 3H) 5.40 (s, 2H) 6.40 (s, 1H) 6.84 (dd, J=7.07, 1.77 Hz, 1H) 7.00-7.15 (m, 2H) 7.27 (s, 1H) 7.93 (s, 1H) 8.09 (s, 1H) 8.23 (s, 1H) MS [m+H] calc'd C₂₅ H₂₆N₈O₂ 471.22 and 472.22; found 471.22 and 472.22.

Example 309 (5-Cyclopropyl-1H-pyrazol-3-yl)-{7-[1-(3,5-dimethoxy-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.68-0.83 (m, 2H) 0.95-1.14 (m, 2H) 1.87-2.06 (m, 1H) 2.50 (s, 3H) 3.75 (s, 6H) 5.34 (s, 2H) 6.39 (s, 1H) 6.46 (s, 3H) 7.29 (s, 1H) 7.94 (s, 1H) 8.12 (s, 1H) 8.29 (s, 1H) MS [m+H] calc'd C₂₅ H₂₆N₈O₂ 471.22 and 472.22; found 471.22 and 472.22.

Example 310 [7-(1-Benzo[1,2,5]oxadiazol-5-ylmethyl-1H-pyrazol-4-yl)-2-methyl-imidazo[1,2-c]pyrimidin-5-yl]-(5-cyclopropyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.62-0.82 (m, 2H) 0.88-1.08 (m, 2H) 1.84-2.07 (m, 1H) 2.51 (s, 3H) 5.58 (s, 2H) 6.40 (s, 1H) 7.33 (s, 1H) 7.45 (dd, J=9.35, 1.26 Hz, 1H) 7.74 (s, 1H) 7.92 (d, J=9.35 Hz, 1H) 7.96 (s, 1H) 8.19 (s, 1H) 8.44 (s, 1H) MS [m+H] calc'd C₂₃ H₂₀N₁₀O 453.19 and 454.19; found 453.19 and 454.19.

Example 311 2-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzonitrile

¹H NMR (400 MHz, MeOD) δ ppm 0.67-0.89 (m, 2H) 0.93-1.19 (m, 2H) 1.76-2.12 (m, 1H) 2.50 (s, 3H) 5.64 (s, 2H) 6.43 (s, 1H) 7.31 (s, 1H) 7.45 (d, J=8.34 Hz, 1H) 7.50-7.59 (m, 1H) 7.64-7.74 (m, 1H) 7.81 (dd, J=7.71, 1.14 Hz, 1H) 7.97 (s, 1H) 8.14 (s, 1H) 8.42 (s, 1H) MS [m+H] calc'd C₂₄ H₂₁N₉ 436.19 and 437.19; found 436.19 and 437.19.

Example 312 (5-Cyclopropyl-1H-pyrazol-3-yl)-[2-methyl-7-(1-pyridin-2-ylmethyl-1H-pyrazol-4-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.71-0.91 (m, 2H) 0.94-1.17 (m, 2H) 1.88-2.10 (m, 1H) 2.51 (s, 3H) 5.53 (s, 2H) 6.43 (s, 1H) 7.23-7.35 (m, 2H) 7.34-7.48 (m, 1H) 7.76-7.91 (m, 1H) 7.97 (s, 1H) 8.14 (s, 1H) 8.43 (s, 1H) 8.55 (d, J=4.29 Hz, 1H) MS [m+H] calc'd C₂₂ H₂₁N₉ 412.19 and 413.19; found 412.19 and 413.19.

Example 313 3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-N-ethyl-benzamide

¹H NMR (400 MHz, MeOD) δ ppm 0.71-0.81 (m, 2H) 0.96-1.11 (m, 2H) 1.21 (t, J=7.20 Hz, 3H) 1.90-2.08 (m, 1H) 2.50 (s, 3H) 3.40 (q, J=7.24 Hz, 2H) 5.48 (s, 2H) 7.31 (s, 1H) 7.42-7.58 (m, 2H) 7.73-7.84 (m, 2H) 7.85-8.04 (m, 2H) 8.13 (s, 1H) 8.36 (s, 1H) MS [m+H] calc'd C₂₆ H₂₇N₉O 482.23 and 483.23; found 482.23 and 483.23.

Example 314 3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-yl methyl}-benzonitrile

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.68-0.82 (m, 2H) 0.93-1.07 (m, 2H) 1.91-2.10 (m, 1H) 2.43 (s, 3H) 5.53 (s, 2H) 6.50 (s, 1H) 7.37 (s, 1H) 7.55-7.71 (m, 2H) 7.74-7.97 (m, 2H) 8.20 (s, 1H) 8.32 (s, 1H) 8.56 (s, 1H) 10.86 (s, 1H) 12.40 (s, 1H) MS [m+H] calc'd C₂₄ H₂₁N₉ 436.19 and 437.19; found 436.19 and 437.19.

Example 315 3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-N-thiazol-2-yl-benzamide

¹H NMR (400 MHz, MeOD) δ ppm 0.62-0.82 (m, 2H) 0.85-1.03 (m, 2H) 1.66-1.86 (m, 1H) 2.41 (s, 3H) 5.54 (s, 2H) 6.50 (s, 1H) 7.26-7.32 (m, 1H) 7.33-7.38 (m, 1H) 7.51-7.61 (m, 3H) 8.02 (s, 1H) 8.04-8.12 (m, 1H) 8.18 (s, 1H) 8.25-8.32 (m, 1H) 8.53 (s, 1H) MS [m+H] calc'd C₂₇ H₂₄N₁₀OS 537.19 and 538.19; found 537.19 and 538.19.

Example 316 (5-Cyclopropyl-1H-pyrazol-3-yl)-[2-methyl-7-(1-phenethyl-1H-pyrazol-4-yl)-imidazo[1,2-c]pyrimidin-5-yl]-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.69-0.89 (m, 2H) 0.98-1.18 (m, 2H) 1.31 (t, J=7.33 Hz, 2H) 1.91-2.12 (m, 1H) 2.50 (s, 1H) 4.45 (t, J=6.82 Hz, 2H) 6.36 (s, 1H) 7.03-7.40 (m, 5H) 7.95 (s, 1H) 8.00 (s, 1H) 8.11 (s, 1H) MS [m+H] calc'd C₂₄ H₂₄N₈ 425.21 and 426.2; found 425.21 and 426.2.

Example 317 (5-Cyclopropyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(4-pyrazol-1-yl-benzyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.66-0.80 (m, 2H) 0.93-1.06 (m, 2H) 1.87-2.03 (m, 1H) 2.51 (s, 3H) 5.47 (s, 2H) 6.38 (s, 1H) 6.53 (dd, J=2.53, 1.77 Hz, 1H) 7.31 (s, 1H) 7.47 (d, J=8.84 Hz, 2H) 7.72 (d, J=1.52 Hz, 1H) 7.78 (d, J=8.59 Hz, 2H) 7.96 (s, 1H) 8.15 (s, 1H) 8.24 (d, J=2.53 Hz, 1H) 8.33 (s, 1H) MS [m+H] calc'd C₂₆ H₂₄N₁₀ 477.22 and 478.22; found 477.22 and 478.22.

Example 318 2-{4-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzonitrile

¹H NMR (400 MHz, MeOD) δ ppm 2.38 (s, 3H) 2.51 (s, 3H) 5.65 (s, 2H) 6.59 (s, 1H) 7.32 (s, 1H) 7.46 (d, J=7.33 Hz, 1H) 7.49-7.59 (m, 1H) 7.65-7.74 (m, 1H) 7.82 (d, J=0.51 Hz, 1H) 7.99 (s, 1H) 8.17 (s, 1H) 8.48 (s, 1H) MS [m+H] calc'd C₂₂ H₁₉N₉ 410.18 and 411.19; found 410.18 and 411.19.

Example 319 (5-Cyclopropyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(3-pyrrol-1-yl-benzyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.56-0.85 (m, 2H) 0.87-1.09 (m, 2H) 1.76-2.08 (m, 2H) 2.38 (s, 3H) 5.45 (s, 2H) 6.13-6.45 (m, 2H) 7.09-7.26 (m, 3H) 7.34-7.53 (m, 3H) 7.69 (s, 1H) 8.04 (s, 1H) 8.22 (s, 1H) MS [m+H] calc'd C₂₇ H₂₅N₉ 476.22 and 477.22; found 476.22 and 477.22.

Example 320 N-Ethyl-4-{4-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzamide

¹H NMR (400 MHz, MeOD) δ ppm 1.21 (t, J=7.20 Hz, 3H) 2.36 (s, 3H) 2.51 (s, 3H) 3.33-3.48 (m, 2H) 5.50 (s, 2H) 6.53 (s, 1H) 7.31 (s, 1H) 7.38 (d, J=8.59 Hz, 2H) 7.82 (d, J=8.59 Hz, 2H) 7.97 (s, 1H) 8.16 (s, 1H) 8.39 (s, 1H) MS [m+H] calc'd C₂₄ H₂₅N₉O 456.22 and 457.22; found 456.22 and 457.22.

Example 321 (5-Cyclopropyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(3-nitro-benzyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.60-0.85 (m, 2H) 0.95-1.10 (m, 2H) 1.84-2.14 (m, 1H) 2.51 (s, 3H) 5.58 (s, 2H) 6.41 (s, 1H) 7.32 (s, 1H) 7.64 (t, J=7.83 Hz, 1H) 7.73 (d, J=8.34 Hz, 1H) 7.97 (s, 1H) 8.11-8.29 (m, 3H) 8.43 (s, 1H) MS [m+H] calc'd C₂₃ H₂₁N₉O₂ 456.18 and 457.18; found 456.18 and 457.18.

Example 322 (5-Cyclopropyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(2-morpholin-4-yl-ethyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.76-0.87 (m, 2H) 1.00-1.12 (m, 2H) 1.94-2.07 (m, 1H) 2.51 (s, 3H) 3.32-3.51 (m, 4H) 3.72 (t, J=5.81 Hz, 2H) 3.85-4.09 (m, 4H) 4.71 (t, J=5.81 Hz, 2H) 6.44 (s, 1H) 7.34 (s, 1H) 7.98 (s, 1H) 8.17 (s, 1H) 8.40 (s, 1H) MS [m+H] calc'd C₂₂ H₂₇N₉O 434.23 and 435.23; found 434.23 and 435.23.

Example 323 {7-[1-(3-Amino-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-cyclopropyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.59-0.86 (m, 2H) 0.97-1.16 (m, 2H) 1.86-2.11 (m, 1H) 2.50 (s, 3H) 5.36 (s, 2H) 6.39 (d, J=1.77 Hz, 1H) 6.76-6.98 (m, 3H) 7.24 (t, J=7.83 Hz, 1H) 7.30 (s, 1H) 7.95 (s, 1H) 8.12 (s, 1H) 8.31 (s, 1H) MS [m+H] calc'd C₂₃ H₂₃N₉ 426.21 and 427.21; found 426.21 and 427.21.

Example 324 {7-[1-(2,5-Dichloro-benzyl)-1H-pyrazol-4-yl]-2-methyl-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 2.37 (s, 3H) 2.51 (s, 3H) 5.54 (s, 2H) 6.55 (s, 1H) 7.16 (d, J=2.02 Hz, 1H) 7.26-7.43 (m, 2H) 7.43-7.55 (m, 1H) 7.98 (s, 1H) 8.19 (s, 1H) 8.41 (s, 1H) MS [m+H] calc'd C₂₁ H₁₈C₁₂N₈ 453.1, 454.1 and 455.1; found 453.1, 454.1 and 455.1.

Example 325 {2-Methyl-7-[1-(2-piperidin-1-ylethyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 1.63-2.10 (m, 6H) 2.39 (s, 3H) 2.51 (s, 3H) 2.88-3.20 (m, 2H) 3.53-3.80 (m, 4H) 4.70 (t, J=6.19 Hz, 2H) 6.55 (s, 1H) 7.32 (s, 1H) 7.98 (s, 1H) 8.21 (s, 1H) 8.40 (s, 1H) MS [m+H] calc'd C₂₁ H₂₇N₉ 406.24 and 407.24; found 406.24 and 407.24.

Example 326 2-{4-[2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-yl}-N-phenyl-acetamide

¹H NMR (400 MHz, MeOD) δ ppm 2.37 (s, 3H) 2.51 (s, 3H) 5.14 (s, 2H) 6.59 (s, 1H) 7.12 (t, J=7.45 Hz, 1H) 7.32 (t, J=8.08 Hz, 3H) 7.58 (d, J=7.33 Hz, 2H) 7.98 (s, 1H) 8.17 (s, 1H) 8.42 (s, 1H) MS [m+H] calc'd C₂₂ H₂₁N₉O 428.19 and 429.19; found 428.19 and 429.19.

Example 327 {2-Methyl-7-[1-(1-methyl-2-phenyl-ethyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-(5-methyl-1H-pyrazol-3-yl)-amine

¹H NMR (400 MHz, MeOD) δ ppm 0.94 (m, Hz, 2H) 2.37 (s, 3H) 2.50 (s, 3H) 4.84 (d, J=10.11 Hz, 3H) 5.24-5.47 (m, 1H) 6.52 (s, 1H) 7.21-7.50 (m, 5H) 7.96 (s, 1H) 8.14 (s, 1H) 8.40 (s, 1H) MS [m+H] calc'd C₂₃ H₂₄N₈ 413.21 and 414.21; found 413.21 and 414.21.

Example 328 N-(3-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methyl-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-phenyl)-2-methoxy-acetamide

¹H NMR (400 MHz, MeOD) δ ppm 0.71-0.81 (m, 2H) 0.86-0.97 (m, 2H) 1.94-2.06 (m, 1H) 2.86 (s, 3H) 2.99 (s, 3H) 3.46 (s, 3H) 4.01 (s, 2H) 5.42 (s, 2H) 7.10 (d, J=7.33 Hz, 1H) 7.26-7.44 (m, 2H) 7.55 (d, J=8.34 Hz, 1H) 7.64 (s, 1H) 7.97 (d, J=8.08 Hz, 2H) 8.13 (s, 1H) 8.33 (s, 1H) MS [m+H] calc'd C₂₆ H₂₇N₉O₂ 498.23 and 499.23; found 498.23 and 499.23.

Example 329 4-Fluoro-2-{4-[2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-imidazo[1,2-c]pyrimidin-7-yl]-pyrazol-1-ylmethyl}-benzonitrile

¹H NMR (400 MHz, MeOD) δ ppm 2.38 (s, 3H) 2.51 (s, 3H) 5.66 (s, 2H) 6.59 (s, 1H) 7.17 (dd, J=9.09, 2.53 Hz, 1H) 7.25-7.43 (m, 2H) 7.88 (dd, J=8.72, 5.18 Hz, 1H) 8.00 (s, 1H) 8.19 (s, 1H) 8.50 (s, 1H) MS [m+H] calc'd C₂₂ H₁₈FN₉ 428.17 and 429.17; found 428.17 and 429.17.

Example 330 (5-Methyl-1H-pyrazol-3-yl)-{2-methyl-7-[1-(2-trifluoromethoxy-benzyl)-1H-pyrazol-4-yl]-imidazo[1,2-c]pyrimidin-5-yl}-amine

¹H NMR (400 MHz, MeOD) δ ppm 2.36 (s, 3H) 2.50 (s, 3H) 5.52 (s, 2H) 6.53 (s, 1H) 7.21-7.42 (m, 4H) 7.42-7.56 (m, 1H) 7.97 (s, 1H) 8.16 (s, 1H) 8.33 (s, 1H) MS [m+H] calc'd C₂₂ H₁₉F₃N₈O 469.16; and 470.16; found 469.16 and 470.16.

Example 331 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.57 (s, 1H) 8.06 (m, 2H) 7.83 (s, 1H) 7.51 (m, 1H) 7.24(d, J=8 Hz, 1H) 7.14 (m, 1H) 6.96 (s, 1H) 3.94 (s, 3H) 1.95 (m, 1H) 0.97 (m, 2H) 0.71 (m, 2H). [M+H] calc'd for C₁₉ H₁₉N₆O, 347; found, 347.

Example 332 3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzonitrile

¹H NMR (400 MHz, DMSO) δ 8.59 (s, 1H) 8.55 (s, 1H) 8.48 (d, J=8.0 Hz, 1H) 7.97 (m, 2H) 7.87 (s, 1H) 7.76 (m, 1H) 7.11 (s, 1H) 6.48 (s, 1H) 1.97 (m, 1H) 1.02 (m, 2H) 0.77 (m, 2H). [M+H] calc'd for C₁₉ H₁₆N₇, 342; found, 342.

Example 333 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.55 (s, 1H) 7.99 (s, 1H) 7.80 (s, 2H) 7.68 (s, 1H) 7.17 (s, 1H) 6.55 (s, 1H) 2.37 (s, 1H) 1.97 (m, 1H) 1.02 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₂₀ H₂₁N₆, 345; found, 345.

Example 334 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-p-tolylimidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO δ 8.55 (s, 1H) 8.06 (d, J=8.0 Hz, 2H) 8.00 (s, 1H) 7.66 (s, 1H) 7.38 (d=8.0 Hz, 2H) 6.52 (s, 1H) 2.38 (s, 3H) 1.98 (m, 1H) 1.01 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₁₉ H₁₉N₆, 331; found, 331.

Example 335 7-(5-chloro-2-methoxyphenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.58 (s, 1H) 8.18 (s, 1H) 8.07 (s, 1H), 7.94 (s, 1H) 7.56 (d, J=8.0 Hz, 1H) 7.28 (d, J=8.0 Hz, 1H) 6.40 (s, 1H) 3.97 (s, 3H) 1.97 (m, 1H) 1.02 (m, 2H) 0.75 (m, 2H). [M+H] calc'd for C₁₉ H₁₈ClN₆O, 381; found, 381.

Example 336 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxy-5-methylphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.57 (s, 1H) 8.07 (s, 1H) 7.97 (s, 1H), 7.89 (s, 1H) 7.35 (d, J=8.0 Hz, 1H) 7.15 (d, J=8.0 Hz, 1H) 6.49 (s, 1H) 3.91 (s, 3H) 2.34 (s, 1H) 1.95 (m, 1H) 1.01 (m, 2H) 0.71 (m, 2H). [M+H] calc'd for C₂₀ H₂₁N₆O, 361; found, 361.

Example 337 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.56 (s, 1H) 8.01 (s, 1H) 7.77 (s, 1H) 7.36 (s, 2H) 6.66 (s, 1H) 6.57 (s, 1H) 3.86 (s, 6H) 1.95 (m, 1H) 0.98 (m, 2H) 0.73 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆O₂, 377; found, 377.

Example 338 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-methoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.55 (s, 1H) 8.13 (d, J=8.0 Hz, 2H) 8.02 (s, 1H) 7.62 (s, 1H) 7.11 (d, J=8.0 Hz, 2H) 6.52 (s, 1H) 3.85 (s, 3H) 1.98 (m, 1H) 1.01 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₁₉H₁₉N₆O, 347; found, 347.

Example 339 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(pyrimidin-5-yl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 9.49 (s, 2H) 9.28 (s, 1H) 8.57 (s, 1H) 7.96 (s, 1H) 7.94 (s, 1H) 6.50 (s, 1H) 1.99 (M, 1H) 1.00 (m, 2H) 0.75 (m, 2H). [M+H] calc'd for C₁₆H₁₅N₈, 319; found, 319.

Example 340 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(pyridin-3-yl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 9.37 (s, 1H) 8.75 (d, J=4.0 Hz, 1H) 8.62 (m, 2H) 8.08 (s, 1H) 7.88 (s, 1H) 7.69 (m, 1H) 6.51 (s, 1H) 1.99 (m, 1H) 1.00 (m, 2H) 0.75 (m, 2H). [M+H] calc'd for C₁₇H₁₆N₇, 318; found, 318.

Example 341 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,4-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.56 (s, 1H) 8.03 (s, 1H) 7.79 (m, 2H) 7.69 (s, 1H) 7.14 (d=J=8.0 Hz, 1H) 6.59 (s, 1H) 3.90 (s, 3H) 3.85 (s, 3H) 1.96 (m, 1H) 0.98 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆O₂, 377; found, 377.

Example 342 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,3-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.58 (s, 1H) 8.05 (s, 1H) 7.30 (m, 2H) 7.23 (m, 2H) 6.35 (s, 1H) 2.32 (s, 3H) 2.27 (s, 3H) 1.90 (m, 1H) 0.93 (m, 2H) 0.64 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆, 345; found, 345.

Example 343 7-(benzo[d][1,3]dioxol-5-yl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.53 (s, 1H) 8.00 (s, 1H) 7.75 (d, J=8.0 Hz, 1H) 7.71 (s, 1H) 7.62 (s, 1H) 7.10 (d, J=8.0 Hz, 1H) 6.46 (s, 1H) 6.14 (s, 2H) 3.90 (s, 3H) 3.85 (s, 3H) 1.96 (m, 1H) 1.01 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₁₉H₁₇N₆O₂, 361; found, 361.

Example 344 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,6-dimethylphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.58 (s, 1H) 8.07 (s, 1H) 7.24 (m, 2H) 7.15 (m, 2H) 6.21 (s, 1H) 2.15 (s, 3H) 2.07 (s, 3H) 1.80 (m, 1H) 0.90 (m, 2H) 0.61 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆, 345; found, 345.

Example 345 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2,6-dimethoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.48 (s, 1H) 7.99 (s, 1H) 7.43 (t, J=8.0 Hz, 1H) 7.07 (s, 1H) 6.81 (d, J=8.0 Hz, 2H) 6.29 (s, 1H) 3.74 (s, 3H) 3.67 (s, 3H) 1.87 (m, 1H) 0.92 (m, 2H) 0.61 (m, 2H). [M+H] calc'd for C₂₀H₂₁N₆O₂, 377; found, 377.

Example 346 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-methoxypyridin-4-yl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.59 (s, 1H) 8.50 (d, J=8.0 Hz, 1H) 8.34 (d, J=4.0 Hz, 1H) 8.07 (s, 1H) 7.94 (s, 1H) 7.25 (m, 1H) 6.44 (s, 1H) 4.05 (s, 3H) 1.97 (m, 1H) 0.98 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₁₈H₁₈N₇O, 348; found, 348.

Example 347 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-phenoxyphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.54 (s, 1H) 8.16 (d, J=8.0 Hz, 2H) 7.97 (s, 1H) 7.63 (s, 1H) 7.45 (m, 2H) 7.21 (m, 1H) 7.13 (m, 4H) 6.52 (s, 1H) 1.98 (m, 1H) 0.98 (m, 2H) 0.74 (m, 2H). [M+H] calc'd for C₂₄H₂₁N₆O, 409; found, 409.

Example 348 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3-biphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.61 (s, 1H) 8.48 (s, 1H) 8.16 (d, J=8.0 Hz, 1H) 8.06 (s, 1H) 7.87 (s, 1H) 7.82 (d, J=8.0 Hz, 1H) 7.75 (m, 2H) 7.66 (m, 1H) 7.53 (m, 2H) 7.43 (m, 1H) 6.60 (s, 1H) 1.96 (m, 1H) 0.96 (m, 2H) 0.69 (m, 2H). [M+H] calc'd for C₂₄H₂₁N₆, 393; found, 393.

Example 349 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(4-biphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.58 (s, 1H) 8.25 (d, J=8.0 Hz, 2H) 8.03 (s, 1H) 7.87-7.35 (m, 8H) 6.57 (s, 1H) 2.00 (m, 1H) 1.01 (m, 2H) 0.78 (m, 2H). [M+H] calc'd for C₂₄H₂₁N₆, 393; found, 393.

Example 350 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-biphenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.48 (s, 1H) 7.93 (s, 1H) 7.57-7.17 (m, 10H) 5.63 (s, 1H) 1.12 (m, 1H) 0.93 (m, 2H) 0.64 (m, 2H). [M+H] calc'd for C₂₄H₂₁N₆, 393; found, 393.

Example 351 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(2-fluorophenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.59 (s, 1H) 8.09 (m, 1H) 8.01 (s, 1H) 7.57 (m, 2H) 7.42(m, 2H) 6.50 (s, 1H) 1.96 (m, 1H) 0.97 (m, 2H) 0.71 (m, 2H). [M+H] calc'd for C₁₈H₁₆FN₆, 335; found, 335.

Example 352 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(3,5-difluorophenyl)imidazo[1,2-f]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.52 (s, 1H) 7.90 (m, 3H) 7.38 (m, 2H) 6.44 (s, 1H) 1.96 (m, 1H) 1.01 (m, 2H) 0.72 (m, 2H). [M+H] calc'd for C₁₈H₁₅F₂N₆, 353; found, 353.

Example 353 3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-methylbenzamide

¹H NMR (400 MHz, DMSO) δ 8.61 (b, 2H) 8.29 (d, J=8.36 Hz, 1H) 8.04 (s, 1H) 7.93 (d, J=8.36 Hz, 1H) 7.78 (s, 1H) 7.65 (m, 1H) 6.58 (s, 1H) 2.84 (d, J=3.2 Hz, 3H) 1.96 (m, 1H) 1.00 (m, 2H) 0.79 (m, 2H). [M+H] calc'd for C₂₀H₂₀N₇O, 374; found, 374.

Example 354 3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)-N-ethylbenzamide

¹H NMR (400 MHz, DMSO) δ 8.65-8.60 (b, 2H) 8.29 (d, J=7.8 Hz, 1H) 8.04 (s, 1H) 7.93 (d, J=7.8 Hz, 1H) 7.78 (s, 1H) 7.65 (m, 1H) 6.57 (s, 1H) 3.33 (m, 2H) 1.96 (m, 1H) 1.16 (t, J=7.0 Hz, 3H) 0.99 (m, 2H) 0.79 (m, 2H). [M+H] calc'd for C₂₁H₂₂N₇O, 388; found, 388.

Example 355 N-cyclopropyl-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide

¹H NMR (400 MHz, DMSO) δ 8.60 (s, 1H) 8.57 (s, 1H) 8.29 (d, J=8.6 Hz, 1H) 8.05 (s, 1H) 7.93 (d, J=8.6 Hz, 1H) 7.78 (s, 1H) 7.65 (m, 1H) 6.57 (s, 1H) 2.88 (m, 1H) 1.96 (m, 1H) 0.98 (m, 2H) 0.79 (m, 2H) 0.74 (m, 2H) 0.61 (m, 2H). [M+H] calc'd for C₂₂H₂₂N₇O, 400; found, 400.

Example 356 N-(2-cyanoethyl)-3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzamide

¹H NMR (400 MHz, DMSO) δ 8.64 (s, 1H) 8.61 (s, 1H) 8.33 (d, J=7.8 Hz, 1H) 8.05 (s, 1H) 7.97 (d, J=7.8 Hz, 1H) 7.78 (s, 1H) 7.68 (m, 1H) 6.57 (s, 1H) 3.55 (q, J=6.28 Hz, 2H) 2.82 (t, J=6.28 Hz, 2H) 1.96 (m, 1H) 0.98 (m, 2H) 0.81 (m, 2H). [M+H] calc'd for C₂₂H₂₁N₈O, 413; found, 413.

Example 357 (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)(pyrrolidin-1-yl)methanone

¹H NMR (400 MHz, DMSO) δ 8.61 (s, 1H) 8.31 (s, 1H) 8.25 (d, J=7.56 Hz, 1H) 8.09 (s, 1H) 7.83 (s, 1H) 7.64 (m, 2H) 6.48 (s, 1H) 3.52 (t, J=6.84 Hz, 2H) 3.39 (t, J=6.84 Hz, 2H) 1.90 (m, 1H) 0.98 (m, 2H) 0.73 (m, 2H). [M+H] calc'd for C₂₃H₂₄N₇O, 414; found, 414.

Example 358 Methyl 3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzoate

¹H NMR (400 MHz, DMSO) δ 8.78 (s, 1H) 8.61 (s, 1H) 8.42 (d, J=8.08 Hz, 1H) 8.11 (d, J=8.08 Hz, 1H) 8.03 (s, 1H) 7.82 (s, 1H) 7.72 (m, 1H) 6.57 (s, 1H) 3.93 (s, 3H) 1.98 (m, 1H) 1.00 (m, 2H) 0.79 (m, 2H). [M+H] calc'd for C₂₀H₁₉N₆O₂, 375; found, 375.

Example 359 (3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)phenyl)methanol

¹H NMR (400 MHz, DMSO) δ 8.61 (s, 1H) 8.17 (s, 1H) 8.07 (s, 1H) 8.03 (d, J=7.08 Hz, 1H) 7.73 (s, 1H) 7.50 (m, 2H) 6.57 (s, 1H) 4.62 (s, 2H) 1.97 (m, 1H) 1.00 (m, 2H) 0.78 (m, 2H). [M+H] calc'd for C₁₉H₁₉N₆O, 347; found, 347.

Example 360 N-ethyl-2-methoxy-N-methyl-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

¹H NMR (400 MHz, DMSO) δ 8.72 (s, 1H) 8.41 (d, J=9.1 Hz, 1H) 8.36 (s, 1H) 7.71 (s, 1H) 7.41(d, J=9.1 Hz, 1H) 6.66 (s, 1H) 3.98 (s, 3H) 3.16 (q, J=6.8 Hz, 2H) 2.78 (s, 3H) 2.44 (s, 3H) 2.29 (s, 3H) 1.03 (t, J=6.8 Hz, 3H). [M+H] calc'd for C₂₁H₂₆N₇O₃S, 456; found, 456.

Example 361 N-(cyclopropylmethyl)-2-methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino) imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

¹H NMR (400 MHz, DMSO) δ 8.71 (s, 1H) 8.40 (d, J=8.8 Hz, 1H) 8.36 (s, 1H) 7.69 (s, 1H) 7.38(d, J=8.8 Hz, 1H) 6.67 (s, 1H) 3.99 (s, 3H) 2.72 (br, 2H) 2.45 (s, 3H) 2.31 (s, 3H) 0.71 (m, 1H) 0.24 (m, 2H) 0.02 (m, 2H). [M+H] calc'd for C₂₂H₂₆N₇O₃S, 468; found, 468.

Example 362 N-cyclopropyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

¹H NMR (400 MHz, DMSO) δ 8.69 (s, 1H) 8.44 (d, J=8.0 Hz, 1H) 8.32 (s, 1H) 7.90 (d, J=8.0 Hz, 1H) 7.77 (m, 1H) 7.73 (s, 1H) 6.67 (s, 1H) 2.42 (s, 3H) 2.29 (s, 3H) 2.12 (m, 1H) 0.46 (m, 2H), 0.38 (m, 2H). [M+H] calc'd for C₂₀H₂₂N₇O₂S, 424; found, 424.

Example 363 N-ethyl-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-yl)benzenesulfonamide

¹H NMR (400 MHz, DMSO) δ 8.65 (s, 1H) 8.43 (d, J=7.6 Hz, 1H) 8.37 (s, 1H) 7.92 (d, J=8.0 Hz, 1H) 7.77 (m, 1H) 7.67 (s, 1H) 6.65 (s, 1H) 2.83 (q, J=6.8 Hz, 2H) 2.45 (s, 3H) 2.30 (s, 3H) 0.97 (t, J=6.8 Hz, 3H). [M+H] calc'd for C₁₉H₂₂N₇O₂S, 412; found, 412.

Example 364 N-(2-hydroxyethyl)-2-methoxy-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino) imidazo[1,2-c]pyrimidin-7-yl)benzenesulfonamide

¹H NMR (400 MHz, DMSO) δ 8.70 (s, 1H) 8.41 (d, J=8.6 Hz, 1H) 8.35 (s, 1H) 7.70 (s, 1H) 7.40(d, J=8.6 Hz, 1H) 6.67 (s, 1H) 3.98 (s, 3H) 3.34 (m, 2H) 2.84(m, 2H) 2.44 (s, 3H) 2.31 (s, 3H). [M+H] calc'd for C₂₀H₂₄N₇O₄S, 458; found, 458.

Example 365 7-(4-methoxy-3-(morpholinosulfonyl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.71 (s, 1H) 8.46 (d, J=8.6 Hz, 1H) 8.35 (s, 1H) 7.71 (s, 1H) 7.44(d, J=8.6 Hz, 1H) 6.66 (s, 1H) 3.98 (s, 3H) 3.60 (m, 4H) 3.10(m, 4H) 2.44 (s, 3H) 2.29 (s, 3H). [M+H] calc'd for C₂₂H₂₆N₇O₄S, 484; found, 484.

Example 366 7-(4-methoxy-3-(tetrahydro-2H-pyran-4-ylsulfonyl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.73 (s, 1H) 8.42 (d, J=8.6 Hz, 1H) 8.35 (s, 1H) 7.70 (s, 1H) 7.37(d, J=8.6 Hz, 1H) 6.66 (s, 1H) 3.99 (s, 3H) 3.68 (m, 2H) 3.17 (m, 3H) 2.45 (s, 3H) 2.30 (s, 3H) 1.46(m, 4H). [M+H] calc'd for C₂₃H₂₇N₆O₄S, 483; found, 483.

Example 367 N-(2-(2-(dimethylamino)ethoxy)-5-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino) imidazo[1,2-c]pyrimidin-7-yl)phenyl)cyclopropanesulfonamide

¹H NMR (400 MHz, CD₃OD) δ 8.49 (s, 1H) 8.06 (s, 1H) 8.01 (d, J=8.8 Hz, 1H) 7.56 (s, 1H) 7.27(d, J=8.8 Hz, 1H) 6.73 (s, 1H) 4.54 (t, J=5.0 Hz, 2H) 3.69 (t, J=5.0 Hz, 2H) 3.05 (s, 6H) 2.66 (m, 1H) 2.55 (s, 3H) 2.39 (s, 3H) 1.05 (m, 2H) 0.95 (m, 2H). [M+H] calc'd for C₂₄H₃₁N₈O₃S, 511; found, 511.

Example 368 N-(2-hydroxyethyl)-3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)benzenesulfonamide

¹H NMR (400 MHz, Acetone-d₆) δ 8.80 (s, 1H) 8.38 (d, J=7.6 Hz, 1H) 8.23 (s, 1H) 8.04 (m, 2H) 7.78(m, 1H) 6.76 (s, 1H) 3.63 (t, J=5.6, 2H) 3.14 (m, br, 2H) 2.57 (s, 3H) 2.40 (s, 3H). [M+H] calc'd for C₁₉H₂₂N₇O₃S, 428; found, 428.

Example 369 3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-]pyrimidin-7-yl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide

¹H NMR (400 MHz, Methanol-d₆) δ 8.75 (s, 1H) 8.40 (d, J=8.3 Hz, 1H) 8.09 (s, 1H) 7.98 (d, J=8.3 Hz, 1H) 7.74 (m, 1H) 7.72 (s, 1H) 6.64 (s, 1H) 3.68 (t, J=9.0 Hz, 2H) 2.57 (s, 3H) 2.40 (s, 3H). [M+H] calc'd for C₁₉H₁₉F₃N₇O₂S, 466; found, 466.

Example 370 7-(3-(2-(dimethylamino)ethoxy)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO-d₆) δ 8.29 (s, 1H) 7.79 (m, 2H) 7.66 (s, 1H) 7.49 (m, 1H) 7.14 (d, J=8.6 Hz, 1H) 6.63 (s, 1H) 4.42 (t, J=4.2 Hz, 2H) 3.55 (t, J=4.2 Hz, 2H) 2.89 (s, 6H) 2.42 (s, 3H) 2.30 (s, 3H). [M+H] calc'd for C₂₁H₂₆N₇O, 392; found, 392.

Example 371 2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(pyrrolidin-1-ylsulfonyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO-d₆) δ 8.64 (s, 1H) 8.49 (d, J=8.6 Hz, 1H) 8.37 (s, 1H) 7.93 (d, J=8.6 Hz, 1H) 7.82 (m, 2H) 6.62 (s, 1H) 3.20 (m, 4H) 2.46 (s, 3H) 2.30 (s, 3H) 1.65 (m, 4H). [M+H] calc'd for C₂₁H₂₄N₇O₂S, 438; found, 438.

Example 372 7-(3-(3-aminopyrrolidin-1-ylsulfonyl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO-d₆) δ 8.66 (s, 1H) 8.53 (d, J=8.0 Hz, 1H) 8.38 (s, 1H) 7.93 (d, J=8.0 Hz, 1H) 7.84 (m, 2H) 6.64 (s, 1H) 3.73 (m, 1H) 3.45 (m, 2H) 3.32 (m, 1H) 3.20 (m, 2H) 2.46 (s, 3H) 2.30 (s, 3H) 1.82 (m, 1H). [M+H] calc'd for C₂₁H₂₅N₈O₂S, 453; found, 453.

Example 373 3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(3-(pyrrolidin-1-yl)propyl)benzenesulfonamide

¹H NMR (400 MHz, Methanol-d₄) δ 8.75 (s, 1H) 8.40 (d, J=8.0 Hz, 1H) 8.07 (s, 1H) 7.98 (d, J=8.0 Hz, 1H) 7.78 (m, 1H) 7.76 (s, 1H) 6.66 (s, 1H) 3.62 (br, 2H) 3.25 (m, 2H) 3.01 (m, 4H) 2.56 (s, 3H) 2.40 (s, 3H) 2.12 (br, 2H) 2.00 (br, 2H) 1.93 (m, 2H). [M+H] calc'd for C₂₄H₃₁N₈O₂S, 495; found, 495.

Example 374 3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-p-tolylbenzenesulfonamide

¹H NMR (400 MHz, Methanol-d₄) δ 8.21 (s, 1H) 8.05 (s, 1H) 7.73 (d, J=6.8 Hz, 1H) 7.65 (d, J=8.6 Hz, 2H) 7.50 (s, 1H) 7.33 (m, 1H) 7.21 (d, J=8.6 Hz, 2H) 7.02 (d, J=6.8 Hz, 1H) 6.77 (s, 1H) 2.56 (s, 3H) 2.40 (s, 3H) 2.30 (s, 3H). [M+H] calc'd for C₂₄H₂₄N₇O₂S, 474; found, 474.

Example 375 N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(4-methylpiperazin-1-ylsulfonyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO) δ 8.60 (m, 3H) 8.02 (s, 1H) 7.95 (m, 3H) 6.63 (s, 1H) 3.81 (br, 2H) 3.46 (br, 2H) 3.21 (br, 2H) 2.77 (s, 3H) 2.60 (br, 2H) 2.31 (s, 3H). [M+H] calc'd for C₂₁H₂₅N₈O₂S, 453; found, 453.

Example 376 7-(1-(ethylsulfonyl)-1H-indol-6-yl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, DMSO-d₆) δ 8.90 (s, 1H) 8.31 (s, 1H) 8.09 (s, 1H) 8.02 (d, J=8.3 Hz, 1H) 7.84 (d, J=8.3 Hz, 1H) 7.70 (d, J=4.0 Hz, 1H) 6.90 (m, 2H) 3.64 (q, J=7.4 Hz, 2H) 2.56 (s, 3H) 2.45 (s, 3H) 1.21 (t, J=7.4 Hz, 3H). [M+H] calc'd for C₂₁H₂₂N₇O₂S, 436; found, 436.

Example 377 N-(6-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-1H-indol-3-yl)ethanesulfonamide

¹H NMR (400 MHz, Methanol-d₄) δ 8.90 (s, 1H) 8.02 (m, 2H) 7.89 (s, 1H) 7.60 (m, 2H) 6.81 (s, 1H) 2.95 (q, J=6.6 Hz, 2H) 2.54 (s, 3H) 2.45 (s, 3H) 1.03 (t, J=6.6 Hz, 3H). [M+H] calc'd for C₂₁H₂₃N₈O₂S, 451; found, 451.

Example 378 (3-(7-phenylimidazo[1,2-c]pyrimidin-5-ylamino)-1H-pyrazol-5-yl)methanol

¹H NMR (400 MHz, DMSO-d₆) δ 8.59 (s, 1H) 8.18 (d, J=6.0 Hz, 2H) 8.02 (s, 1H) 7.70 (s, 1H) 7.54 (m, 3H) 6.78 (s, 1H) 4.55 (s, 2H). [M+H] calc'd for C₁₆H₁₅N₆O, 307; found, 307.

Example 379 7-(3-(5-amino-2-methylthiophen-3-yl)phenyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, Methanol-d₄) δ 8.35 (s, 1H) 8.30 (d, J=6.8 Hz, 1H) 8.08 (s, 1H) 7.74 (m, 3H) 7.52 (s, 1H) 6.56 (s, 1H) 2.57 (s, 3H) 2.38 (s, 6H). [M+H] calc'd for C₂₂H₂₂N₇S, 416; found, 416.

Example 380 2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-phenyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, CD₃OD) 8.04 (d, J=7.2 Hz, 2H) 7.48-7.58 (m, 3H) 6.67 (s, 1H) 6.40 (s, 1H) 4.51-4.62 (m, 2H) 4.02-4.07 (m, 1H) 2.34 (s, 3H). [M+H] calc'd for C₁₇H₁₉N₆, 307; found, 307.

Example 381 7-(3-(Ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, CD₃OD) 8.69 (m, 1H) 8.46 (d, J=8.0 Hz, 1H) 8.30 (d, J=2.8 Hz, 1H) 8.24 (s, 1H) 8.11 (d, J=8.0 Hz, 1H) 8.02 (d, J=2.8 Hz, 1H) 7.82 (t, J=8.0 Hz, 1H) 6.14 (s, 1H) 3.28 (q, J=7.2 Hz, 2H) 2.38 (s, 3H) 1.25 (t, J=7.2 Hz, 3H). [M+H] calc'd for C₁₈H₁₉N₆O₂S, 383; found, 383.

Example 382 2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(piperazin-1-ylmethyl) phenyl) imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, CD₃OD) 8.24-8.26 (m, 2H) 8.08 (s, 1H) 7.61-7.69 (m, 3H) 6.58 (s, 1H) 3.47-3.50 (m, 4H) 3.36-3.78 (m, 4H) 2.57 (s, 3H) 2.39 (s, 3H). [M+H] calc'd for C₂₂H₂₇N₈, 403; found, 403.

Example 383 (S)-1-(3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenylsulfonyl)pyrrolidin-3-ol

¹H NMR (400 MHz, CD₃OD) 8.64 (m, 1H) 8.33 (d, J=7.2 Hz, 1H) 8.05 (s, 1H) 7.93 (d, J=7.2 Hz, 2H) 7.68-7.73 (m, 2H) 6.60 (s, 1H) 4.25-4.27 (m, 1H) 3.18-3.40 (m, 4H) 2.56 (s, 3H) 2.39 (s, 3H) 1.72-1.87 (m, 2H). [M+H] calc'd for C₂₁H₂₄N₇O₃S, 453; found, 453.

Example 384 2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(3-(methylamino)pyrrolidin-1-ylsulfonyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, CD₃OD) 8.68 (m, 1H) 8.42 (d, J=7.8 Hz, 1H) 8.08 (s, 1H) 7.96 (d, J=7.8 Hz, 1H) 7.79 (t, J=7.8 Hz, 1H) 7.75 (s, 1H) 6.60 (s, 1H) 3.70-3.75 (m, 1H) 3.39-3.57 (m, 3H) 3.14-3.19 (m, 1H) 2.67 (s, 3H) 2.57 (s, 3H) 2.40 (s, 3H) 2.20-2.29 (m, 1H) 1.93-2.06 (m, 1H). [M+H] calc'd for C₂₂H₂₇N₈O₂S, 467; found, 467.

Example 385 2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(piperidin-1-ylmethyl) phenyl) imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, CD₃OD) 8.28-8.32 (m, 2H) 8.09 (s, 1H) 7.67-7.70 (m, 3H) 6.57 (s, 1H) 4.42 (s, 2H) 3.49-3.53 (m, 2H) 2.98-3.05 (m, 2H) 2.57 (s, 3H) 2.39 (s, 3H) 1.71-1.98 (m, 5H) 1.50-1.54 (m, 1H). [M+H] calc'd for C₂₃H₂₈N₇, 402; found, 402.

Example 386 N,4-Dimethyl-5-(3-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)phenyl)thiazol-2-amine

¹H NMR (400 MHz, CD₃OD) 8.23 (m, 1H) 8.16 (m, 1H) 8.06 (s, 1H) 7.72 (s, 1H) 7.61-7.64 (m, 2H) 6.54 (s, 1H) 3.15 (s, 3H) 2.56 (s, 3H) 2.39 (s, 3H) 2.38 (s, 3H). [M+H] calc'd for C₂₂H₂₃N₈S, 431; found, 431.

Example 387 2-Methyl-N-(5-methyl-1H-pyrazol-3-yl)-7-(3-(piperazin-1-ylsulfonyl)phenyl) imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, CD₃OD) 8.72 (s, 1H) 8.50 (d, J=7.6 Hz, 1H) 8.11 (s, 1H) 7.97 (d, J=7.6 Hz, 1H) 7.84 (m, 1H) 7.79 (s, 1H) 6.62 (s, 1H) 3.30 (m, 8H) 2.58 (s, 3H), 2.40 (s, 3H). [M+H] calc'd for C₂₁H₂₅N₈O₂S, 453; found, 453.

Example 388 3-(2-Methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-yl)-N-(pyrrolidin-3-yl)benzenesulfonamide

¹H NMR (400 MHz, CD₃OD) 8.71 (s, 1H) 8.37 (d, J=7.6 Hz, 1H) 8.08 (s., 1H) 7.99 (d, J=7.6 Hz, 1H) 7.73-7.76 (m, 2H) 6.63 (s, 1H) 3.89 (m, 1H) 3.24-3.39 (m, 4H) 2.57 (s, 3H) 2.40 (s, 3H) 2.07-2.15 (m, 1H) 1.89-1.94 (m, 1H). [M+H] calc'd for C₂₁H₂₅N₈O₂S, 453; found, 453.

Example 389 N-Cyclopropyl-2-(3-(7-phenylimidazo[1,2-c]pyrimidin-5-ylamino)-1H-pyrazol-5-yl)acetamide

[M+H] calc'd for C₂₀H₂₀N₇O, 374; found, 374.

Example 390 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-(methoxymethyl)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-2-methoxyacetamide

¹H NMR (400 MHz, CDCl3:MDOD 10:1) δ ppm 8.06 (s, 1H) 7.64 (d, J=8.6 Hz, 2H) 7.48 (d, J=8.6 Hz, 4H) 6.54 (s, 1H) 6.00 (s, 1H) 4.47 (s, 2H) 3.95 (s, 2H) 3.41 (s, 3H) 3.33 (s, 3H) 1.72-1.81 (m, 1H) 0.89-0.97 (m, 2H) 0.63-0.71 (m, 2H). LCMS (M+1) calcd for C₂₃H₂₆N₇O₃S 480; found 480.

Example 391 Ethyl 2-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenylamino)-2-oxoacetate

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 8.15 (s, 1H) 7.76 (d, J=8.3 Hz, 2H) 7.52 (m, 3H) 6.65 (s, 1H) 6.05 (s, 1H) 6.05 (s, 1H) 4.32 (q, J=7.2 Hz, 2H) 3.25 (s, 1H) 2.14 (s, 3H) 1.33 (t, J=7.2 Hz, 3H). LCMS (M+1) calcd for C₂₀H₂₀N₇O₃S 438; found 438.

Example 392 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)tetrahydrofuran-2-carboxamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 8.10 (s, 1H) 7.65 (d, J=8.6 Hz, 2H) 7.46-7.53 (m, 3H) 6.58 (s, 1H) 5.98 (s, 1H) 4.38 (dd, J=8.2, 6.2 Hz, 1H) 3.97-4.03 (m, 1H) 3.87 (q, J=7.4 Hz, 1H) 3.28 (s, 1H) 3.24 (s, 1H) 2.24-2.34 (m, 1H) 2.15 (s, 3H) 2.02 (ddd, J=13.5, 6.6, 6.4 Hz, 1H) 1.83-1.94 (m, 2H). LCMS (M+1) calcd for C₂₁H₂₂N₇O₂S, 436; found 436.

Example 393 N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)furan-2-carboxamide

¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.97 (s, 1H) 10.52 (s, 1H) 8.23 (s, 1H) 8.00 (s, 1H) 7.96-7.98 (m, 2H) 7.61 (d, J=8.8 Hz, 2H) 7.39 (dd, J=3.5, 0.8 Hz, 1H) 6.72 (dd, J=3.5, 1.8 Hz, 1H) 6.67 (s, 1H) 5.79 (s, 1H) 2.52 (s, 1H) 2.34 (s, 3H) 2.08 (s, 3H).

LCMS (M+1) calcd for C₂₂H₂₀N₇O₂S, 446; found 446.

Example 394 (S)-N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)tetrahydrofuran-2-carboxamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.81 (s, 1H) 7.64 (d, J=8.6 Hz, 2H) 7.48 (d, J=8.6 Hz, 2H) 6.52 (s, 1H) 5.90 (s, 1H) 5.21 (s, 1H) 4.37 (dd, J=8.3, 6.1 Hz, 1H) 4.01-3.35 (m, 2H) 3.28 (s, 2H) 2.32 (s, 3H) 2.24-2.30 (m, 1H) 2.11 (s, 3H) 2.03 (m, 1H) 1.82-1.90 (m, 2H). LCMS (M+1) calcd for C₂₂H₂₄N₇O₂S, 450; found 450.

Example 395 N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)isoxazole-5-carboxamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 8.34 (s, 1H) 7.78-7.89 (m, 3H) 7.52 (d, J=8.1 Hz, 2H) 7.02 (s, 1H) 6.60 (s, 1H) 6.03 (s, 1H) 3.28 (s, 1H) 2.34 (s, 3H) 2.15 (s, 3H). LCMS (M+1) calcd for C₂₁H₁₉N₈O₂S, 447; found 447.

Example 396 5-methyl-N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)isoxazole-3-carboxamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.86 (s, 1H) 7.78 (d, J=6.8 Hz, 2H) 7.53 (d, J=7.8 Hz, 2H) 6.70 (s, 1H) 6.46 (s, 1H) 5.99 (s, 1H) 3.30 (s, 2H) 3.26 (s, 3H) 2.43 (s, 3H) 2.36 (s, 3H). LCMS (M+1) calcd for C₂₂H₂₁N₈O₂S, 461; found 461.

Example 397 4-methyl-N-(4-(2-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)oxazole-5-carboxamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.92 (s, 1H) 7.79 (s, 1H) 7.72-7.77 (m, 2H) 7.50 (d, J=8.6 Hz, 2H) 6.56 (s, 1H) 5.98 (s, 1H) 3.29 (s, 2H) 2.47 (s, 3H) 2.33 (s, 3H) 2.15 (s, 3H). LCMS (M+1) calcd for C₂₂H₂₁N₈O₂S, 461; found 461.

Example 398 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-5-methylfuran-2-carboxamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.90 (s, 1H) 7.75 (d, J=8.3 Hz, 2H) 7.50 (d, J=8.3 Hz, 2H) 7.12 (d, J=3.3 Hz, 1H) 6.62 (s, 1H) 6.04-6.15 (m, 2H) 2.35 (s, 3H) 2.33 (s, 3H) 1.80 (s, 1H) 1.11-1.23 (m, 2H) 0.89-1.00 (m, 2H) 0.66-0.72 (m, 2H).

LCMS (M+1) calcd for C₂₅H₂₄N₇O₂S, 486; found 486.

Example 399 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-1,5-dimethyl-1H-pyrazole-3-carboxamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.85 (s, 1H) 7.74 (d, J=8.6 Hz, 2H) 7.51 (d, J=8.3 Hz, 2H) 6.65 (s, 1H) 6.55 (s, 1H) 5.93 (s, 1H) 3.76 (s, 3H) 3.31 (s, 1H) 2.35 (s, 3H) 2.25 (s, 3H) 1.75 (m, 1H) 1.16 (s, 2H) 0.83-0.93 (m, 2H) 0.63 (t, J=5.4 Hz, 2H). LCMS (M+1) calcd for C₂₅H₂₆N₉OS, 500; found 500.

Example 400 N-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.79 (s, 1H) 7.71-7.75 (m, 2H) 7.47-7.51 (m, 2H) 6.66 (s, 1H) 6.49 (s, 1H) 6.05 (s, 1H) 4.03 (s, 3H) 3.31 (m, 1H) 2.34 (s, 3H) 2.20 (s, 3H) 1.79 (s, 1H) 0.87-0.95 (m, 2H) 0.67 (dt, J=6.5, 4.8 Hz, 2H). LCMS (M+1) calcd for C₂₅H₂₆N₉OS, 500; found 500.

Example 401 N1-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-N-2-ethyl-N-2-methyloxalamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.81 (s, 1H) 7.71 (d, J=7.8 Hz, 2H) 7.50 (d, J=8.3 Hz, 2H) 6.55 (s, 1H) 3.41 (q, J=7.3 Hz, 2H) 3.31 (s, 1H) 3.23 (s, 2H) 2.95 (s, 3H) 2.35 (s, 3H) 1.79 (m, 1H) 1.22 (t, J=6.9 Hz, 3H) 0.93 (d, J=10.1 Hz, 2H) 0.65 (d, J=1.3 Hz, 2H). LCMS (M+1) calcd for C₂₄H₂₇N₈O₂S, 491; found 491.

Example 402 N1-(4-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-ylthio)phenyl)-N-2-(thiazol-2-yl)oxalamide

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.61-7.70 (m, 3H) 7.34 (d, J=8.6 Hz, 2H) 6.90 (d, J=3.5 Hz, 1H) 6.28 (s, 1H) 7.26 (m, 1H) 5.68 (s, 1H) 2.35 (s, 1H) 2.15 (s, 3H) 1.47-1.56 (m, 1H) 0.94 (s, 5H) 0.64 (q, J=6.6 Hz, 2H) 0.31-0.40 (m, 2H).

LCMS (M+1) calcd for C₂₄H₂₂N₉O₂S₂, 532; found 532.

Example 403 N7,2-dimethyl-N-5-(5-methyl-1H-pyrazol-3-yl)-N-7-(1-methylpyrrolidin-3-yl)imidazo[1,2-c]pyrimidine-5,7-diamine

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.71 (s, 1H) 6.16 (m, 2H) 4.74 (m, 1H) 3.75-3.85 (m, 4H) 3.30 (s, 1H) 3.03 (s, 3H) 2.85 (s, 3H) 2.4-2.5 (m, 1H) 2.31 (m, 1H) 2.28 (s, 3H) 2.25 (s, 3H). LCMS (M+1) calcd for C₁₇H₂₅N₈, 341; found 341.

Example 404 N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(ethoxymethyl)-7-(3-(ethylsulfonyl)phenyl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, MeOD) δ ppm 8.74 (s, 1H) 8.46 (d, J=6.3 Hz, 1H) 8.32 (s, 1H) 8.06 (d, J=7.1 Hz, 1H) 7.81 (t, J=7.8 Hz, 1H) 7.74 (s, 1H) 6.50 (s, 1H) 4.78 (s, 2H) 3.70 (q, J=7.1 Hz, 2H) 3.25-3.30 (m, 2H) 1.94-2.04 (m, 1H) 1.29 (m, 6H) 1.02-1.08 (m, 2H) 0.88 (m, 2H). LCMS (M+1) calcd for C₂₃H₂₇N₆O₃S, 467; found 467.

Example 405 N1-(3-(5-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methylimidazo[1,2-c]pyrimidin-7-yl)phenyl)-N-4-ethylsuccinamide

¹H NMR (400 MHz, MeOD) δ ppm 8.54 (s, 1H) 8.03 (s, 1H) 7.91 (s, 1H) 7.82 (d, J=7.8 Hz, 1H) 7.50-7.52 (m, 2H) 7.45 (m, J=7.8 Hz, 1H) 6.55 (s, 1H) 3.98 (s, 2H) 3.22 (q, J=7.3 Hz, 2H) 2.73 (t, J=6.7 Hz, 2H) 2.61 (t, J=6.7 Hz, 2H) 2.54 (s, 3H) 2.02 (m, 1H) 1.12 (t, J=7.3 Hz, 3H) 1.02-1.08 (m, 2H) 0.80-0.86 (m, 2H). LCMS (M+1) calcd for C₂₅H₂₉N₈O₂, 473; found 473.

Example 406 N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-(1-isopentyl-1H-pyrazol-4-yl)-2-methylimidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 8.07 (s, 1H) 7.84-7.90 (m, 1H) 7.86 (s, 1H) 7.26 (s, 1H) 6.35 (s, 1H) 4.11 (t, J=7.452 Hz, 2H) 2.37 (s, 3H) 1.88 (m, 1H) 1.67-1.75 (m, 2H) 1.51 (m, 1H) 1.01 (q, J=6.2 Hz, 2H) 0.89 and 87 (s, 3H each) 0.74-0.78 (m, 2H). LCMS (M+1) calcd for C₂₁H₂₇N₈, 391; found 391.

Example 407 7-(3-(diethylamino)pyrrolidin-1-yl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)imidazo[1,2-c]pyrimidin-5-amine

¹H NMR (400 MHz, CDCl3:CDOD 10:1) δ ppm 7.62 (s, 1H) 6.37 (s, 1H) 5.87 (s, 1H) 3.95-4.04 (m, 2H) 3.88-3.71 (s, 3H) 3.42 (m, 1H) 3.30-3.19 (s, 4H) 2.38 (s, 3H) 2.17-2.28 (m, 6H) 1.27 (q, J=7.1 Hz, 6H). LCMS (M+1) calcd for C₁₉H₂₉N₈, 369; found 369.

Example 408 2(3-(dimethylamino)methyl-1-(ethylsulfonyl)-1H-indol-6-yl)-N-(5-methyl-1H-pyrazol-3-yl) pyrrolo[1,2-f][1,2,4]triazin-4-amine

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.14 (t, J=7.33 Hz, 3H) 2.35 (s, 3H) 2.83 (d, J=4.55 Hz, 6H) 3.76 (q, J=7.24 Hz, 2H) 4.53 (d, J=4.80 Hz, 2H) 6.73 (dd, J=4.29, 2.53 Hz, 1H) 6.94 (s, 1H) 7.33 (s, 1H) 7.83 (dd, J=2.53, 1.52 Hz, 1H) 8.00 (s, 1H) 8.06 (d, J=8.59 Hz, 1H) 8.33 (d, J=9.09 Hz, 1H) 8.97 (s, 1H) 9.77 (s, 1H) 10.71 (s, 1H) 12.25 (bs. 1H); ESI-MS: m/z calc'd for C23H26N8O2S 478.57; found 479.4 (M+H)⁺.

Example 409 N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino) pyrrolo[1,2-f][1,2,4]triazin-2-ylthio)phenyl)acetamide

¹H NMR (400 MHz, DMSO) δ 10.15 (s, 1H) 8.03 (d, J=0.8 Hz, 1H) 7.98 (s, 1H) 7.76 (s, 1H) 7.69 (d, J=8.8 Hz, 2H) 7.51 (d, J=8.4 Hz, 2H) 7.47 (d, J=8.8 Hz, 1H) 7.21 (d, J=8.8 Hz, 1H) 6.05 (s, 1H) 2.16 (s, 3H) 2.06 (s, 3H). ESI-MS: m/z calc'd for C18H17N7OS 379.12; found 380.3 (M+H)⁺.

Biological Testing

The activity of compounds as protein kinase inhibitors may be assayed in vitro, in vivo or in a cell line. In vitro assays include assays that determine inhibition of either the phosphorylation activity or ATPase activity of the activated protein kinase. Alternate in vitro assays quantitate the ability of the inhibitor to bind to the protein kinase. Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/protein kinase complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with the protein kinase bound to known radioligands.

A. Determination of Inhibition of AIK

The inhibitory properties of compounds relative to AIK may be determined by the Direct Fluorescence Polarization detection method (FP) using a Greiner small volume black 384-well-plate format under the following reaction conditions: 50 mM Hepes pH 7.3, 10 mM MgCl₂, 10 mM NaCl, 1 mM DTT, 0.01% Brij35, 100 nM Fluorescein-LRRASLG peptide (provided by SYNPEP), 5% DMSO, 2.5 uM ATP. Detection of the reaction product is performed by addition of IMAP binding reagent (Molecular Devices). Reaction product may be determined quantitatively by FP using an Analyst HT plate reader (Molecular Devices) with an excitation wavelength at 485 nm and emission at 530 nm and using a Fluorescein 505 dichroic mirror.

The assay reaction may be initiated as follows: 2 ul of (3×) 300 nM Fl-Peptide/7.5 uM ATP was added to each well of the plate, followed by the addition of 2 ul of (3×) inhibitor (2.5 fold serial dilutions for 11 data points for each inhibitor) containing 15% DMSO. 2 ul of (3×) 7.5 nM AIK solution may be added to initiate the reaction (final enzyme concentration was 2.5 nM for AIK). The reaction mixture may then be incubated at room temperature for 45 min, and quenched and developed by addition of 20 ul of 1 to 400 diluted IMAP binding reagent in 1× proprietary IMAP binding buffer. Fluorescence polarization readings of the resulting reaction mixtures may be measured after a 60-minute incubation at room temperature.

IC50 values may be calculated by non-linear curve fitting of the compound concentrations and fluorescent polarization values to the standard IC50 equation. As a reference point for this assay, Staurosporin showed an IC50 of <10 nM.

B. Determination of Inhibition of c-KIT

The inhibitory properties of compounds relative to c-Kit may be determined by the Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) method using a small volume black 384-well-plate (Greiner) format under the following reaction conditions: 50 mM Hepes pH 7.3, 10 mM MgCl2, 10 mM NaCl, 1 mM DTT, 0.01% Brij35, 250 nM Biotin-EGPWLEEEEEAYGWMDF peptide (provided by SYNPEP), 5% DMSO, 100 uM ATP. Detection of the reaction product may be performed by addition of Streptavidin-APC (Prozyme) and Eu-Anti-phosphotyrosine antibody (Perkin Elmer). Reaction product may be determined quantitatively by TR-FRET reading using an Analyst HT plate reader (Molecular Devices) with an excitation wavelength at 330 nm and emission at 615 nm (Europium) compared to 330 nm excitation (Europium) and emission 665 nm (APC) and using an Europium 400 dichroic mirror.

The assay reaction may be initiated as follows: 4 ul of (2.5×) 625 nM Biotin-Peptide/250 uM ATP was added to each well of the plate, followed by the addition of 2 ul of (5×) inhibitor (2.5 fold serial dilutions for 11 data points for each inhibitor) containing 25% DMSO. 4 ul of (2.5×) c-Kit solution may be added to initiate the reaction (final enzyme concentration was 0.13 nM for c-Kit). The reaction mixture may then be incubated at room temperature for 30 min, and quenched and developed by addition of 10 ul of (2×) 3.2 nM Eu-Antibody and 25 nM Streptavidin-APC in 50 mM Hepes pH 7.3, 30 mM EDTA, 0.1% Triton X-100 buffer. TR-FRET readings of the resulting reaction mixtures may be measured after a 60-minute incubation at room temperature on the Analyst HT.

IC50 values may be calculated by non-linear curve fitting of the compound concentrations and ratio metric Eu:APC values to the standard IC50 equation. As a reference point for this assay, Staurosporin showed an IC50 of <5 nM.

The following abbreviations have been used:

ATP Adenosine Triphophatase BSA Bovine Serum Albumin EDTA Ethylenediaminetetraacetic acid GSK3 Glycogen synthase kinase 3 MOPS Morpholinepropanesulfonic acid SPA Scintillation Proximity Assay

It will be apparent to those skilled in the art that various modifications and variations can be made in the compounds, compositions, kits, and methods of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents. 

1. A compound of formula:

wherein: Q is selected from the group consisting of S, SO, SO₂, and O, or Q is absent; Y is selected from the group consisting of (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; R₁ is selected from the group consisting of hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; each R₃ is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or two R₃ are taken together to form a substituted or unsubstituted ring; and R₄ is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted.
 2. The compound of claim 1, wherein the compound is of a formula:

wherein: p is selected from the group consisting of 0, 1, 2, 3, 4 and 5; Q is selected from the group consisting of S, SO, SO₂, and O, or Q is absent; R₁ is selected from the group consisting of hydrogen, nitro, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; each R₃ is independently selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or two R₃ are taken together to form a substituted or unsubstituted ring; R₄ is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, hydroxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, perhalo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl, and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted; and R₂₃ is selected from the group consisting of hydrogen, halo, nitro, cyano, thio, oxy, hydroxy, carbonyloxy, alkoxy, aryloxy, heteroaryloxy, carbonyl, oxycarbonyl, aminocarbonyl, amino, (C₁₋₁₀)alkylamino, sulfonamido, imino, sulfonyl, sulfinyl, (C₁₋₁₀)alkyl, halo(C₁₋₁₀)alkyl, carbonyl(C₁₋₃)alkyl, thiocarbonyl(C₁₋₃)alkyl, sulfonyl(C₁₋₃)alkyl, sulfinyl(C₁₋₃)alkyl, amino(C₁₋₁₀)alkyl, imino(C₁₋₃)alkyl, (C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, hetero(C₃₋₁₂)cycloalkyl(C₁₋₅)alkyl, aryl(C₁₋₁₀)alkyl, heteroaryl(C₁₋₅)alkyl, (C₉₋₁₂)bicycloaryl(C₁₋₅)alkyl, hetero(C₈₋₁₂)bicycloaryl(C₁₋₅)alkyl, (C₃₋₁₂)cycloalkyl, hetero(C₃₋₁₂)cycloalkyl, (C₉₋₁₂)bicycloalkyl, hetero(C₃₋₁₂)bicycloalkyl, aryl, heteroaryl, (C₉₋₁₂)bicycloaryl and hetero(C₄₋₁₂)bicycloaryl, each substituted or unsubstituted, or two R₂₃ are taken together to form a ring.
 3. The compound according to claim 1, wherein Y is phenyl, unsubstituted or substituted with one or more substituents selected from the group consisting of halo, cyano, amino, alkyl, haloalkyl, alkoxy, alkylcarboxy, alkylsulfinyl, aryl, and aryloxy, each unsubstituted or substituted.
 4. The compound according to claim 1, wherein Y is selected from the group consisting of:


5. The compound according to claim 1, wherein Y is selected from the group consisting of:


6. The compound according to claim 1, wherein Y is selected from the group consisting of carboxyaminoaryl, carboxyaminoheteroaryl, aminocarboxyaryl, aminocarboxyheteroaryl, sulfinylaminoaryl, sulfinylaminoheteroaryl, aminosulfinylaryl and aminosulfinylheteroaryl, each unsubstituted or substituted.
 7. The compound according to claim 1, wherein Y is selected from the group consisting of acetamidophenyl and cyclopropylcarboxyaminophenyl, each substituted or unsubstituted.
 8. The compound according to claim 1, wherein Y is substituted with a substituent selected from the group consisting of amino, alkylamino, alkyl, aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy and heterocycloalkyloxy, each unsubstituted or substituted.
 9. The compound according to claim 1, wherein Q is selected from the group consisting of S, SO, SO₂, and O, or Q is absent.
 10. The compound according to claim 1, wherein Q is S.
 11. The compound according to claim 1, wherein Q is absent.
 12. The compound according to claim 1, wherein R₁ is selected from the group consisting of hydrogen and substituted or unsubstituted (C₁₋₄)alkyl.
 13. The compound according to claim 1, wherein each R₃ is independently selected from the group consisting of hydrogen, halo, amino, aminocarboxy, alkyl, hydroxyalkyl, aminoalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, each unsubstituted or substituted.
 14. A compound selected from the group consisting of: 2-(3-(ethylsulfonyl)phenyl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine; 2-(3-(ethylsulfonyl)phenyl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine; N-(5-methyl-1H-pyrazol-3-yl)-2-(3-(methylsulfonyl)phenyl)pyrrolo[1,2-f][1,2,4]triazin-4-amine; N-(5-methyl-1H-pyrazol-3-yl)-2-phenylpyrrolo[1,2-f][1,2,4]triazin-4-amine; 2-(1-(Ethylsulfonyl)-1H-indol-6-yl)-N-(5-methyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine; 2-(1-(Ethylsulfonyl)-1H-indol-6-yl)-6-methyl-N-(5-methyl-1H-pyrazol -3-yl) pyrrolo[1,2-f][1,2,4]triazin-4-amine; 2-(3-((dimethylamino)methyl)-1-(ethylsulfonyl)-1H-indol-6-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl) pyrrolo[1,2-f][1,2,4]triazin-4-amine; 2(3-(dimethylamino)methyl-1-(ethylsulfonyl)-1H-indol-6-yl)-N-(5-methyl-1H-pyrazol-3-yl) pyrrolo[1,2-f][1,2,4]triazin-4-amine; and N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino) pyrrolo[1,2-f][1,2,4]triazin-2-ylthio)phenyl)acetamide.
 15. The compound according to claim 1, wherein the compound is in the form of a pharmaceutically acceptable salt.
 16. The compound according to claim 1, wherein the compound is present in a mixture of stereoisomers.
 17. The compound according to claim 1, wherein the compound comprises a single stereoisomer.
 18. A pharmaceutical composition, consisting of a compound according to claim 1 and at least one pharmaceutical excipient.
 19. The pharmaceutical composition according to claim 18, wherein the composition is a solid formulation adapted for oral administration.
 20. The pharmaceutical composition according to claim 18, wherein the composition is a tablet.
 21. The pharmaceutical composition according to claim 18, wherein the composition is a liquid formulation adapted for oral administration.
 22. The pharmaceutical composition according to claim 18, wherein the composition is a liquid formulation adapted for parenteral administration.
 23. The pharmaceutical composition according to claim 18, wherein the composition is adapted for administration by a route selected from the group consisting of orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, and intrathecally.
 24. A kit comprising: a compound according to claim 1; and instructions which comprise one or more forms of information selected from the group consisting of indicating arthritis for which the compound is to be administered, storage information for the compound, dosing information and instructions regarding how to administer the compound.
 25. The kit according to claim 24, wherein the kit comprises the compound in a multiple dose form.
 26. An article of manufacture comprising: a compound according to claim 1; and packaging materials.
 27. The article of manufacture of claim 26, wherein the packaging material comprises a container for housing the compound.
 28. The article of manufacture of claim 27, wherein the container comprises a label indicating one or more members of the group consisting of arthritis for which the compound is to be administered, storage information, dosing information and/or instructions regarding how to administer the composition.
 29. The article of manufacture of claim 26, wherein the article of manufacture comprises the compound in a multiple dose form.
 30. The compound of claim 1, wherein: R₄ is (C₃₋₁₂)cycloalkyl; Q is absent; and Y is a pyrrolidinyl group substituted with a group selected from (C₁₋₁₀alkyl) and an amide.
 31. The compound of claim 1, wherein: R₄ is (C₃₋₁₂)cycloalkyl; Q is absent; and Y is a pyrrolidinyl group substituted with a group selected from (C₁₋₁₀alkyl) and a halo-substituted-NHheteroarylcarbonyl-group. 